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ABSTRACT 
Introduction  
Obesity is one of the growing health concerns worldwide due to its increasing 
prevalence and increased associated risk of cardiovascular disease (CVD), heart failure, 
diabetes and total mortality. Due to a number of pathological mechanisms, obesity 
significantly increases the risk of heart failure and cardiovascular death. Paradoxically, 
in patients with established heart failure or high cardiovascular risk, a high body mass 
index was associated with a better prognosis and a reduction in the mortality. This has 
been shown consistently in epidemiological studies. However, there have not been any 
weight loss intervention studies to suggest whether therapeutic weight loss is beneficial 
or harmful. 
 
Hypothesis  
The hypothesis of this study was that weight loss intervention in obese patients with 
heart failure or high CVD risk will improve cardiac performance measured as peak 
oxygen consumption (peak VO2) and reduce biomarkers of cardiac risks. 
 
Primary end point 
The primary end point of the study was peak VO2 following acute weight loss (WL, 
week 6) and weight loss maintenance phase (WLM, week16). 
 
Secondary end points 
The secondary end points were  
 Left ventricular ejection fraction (LVEF), heart rate variability (HRV), resting 
plasma b-type natriuretic peptide (BNP), resting plasma norepinephrine, 
 xiii 
antioxidant profile, Alanine aminotransferase (ALT), cholesterol, highly 
sensitive CRP (hsCRP), fasting plasma glucose and insulin, adiponectin, leptin, 
tissue necrotic factor-alpha (TNF-α) and interleukin-6 (IL-6), exploratory 
analysis relating changing in the endpoints to body fat mass (FM) and fat free 
mass (FFM) changes. 
 Comparison of Fat mass measured by 4C model Vs quantitative MRI.  
 
Methods 
Obese patients with either heart failure or a high cardiovascular risk profile (or both) 
were investigated in order to explore the effect of acute weight loss and weight loss 
maintenance on cardiac function and various prognostic indicators.  14 patients were 
recruited of whom 11 completed the study. WL was induced by a liquid meal based diet 
(low energy liquid diet of 800-1000 kcal/day), which was provided for 6 weeks followed 
by a WLM phase of a further 10 weeks with the diet adjusted to individual total energy 
requirements.  
A detailed body composition study by the four compartment model was conducted to 
assess whether changes in body composition in the group would be different to people 
with simple obesity i.e., difference in fat Vs fat free mass. Cardiopulmonary exercise 
testing and echocardiography were performed to assess cardiac function and 
performance. Sympathetic activity assessments (heart rate variability, plasma and urine 
catecholamine) and other biomarkers (insulin, adiponectin, B type natriuretic peptide, 
leptin, sensitive CRP, antioxidant profile) were also measured at baseline and at the end 
of each phase.  
 
Results  
The study demonstrated that acute weight loss and short term weight loss maintenance 
in patients with heart failure and/or high cardiovascular risks were safe.  Mean weight 
loss of 12 kg±4.6 and 14.2 kg±7.3, p <0.0001 were achieved at the end of acute WL and 
 xiv 
WLM maintenance phase respectively. In parallel to the weight loss, a significant loss of 
both fat mass (8.04 kg±3.23 and 11.2 kg±5.82) and fat free mass (4.17 kg±2.05 and 3.24 
kg±3) were seen.  
 
Following the body composition changes, there was a significance increase in the 
primary end point, peak VO2 at 2.64 ml/kg/min±3.71 and 2.44 ml/kg/min±2 (14.34% 
and 13.26% improvement) at the end of acute WL and WLM phases respectively. 
Significant improvements in haemodynamic parameters and reductions in sympathetic 
activity were demonstrated. There were mean reductions of 11.1 bpm±12.7 and 10.6 
bpm±13.4 in resting heart rate, 22.2 mmHg±17.7 and 11.18 mmHg±19.5 in systolic 
blood pressure, 106.6ng/l±170.9 and 116.5 ng/l±114.6 in plasma norepinephrine, 270 
nmol/24h±184.1 and 100 nmol/24h±173 in 24h urinary norepinephrine and increases of 
25.28 ms
2
±118.3 and 165.5 ms
2
±263
 
in high frequency and 33.4 ms
2
±63.5
 
and 82 
ms
2
±62.9
 
low frequency power of heart rate variability).  
 
In addition, improvements i.e. reduction in level of various metabolic parameters that 
normally increase cardiovascular risks (fasting plasma glucose, insulin, total cholesterol, 
triglyceride cholesterol, ALT and tumour necrotic factor-alpha) were also demonstrated. 
 
Paradoxical negative correlations were found in between the pVO2 changes (ml/kg/min) 
and the FFM loss(r= -0.688, p=0.019). Similar paradoxical positive correlation was 
demonstrated in between FM loss and pVO2 (ml/min) (r=0.793, p=0.004) and pVO2 
(ml/FFM kg/min) (r=0.645, p=0.032).  
 
Conclusion 
This thesis aimed to demonstrate whether weight loss or weight loss maintenance was of 
benefit or harm to patients with heart failure and or high cardiovascular risk. The study 
 xv 
was limited by not having a controlled group and based on pilot data. Nevertheless, the 
thesis was unique highlighting various aspects of cardiovascular assessment and 
metabolic risk profile in parallel with weight loss and body composition changes. It 
demonstrated that in obese patients with heart failure/ high CVD, effective therapeutic 
weight reduction resulted in a healthier body composition and subsequent improvement 
in their cardiovascular risk profile. This work will form a basic of larger multicentre 
randomised controlled trial.  
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CHAPTER 1:  INTRODUCTION 
1.1. Obesity 
1.1.1. Definition of obesity 
Obesity is a complex, multi-factorial condition characterised by excess body fat to the 
point where it poses a significant health risk.
1
 Body mass index (BMI)
2
 is a widely 
accepted method of assessing the degree of adiposity. BMI is calculated as the weight 
(in kg) divided by height (in metres squared) (Equation 1). Being overweight and 
obesity can be classified according to BMI (Table 1.1).
2
  
 
Equation 1 BMI = Body Mass Index = body weight (kg)/ height
2
 (m) 
  
Table 1. 1. Classification of obesity 
 
 
 
 
 
  
 
Within each range, a mid-weight goal may represent the most appropriate standard 
because several studies suggest that the risk of mortality increases in both overweight 
Range  BMI 
Underweight  < 18.5 kg/m
2
 
Healthy weight 18.5 – 24.9 kg/m2 
Overweight 25.0 – 29.9 kg/m2 
Obesity 30.0 - 40 kg/m
2
 
Morbid obesity >40 kg/m
2
 
Excess weight ≥ 25.0 kg/m2 
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and underweight people.
3, 4
 However, a person may be within the desirable norm for 
body weight relative to height and frame size, yet still have a high percentage of body 
fat. Generally, men with more than 25% body fat and women with more than 35% body 
fat are considered obese. In contrast, body weight can exceed the ideal standard because 
of large muscle mass; in such a case, the person is not considered obese. 
 
1.1.2. Types of obesity 
Two patterns of fat distribution have been noted in obese individuals: central abdominal 
(android obesity) and gluteo-femoral (gynoid obesity). "Android obesity‖ has been 
linked to the shape of an apple with the pattern of fat distribution mostly over the trunk 
whereas ―gynoid obesity‖ is akin to the shape of a pear, with fat distribution mostly 
around the hips and thighs (Figure 1.1). This terminology was first described by Jean 
Vague
5
 in the 1940s.  Android obesity is more closely associated with diabetes, 
hypertension and cardiovascular diseases than just fatness per se. A generally useful 
method for distinguishing android versus gynoid obesity is to determine waist and hip 
measurements and calculate a waist/hip ratio. A ratio of less than 0.8 in women and less 
than 1.0 in men indicates lower cardiovascular risk
6
. A waist circumference exceeding 
94 cm in men or 80 cm in women is also considered central obesity. These figures are 
based on cross-sectional data from Europids and were the best values for identifying 
people with increased adiposity, defined as a BMI of > 25 kg/m
2
 or WHR ≥ 0.90 for 
men and ≥ 0.85 for women. Therefore, the cut off for waist circumferences is ethnic 
specific (See section 1.2.3, Table 1.4). 
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Figure 1. 1. Types of Obesity 
 
Android obesity (left) demonstrates truncal fat distribution (apple shape) and gynoid 
obesity (right) demonstrates fat distribution around the gluteo-femoral region (pear 
shape). 
Downloaded from http://charlesgoldman.wordpress.com/tag/biological-factors-
affecting-health-and-weight/ 
1.1.3. Epidemiology of Obesity   
Being overweight and obese are global problems, affecting over one
 
billion adults and 
17.6 million children under 5 years of age.
7
 It is one of the most rapidly increasing 
health concerns in the EU as well as globally. Prevalence data from the Europe indicated 
that 35.7 % of the adult population could be considered overweight (BMI >25 kg/m
2
) 
with a further 17.2 % obese (BMI >30 kg/m
2
), resulting in over 53% of the European 
population being classified as either obese or overweight.
8
 The recent Health Survey for 
England
9
 showed that one in four adults was obese in 2004.  The prevalence had risen 
from 13% to 24% in males (40% rise) and 16% to 24% in females (28% rise) compared 
with that of 1993. In addition, the prevalence of obesity among children and adolescents 
is rapidly increasing. In the UK, around 5% of boys and 11% of girls aged 11 to 15 
years were considered obese according to International Obesity Task Force (IOTF) 
definitions.
10
 However, if a more commonly used definition from 1990 Growth Charts 
Chapter 1: Introduction 
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was used, the prevalence was higher at 25% (overweight defines percentile of weight-
for-length or BMI-for-age ≥95th and risk of overweight defines that of between 85th and 
95th percentile). The degree of obesity had also worsened. Morbid obesity (BMI >40 
kg/m
2
) had become a considerable health concern. In 1986, 1 in 200 adult Americans 
were morbidly obese; and this has risen up to 1 in 50 more recently.
11
 The rate of 
increase in BMI >40 was twice as rapid as the rate for BMI >30. Approximately 4% of 
US males and 6% of females were classified as morbidly obese, while comparable 
figures for England were 1% and 3% respectively.
12
 
 
The report from the UK government‘s Foresight project13 indicated that at current 
trends, it was  projected that 36% of males and 28% females in UK will be obese by 
2015,  47% and 36% respectively by 2025, and alarmingly at 60% and 50% respectively 
by 2050 . By 2021, the proportion of adult males with healthy BMI (<25) was estimated 
to be 13% whereas the overweight and obese adult males would equally share the 
remaining 87% of the population (around 43% each) (Figure1.2.). For women, 
proportions of overweight and obese adults were estimated to reach 70% (35% each) 
(Figure 1.3). 
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Figure 1. 2. Probability of males aged 21–60 belonging to a specific BMI group in 
a given year  
[Dots represent each year data from the Heath Survey of England, curves show 
predicted future proportion to 2050, shaded area represent 95% confidence limits]  
  
Figure 1. 3.  Probability of females aged 21–60 belonging to a specific BMI group 
in a given year  
[Dots represent each year data from the Health Survey of England, curves show 
predicted future proportion to 2050, and shaded area represents 95% confidence limits] 
 
BMI 20-25 
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1.2. Obesity and associated health risk  
Health risks are increased with increasing BMI. A BMI > 30 kg/m
2
 increases the risk of 
co-morbidities and mortality exponentially.
14
  
1.2.1. Mortality 
Obesity is strongly associated with all cause mortality.
15-17
 Adams et al
18
 conducted a   
large prospective study of 520 000 people aged 50 to71 years over a 10 year period.  
The study examined the risk of death in relation to BMI after adjusting for age, race or 
ethnic group, level of education, smoking status, physical activity and alcohol intake. 
Excess weight accounted for approximately 7.7% and 11.7% of all premature deaths in 
men and women respectively. The association was much higher in people who never 
smoked (18.1% for men and 18.7% for women). The risks of death amongst obese 
individuals were two to three folds of that of BMI 23.5 to 24.9 whereas in overweight 
individuals it was 20 to 40% higher. BMI >40 kg/m
2
 was associated with an increased 
risk of sudden death.
19
  
1.2.2. Cardiovascular disease and heart failure 
Obesity is known to exert numerous adverse effects on cardiac function.
20, 21 
It is 
associated with an increased risk of essential hypertension,
22, 23
 stroke,
24
 peripheral 
vascular disease, coronary heart disease,
25, 26
 heart failure
25, 27
 and death.
28-30
  Despite the 
common belief that simple obesity without any cardiovascular risk is a benign condition, 
there is evidence that obesity is an independent risk factor for CVD.
29, 31
 Mortality due 
to CVD is almost 50% higher in obese patients than in those of average weight and is 
90% higher in those with severe obesity.
32
 Obese children have also been documented as 
having high CVD risks.
33, 34
  
 
Heart failure is a clinical syndrome characterised by inadequate systemic perfusion to 
meet the body‘s metabolic demands as a result of impaired cardiac pump action. In 
Chapter 1: Introduction 
8 
systolic heart failure, there is reduced cardiac contractility and hence reduced left 
ventricular ejection fraction, whereas in diastolic heart failure, there is reduced cardiac 
relaxation and abnormal ventricular filling. In 1928, the New York Heart Association 
(NYHA) classified heart failure according to clinical severity and prognosis (Table 
1.2).
35
 It is based on the functional capacity of the patients.  
 
Table 1. 2. New York Heart Association (NYHA) classification of heart failure.  
Class I: No limitation is experienced in any activities; there are no symptoms from 
any ordinary activity 
Class II: Mild limitation of activity; patient is comfortable at rest or only mild 
exertion but symptomatic on moderate exertion 
Class III: Marked limitation of any activity; patient is comfortable at rest 
Class IV: Any physical activity brings on discomfort and symptoms occur at rest. 
 
More recently, obesity has been shown to be strongly and independently associated with 
an increased risk of heart failure.
25, 27, 36
 Kenchaiah et al
36
  have studied the relationship 
between BMI and the incidence of heart failure among 5881 participants from the 
Framingham Heart study over 14 years. With each increment of BMI, the risk of heart 
failure rose 5 and 7% in men and women respectively after adjustment for established 
risk factors. Overweight women had a 50% increased risk of heart failure, and obese 
women were twice as likely to develop heart failure compared with normal weight 
individuals. Overweight and obese men had a 20% and 90% increase risk respectively of 
developing heart failure.  
 
The pathophysiology of heart failure in obese individuals is complex. Obesity is a major 
risk factor for developing hypertension, diabetes and left ventricular hypertrophy that in 
turn contribute up to 90% of the risk of developing heart failure.
37
 The structural and 
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haemodynamic alteration, in conjunction with hypertension, coronary heart disease, 
obesity cardiomyopathy, insulin resistance syndrome, increases the risk of heart failure 
in obesity.  
 
Effects on ventricular function and haemodynamic changes 
Obesity produces a variety of structural and haemodynamic changes to the myocardium. 
In early obesity, excess body weight increases metabolic demand and the subsequent 
expansion in total intravascular volume
38
 results in an increase in cardiopulmonary 
volume or pre-load. Therefore, the cardiac workload is greater at any given level of 
activity in obese subjects. Increased stroke volume is a major attributable factor for the 
higher cardiac output seen in these individuals. Because of the high right ventricular 
filling pressure and volume, the Starling curve is shifted to the left (Figure 1.4). Over 
time, this may result in dilatation of the ventricular chamber therefore predisposing to 
increased myocardial mass and development of eccentric left ventricular hypertrophy 
(LVH).
39, 40
 A long history of obesity, with an increase in left ventricular mass, is 
associated with both systolic and diastolic dysfunction leading to a propensity
 
for more 
complex ventricular dysrhythmias. These early abnormalities as well as impairment in 
both
 
diastolic and systolic ventricular function, can be reversed following marked,
 
purposeful weight reduction.
41 
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Figure 1. 4. Frank Starling curves 
 
 
 
 
 
 
 
 
 
 
Cardiomyopathy of Obesity  
 The development of obesity related cardiomyopathy has been recognised since 1818 
when Cheyne described a historic case in which he observed a fatty heart as well as 
Cheyne-Stokes respiration in an obese patient.
42
 Autopsy revealed an increased heart 
weight and left and right ventricular hypertrophy in proportional to the degree of 
obesity.
43
 The pathognomonic histological feature of obesity related cardiac pathology is 
diffused myocyte hypertrophy.
44
  Fatty infiltration of the myocardium and excessive 
epicardial fat deposition are also closely associated with the duration of obesity.
45, 46
 It 
was observed that the initial fatty deposit is most likely due to metaplasia rather than 
infiltration.
47
 This may represent an adaptive response to the environment by 
substituting sensitive cells with more resistant ones to enduring stress. The intracellular 
accumulation of fat in between muscle fibres results in myocyte degeneration leading to 
cardiac conduction defects.
48
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In addition to those structural and histological changes, severe obesity has been found to 
be associated with idiopathic dilated cardiomyopathy. Kasper et al
49
 compared patients 
with a diagnosis of congestive cardiac failure (49 patients with marked obesity defined 
by BMI >35 kg/m
2
 and 409 lean) where idiopathic dilated cardiomyopathy was 
diagnosed as the cause of heart failure in 77% obese individuals compared with <35% 
of lean subject (p<0.001). In a reported case series, dilated cardiomyopathy was the 
most common cause of death in 22 severely obese individuals (average weight 175kg) 
due to sudden cardiac death.
50
 Fatal arrhythmia was a frequently cause of death in these 
individuals.
51
 The mechanism of obesity cardiomyopathy is multifactorial.
52
 The most 
important mechanisms are metabolic disturbances (section 1.2.3), activation of the renin 
angiotensin aldosterone system, sympathetic nervous systems, haemodynamic changes 
and geometric remodelling and endothelial dysfunction.
43
  
Coronary heart disease (CHD) 
Obesity and being overweight have long been known as risk factors for the development 
of CHD. Anderson et al reviewed 11 studies to investigate the relationship of body 
weight and CHD risk.
53
 The relative risks of developing CHD were 2.72 and 2.8 times 
higher in obese women and men respectively compared to non-obese subjects. Obesity 
is the major contributor to dyslipidaemia, hypertension, diabetes that are in turn major 
risk factors for developing CHD.  
 
Obesity, particularly visceral adiposity, is strongly associated with a typical 
dyslipidaemic pattern: elevated low-density lipoprotein cholesterol (LDL-C) and 
triglyceride (TG) and reduced high-density lipoprotein cholesterol (HDL) level
54
 (see 
detail on section 1.2.3). An elevated total cholesterol level is an established as risk 
factor for CHD.
55, 56
 There is increasing evidence to suggest that CHD is a manifestation 
of a chronic inflammatory response
 
to injury or infection. The normal endothelium can 
be disrupted by either infection or injury leading to the formation of fatty streaks or 
early atherosclerosis.
57
 The early signs of atherosclerosis are deposition of cholesterol 
ester in monocyte–derived macrophage foam cells in the intima of large muscular 
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arteries.
58, 59
 This process begins in early life (5-10 years old). With time, the 
atherosclerotic lesion becomes more complex. Activated foam cells release 
chemoattractant molecules, cytokines, and growth factors.
 
This attracts more 
lymphocytes to the lesion, and in turn, add
 
to the pool of effector molecules that expand 
and perpetuate
 
the inflammatory response.
57
 As this cycle is repeated, the plaque
 
develops a fatty core covered by a fibrous matrix that stabilizes
 
the structure.
57
  There is 
emerging evidence that 70% of
 
all fatal acute myocardial infarctions and sudden 
coronary deaths
 
are attributable to plaque rupture
60, 61
 or plaque erosion.
62
  
 
In addition to dyslipidaemia, obesity also increases the risk of developing hypertension.  
In patients with hypertension, the concentration of angiotensin II, the principle product 
of the renin angiotensin aldosterone system, is often elevated. Angiotensin II not only is 
a potent vasoconstrictor but also stimulates the growth of vascular smooth muscles and 
hence contributing to atherogenesis.
63
 Angitensin II, by binding to the specific receptor 
of smooth muscle, activates phospholipase C resulting in intracellular calcium 
accumulation and hence increases smooth muscle contraction, protein synthesis and 
smooth muscle hypertrophy.
64
 Together with dyslipidaemia, angiotensin II has 
synergistic effects generating reactive oxygen species (ROS) in the vessel wall.
65
 
Angiotensin II increases smooth-muscle lipoxygenase activity, and subsequently 
increases inflammation and the oxidation of LDL.  
 
Lowering
 
cholesterol levels, particularly LDL-C, has been the focus of preventing CHD 
and its sequealae
 
for almost 25 years.
66
 Evidence
 
suggests that lipid-lowering  therapy 
reduces inflammation,
 
which may reduce the risk of cardiovascular events, even for
 
individuals with normal LDL-C levels (<130 mg/dL or 3.4mmol/l)
 
based on the 
National Cholesterol Education Program (NCEP) Adult
 
Treatment Panel III (ATP III) 
guidelines.
67
 More recently Ridker et al
68
 has studied a 17802 healthy individuals with 
normal LDL-C (< 130mg/dL or 3.4 mmol/l) but elevated high-sensitive C-reactive 
protein (hsCRP), a marker of inflammation, randomly assigned to rosuvastatin or 
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placebo. They have demonstrated that in rosuvastatin treated group, there were 
significant reduction in incidence of major cardiovascular events including myocardial 
infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke 
(hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization 
or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 
for the combined end point of myocardial infarction, stroke, or death from 
cardiovascular causes.   
 
Hypertension 
Hypertension is 6 times more frequent in obese subjects than lean individuals.
69
 60% of 
obese individuals suffer from hypertension.
45
 Weight gain in young individuals is a 
significant risk factor for subsequent development of hypertension. Every10kg of excess 
body weight is associated with a 3/2.2 mmHg rise in systolic and diastolic blood 
pressure respectively.
70
 This implies an estimated 12% increased risk of CHD and 24% 
increase risk of stroke.
71
  Weight loss in obese and overweight patients has showed to be 
an effective measure to reduce blood pressure. Neter et al
72
 conducted a meta analysis of 
24 randomised controlled trials wherein a 5kg weight loss resulted in a 4.4/3.6 mmHg 
reduction in  blood pressure.  
Arrhythmia 
Obesity confers an increased risk of arrhythmias and sudden cardiac death, even in the 
absence of cardiac dysfunction. In the Framingham study, obese men and women had 
increased mortality due to unexplained sudden cardiac arrest. This was estimated to be 
40 times higher in obese than non obese individuals.
73
 QTc interval prolongation is 
observed in relatively higher percentage in obese subjects and the association is more 
pronounced in severely obese individuals (about 8% had QTc of >0.44 seconds and 2% 
with QTc of >0.46 seconds).
74
 The clinical significance of obesity-associated prolonged 
QT interval remains unclear. Elevated levels of circulating free fatty acid in obese 
individuals may affect the cardiac repolarisation partly due to higher plasma 
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catecholamines.
75
 Hyperglycaemia may reduce nitric oxide (NO) availability leading to 
increased vasomotor tone and ventricular instability.
76
 In addition, as previously stated 
dilated cardiomyopathy is often seen in morbidly obese subjects and fatal arrhythmias is 
the frequent cause of death.
51
  
Stroke 
Obesity is a potential modifiable risk factor for stroke since it increases the risk of 
diabetes, dyslipidaemia and hypertension. In a recent cohort of 21 414 men, obese men 
were shown to have a significantly higher multiple adjusted relative risk of developing 
stroke. (2.00 for stroke, 1.95 for ischaemic stroke, and 2.25 for haemorrhagic stroke).
77
 
 
1.2.3. Metabolic syndrome and diabetes 
Metabolic syndrome is defined as the constellation of metabolic risk factors including 
central obesity, atherogenic dyslipidaemia, hypertension and insulin resistance (impaired 
glucose tolerance, impaired fasting glucose, type 2 diabetes and hyperinsulinaemia). The 
cluster of obesity, dyslipidaemia, hypertension and diabetes has been noted since mid 
1960s.
78
 The link between this cluster and the insulin resistance was first described by 
Professor Reaven at Stanford in his Banting lecture in 1988.
79
  He called this entity 
―Syndrome X‖, later to be termed metabolic syndrome. 80-82 The World Heath 
Organization,
83
 European Group for study of insulin resistance (ERIG) and NCEP/ATP 
III
54
  have since separately developed different criteria to define the metabolic 
syndrome. More recently, the International Diabetes Federation has developed a new 
consensus statement for criteria of metabolic syndrome (Table1.3).
80
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Table 1. 3. Definition of metabolic syndrome (The International Diabetes 
Federation) 
Central obesity Waist circumference—ethnicity specific 
plus any two of the following: 
Raised triglycerides ≥ 1.7 mmol/l or specific treatment for this lipid 
abnormality 
Reduced HDL cholesterol  1.03 mmol/l in males 
< 1.29 mmol/l  in females 
or specific treatment for this lipid abnormality 
Raised blood pressure Systolic: ≥ 130 mmHg or 
Diastolic: ≥ 85 mmHg or  
treatment of previously diagnosed hypertension 
Raised fasting plasma glucose 
 
 ≥ Fasting plasma glucose ≥ 5.6 mmol/l or 
previously diagnosed Type 2 diabetes.  
If > 5.6 mmol/l, oral glucose tolerance test is 
strongly recommended but is not necessary to 
define presence of the syndrome 
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Central obesity is the key component of the new definition of metabolic syndrome and 
most easily measured by waist circumference with cut-points that are gender and ethnic-
group specific (Table 1.4). 
Table 1. 4. Country/ethnic-specific values for waist circumference 
Country/ethnic group 
 
Waist circumference (as measure of 
central obesity) 
Europids Male ≥ 94 cm,  Female ≥ 80 cm 
South Asians  Male ≥ 90 cm,  Female ≥ 80 cm 
Chinese  Male ≥ 90 cm,  Female ≥ 80 cm 
Japanese Male ≥ 90 cm,  Female ≥ 80 cm 
Ethnic South and Central Americans Use South Asian recommendations 
Sub-Saharan Africans Use European data  
Eastern Mediterranean and Middle East Use European data  
 
The pathogenesis of metabolic syndrome is complex and has yet to be fully evaluated. 
However, it is thought that central obesity and insulin resistance are the key culprits in 
the development of metabolic syndrome leading toward to a  prothrombotic and 
proinflammatory state.
80-82
  
 
Obesity is a critical determinant of dyslipidaemia, operating through a number of 
metabolic influences that include reduced insulin sensitivity and changes in fatty acid 
metabolism. Variations in the nature and magnitude of the dyslipidaemia are due to the 
interaction of genetic factors with environmental influences, most notably diet and 
physical activity, and possibly stress.
84
 Previously, adipocytes were considered to be 
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little more than inert storage depots, storing fat as triglyceride in the fed state, and 
releasing fuel as fatty acids and glycerol in times of fasting. It is now clear that 
adipocytes are dynamic endocrine glands as well as an active metabolic cells that secrete 
important hormones, cytokines and vasoactive substances; tumour necrosis factor alpha 
(TNFα), leptin, plasminogen activator inhibitor-1 (PAI-1), interleukin-6 (IL-6), resistin, 
and angiotensinogen.
85
  These exert marked influences on metabolic function and 
cardiovascular risk in a number of organ systems throughout the body. PAI-1 being an 
endogenous inhibitor of tissue plasminogen activator (tPA),  increases the risk of 
intravascular thrombus formation and plays a key role in promoting thrombosis in a 
ruptured coronary plaque.
86
 IL-6 and TNFα are inflammatory mediators. Intravascular 
inflammation is a key event in atherogenesis. IL-6 stimulates the production of C-
reactive protein (CRP) from the liver.  CRP is an important marker of vascular 
inflammation and predictor of atherogenesis.
87
 Angiotensinogen is a precursor of 
angiotensin II, a potent vasoconstrictor, and activates the renin angiotensin aldosterone 
system. In 1998, leptin was shown to enhance cellular immune responses,
88
 as well as 
increase blood pressure.
89
 Leptin decreases insulin sensitivity when given to obese rats. 
Adiponectin is distinct from other adipokines in that it improves insulin sensitivity and 
inhibits vascular inflammation.
90
   
 
Obesity is the most powerful environmental risk factor for type 2 diabetes. A strong 
positive correlation between obesity and the relative risk of diabetes has been 
established in both men
91
  and women.
92
 Men with a BMI of ≥ 35 kg/m2 have a 
multivariate relative risk of 42.1 compared with men with a BMI < 23.0 kg/m
2
. The age 
adjusted relative risk is greater in women, with a nearly 100-fold increase in the risk of 
developing diabetes if BMI is ≥35 kg/m2 compared those  with BMI is <22 kg/m2. The 
risk of developing diabetes can be minimised by having a lean body weight on entering 
adulthood and avoiding even modest weight gain throughout life. 
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1.2.4. Non alcoholic fatty liver disease (NAFLD) 
Non alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of liver 
damage, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), 
advanced fibrosis, and cirrhosis.
93
 Obesity and insulin resistance are strongly linked to 
NAFLD.
94, 95
 In an autopsy series of 351 patients, 70% of obese patients had hepatic 
steatosis and the degree of steatosis was proportional to the degree of obesity.
96
 In a 
study of 100 morbidly obese patients who underwent Roux-en-Y gastric bypass surgery, 
98% of the patients were found to have histological changes in the liver ranging from 
mild fatty infiltration to severe cirrhosis.
97
 Insulin resistance is a major contributing 
factor to the development of NAFLD in obese subjects.
94, 95
 It has recently been 
suggested that visceral adiposity and insulin resistance promote the hepatic influx of free 
fatty acid resulting in increased triglyceride synthesis and decrease hepatic triglyceride 
export leading to hepatic steatosis. A small proportion of these patients developed 
NASH.  
1.2.5. Other Co-morbidities  
There has been growing evidence that the adverse outcome of obesity is not limited to 
CVD but affect on various health issues.
98, 99
 
 Malignancy 
Mortality from cancer among non-smoking obese people is elevated by around 40% 
compared to non-obese people.
100
 Compared to  women with normal weight, obese 
women have higher mortality rate from certain malignancies including endometrium, 
cervix, ovary, gallbladder and breast (post menopausally).
101
 Obese individuals with 
BMI >35kg/m
2
 have increased mortality from colonic cancer.
102
  
 Mechanical complication 
Obesity is associated with many less serious but debilitating conditions such as 
shortness of breath, back pain,
103-106
  reduced mobility and poor quality of life, as well as 
an increased psychological and social burden.  
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 Endocrine or other metabolic abnormalities. 
Obesity is frequently associated with hyperandrogenism in women because 
hyperinsulinaemia causes increased ovarian androgen secretion. This may result in 
hirsutism, anovulatory cycles, and decreased fertility. 
 Sleep apnoea107-109 
Obesity also is an underlying cause of sleep apnoea, 50 to 75% of those patients are 
obese. Sleep apnoea is associated with traffic accidents, cardiovascular disease and 
stroke. It also associated with raised pulmonary arterial pressure and pulmonary 
hypertension (in 25% of patients). 
 
1.3. Prognostic indicators of cardiovascular mortality in heart failure 
There are established various echocardiographic measurements, physiological 
parameters and biomarkers being used as prognostic indicators for cardiovascular 
mortality.
110
  
 
1.3.1. Left ventricular ejection fraction 
Left ventricular ejection fraction (LVEF) is recommended by the American Heart 
Association as routine assessment of patients with heart failure to guide therapy. It can 
be measured by two-dimensional echocardiography, equilibrium radionuclide 
angiography, left ventricular contrast angiography or more recently with cardiac MRI.
111
  
LVEF is a well established prognostic indicator of prognosis in heart failure patients.
112, 
113
 Curtis et al
111
 studied  7788 patients with heart failure with a median follow up of 37 
months. In patients with LVEF ≤ 45%, all cause mortality decreased in a near linear 
fashion across successively higher LVEF groups (LVEF < 15% at 51.7%; LVEF 36% to 
45% at 25.6%; p < 0.0001).   
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1.3.2. Peak oxygen uptake and anaerobic threshold  
Measurement of oxygen uptake (VO2)  in patients with chronic heart failure was first 
described by Weber et al
114
 as a non invasive method for characterising cardiac reserve 
and cardiac functional status in these patients. Both peak VO2 and aerobic threshold 
(AT) measurement during cardiopulmonary exercise testing has proved to be an 
objective, reproducible, safe, and non-invasive method for characterizing cardiac 
reserve.
115
 VO2 can be influenced by the O2 carrying capacity of the blood (available 
haemoglobin and the arterial O2 saturation, dissociation shift curve with temperature and 
carbon dioxide), cardiac function, peripheral blood flow and tissue perfusion.
116
 VO2 
increases linearly during incremental exercise until it is limited by one or more of the 
determinants (stroke volume, heart rate or tissue extraction) and VO2 versus work rate 
then may begin to plateau. VO2 at plateau is called maximum VO2 (VO2 max). However, 
a clear plateau can be difficult to achieve because of the symptom limitation of exercise. 
Therefore, peak exercise oxygen consumption measured during maximal exercise 
testing (pVO2) is more frequently used as an estimate of VO2 max. Decreased peak VO2 
or aerobic capacity is associated with increased cardiovascular disease and all-cause 
mortality.
117, 118
 Peak VO2 is a strong predictor of mortality and is commonly used in the 
evaluation of patients to determine the severity of heart failure and is an indication for 
cardiac transplantation.
110, 115
 Heart failure patients with peak VO2 >14 ml/kg/min had a 
relatively better prognosis compared to those with a lower peak VO2. The prognosis was 
similar to those who had cardiac transplant (approximately 90% at one year) and cardiac 
transplantation in this particular group would not improve their outcome. Peak VO2 of 
14 ml/kg/min has therefore been widely used as a cut off value for cardiac 
transplantation. 
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1.3.3. Minute ventilation and carbon dioxide output slope 
The relationship between minute ventilation and carbon dioxide output (VE/VCO2) is 
part of the measurement derived during cardiopulmonary exercise testing. During 
exercise, there is a linear relation between ventilation (VE) and the CO2 production.  
The slope of the relation between the two represents the ventilatory response. In patients 
with chronic heart failure, there is greater ventilation for a particular CO2 production 
rate indicated by an increased VE/VCO2 slope (Figure 1.5). This VE/VCO2 slope has 
recently been demonstrated as a prognostic indicator for heart failure.
119, 120
  It has 
consistently shown that a high slope is a significant predictor of mortality
119-121
 and 
hospitalisation
122
 in heart failure patients. 
 
Figure 1. 5. Example of VE/VCO2 slope in normal, mild heart failure and 
moderate heart failure
123
  
 
1.3.4. B- type natriuretic peptide  
B- type natriuretic peptide (BNP) is a cardiac neurohormone with 32 amino acid 
residues secreted from the atria and ventricles. It is released as a proBNP and then 
enzymatically cleaved to N-terminal-proBNP and BNP in response to the ventricular 
wall stretch or dilation, and/or increased cardiac chamber pressures resulting from fluid 
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overload (Figure 1.6). Increased BNP secretion causes vasodilatation, increased sodium 
excretion, and diuresis, thus lowering blood volume and arterial blood pressure. 
Physiological responses to, or associated with, exercise, posture, and diuretics, 
angiotensin converting enzyme inhibitor, adrenergic agonist, sodium intake, thyroid 
hormones and glucocorticoids are linked with increases in circulating BNP.
124
 Levels 
also are increased with age, female gender, and during daytime compared to night. 
 
Plasma BNP level is a sensitive and specific marker of left ventricular dysfunction 
(LVD) with 73% sensitivity and up to 85% specificity for echocardiographic mild 
LVD.
125 
Falls in circulating BNP are associated with increased EF and ventricular 
volumes, and therefore may serve as a useful marker of ventricular remodelling such as 
that seen in progressive heart failure.
126 
In patients with stable chronic heart failure, a 
rise in BNP together with a fall in percent VO2 is a sign of poor prognosis. de Groote et 
al
127 
showed a high BNP level (>109 pg/ml) alone, was a predictor of reduced survival. 
In heart failure patients, each 100 pg/ml increase of BNP was associated with a 35% 
increase in the relative risk of death.
128 
 
The relationship between BNP and obesity has been investigated in several recent 
studies and has confirmed that, similar to the non-obese,  there is an inverse 
relationships between BMI and BNP concentration in subjects with
129
 or without
130
 
heart failure. Das et al
131
confirmed the association inverse correlation between BMI and 
a BNP level, that remained when LBM replaced BMI. The relative importance of the 
increased FFM or LBM in obesity in accounting for low BNP levels is therefore not 
known. 
 
 Investigating plasma BNP levels as a marker of cardiac function in obese patients with 
heart failure and its response to therapeutic weight loss is therefore of theoretical and 
clinical interest. 
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Figure 1. 6. Human BNP , pro-BNP and NT-proBNP 
132
 
 
 
B-type natriuretic peptide (BNP) is produced as pre–prohormone BNP (pro-BNP), 
processed to pro-BNP, and then cleaved by corin to mature, biologically active 32–
amino acid (aa) BNP and non–biologically active N-terminal (NT)-pro-BNP.  
1.3.5. Sympathetic nervous system activation: Plasma norepinephrine 
The catecholamines: Norepinephrine (NE), epinephrine and dopamine; are synthesized 
in the central nervous system, sympathetic nervous system and chromaffin cells of 
adrenal medulla. In 1946, NE was first isolated and identified in the sympathetic 
nervous system by Von Euler
133
 demonstrating  that sympathetic neurons use NE, rather 
than epinephrine, as a neurotransmitter. He later developed sensitive methods for 
measuring tissue norepinephrine.
134
 In 1954, Vogt
135
 demonstrated that NE was present 
in the brain. The biosynthesis pathway of catecholamine was proposed by Blaschko
136
 in 
1939, and it was finally established by Udenfriend and colleagues.
137
  The precursor of 
catecholamine is the amino acid L-tyrosine which is ingested with NE food or 
synthesized in the liver from phenylalanine. All biosynthesis reactions occur within the 
sympathetic nerve terminal apart from the final step that occurs exclusively in the 
adrenal medulla. This step is catalyzed by phenylethanolamine-N-methyltransferase 
(PNMT).  The NE released from the nerve ending either bind to the post-synaptic 
receptor (adrenergic receptor) for its action or reuptake by the pre-synaptic terminal. 
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The adrenergic receptors can be subdivided into α (α1 and α2) and β (β1 and β2) adreno-
receptors. These receptors are coupled by G proteins to the various effector proteins and 
subsequent cascade of reaction giving rise to a series of sympathetic activities.  
1.3.6. Sympathetic nervous system in cardiovascular disease 
In congestive heart failure, sympathetic nervous system activation is one of the 
important pathophysiological mechanisms evidenced by having higher plasma 
concentration of NE.
138
 It was suggested that heart failure patients have an increased 
release of norepinephrine into the plasma and reduced renal clearance from plasma 
(higher cardiorenal spillover of NE) compared with subjects with normal cardiac 
function.
139
 In addition, plasma NE concentration is significantly and independently 
correlated with mortality in congestive heart failure. In a study by Cohn et al,
140
 plasma 
NE level below 600 pg/ml were uniformly associated with better than average survival 
and values above this level were associated with poorer prognosis.  
 
It has been recognised that there is a significant relationship between autonomic nervous 
system activity and cardiovascular mortality, including sudden cardiac death in both 
ischaemic cardiomyopathy
141
 and chronic heart failure.
142 
Experimental evidence has 
shown an association between a propensity of lethal arrhythmias and signs of either 
increased sympathetic activity or reduced vagal activity.
143  
Heart rate variability (HRV) 
is a commonly used method of accessing autonomic function (See detail in Chapter 2). 
Bilchick et al
141
 has demonstrated that in a group of patients with congestive cardiac 
failure, low HRV by the measure of standard deviation of normal- normal interval 
(SDNN) of <65.3 ms was the useful predictor of sudden cardiac death and survival. 
Similar findings were also found in patients with a history of myocardial infaction.
144
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1.4. Weight loss in obese patients with heart failure 
Weight loss has been recognized as a key factor in the control and prevention of 
coronary heart disease, hypertension, type 2 diabetes, dyslipidaemia, cardiorespiratory 
failure and other chronic degenerative diseases in obese patients. 
As previously stated, an increased BMI is associated with increased risk of heart failure. 
Paradoxically, several studies have showed that obese patients with heart failure seem to 
have a more favourable clinical prognosis than non-obese counterparts.  Lavie et al
145
  
investigated 209 ambulatory patients with chronic heart failure retrospectively looking 
at their body composition by means of weight and skin fold thickness in relation to 
clinical events (cardiovascular death or urgent transplantation). Patients in the higher 
quartile for BMI had greater event-free survival. Every 1% absolute increase in percent 
body fat was associated with a >13% reduction in major events. However, as the 
authors‘ concluded, the study did not answer whether this was causal or merely a 
speculative association.  These findings were in line with a more recent study by 
Kenchaiah et al.
146
 They studied 1831 patients with heart failure over with a median 
follow-up of 37.7 months. In patients with a BMI <35kg/m
2
, a decrease in 1 BMI unit 
was associated with   a 3.3 % increased in all cause mortality adjusted to age and sex. 
Lower BMI patients had much higher graded risk of fully adjusted all caused mortality 
in comparison with those with a BMI between 30-35 kg/m
2
. It was estimated 22.3%, 
44.7% and 69.7% increased risk in BMI group of 25-29.9, 22.5-24.9 and <22.5 kg/m
2
 
respectively. Kenchaiah et al
27
 reviewed 10 studies on the impact of obesity on survival 
after the onset of heart failure. Most studies suggested an increase in BMI recorded at 
the time of studies on heart failure was associated with a decline in mortality. However, 
most of these studies were conducted in patients with advanced heart failure where 
cardiac cachexia may have contributed to involuntary weight loss, and excess mortality. 
Anker et al 
147
 showed that the cachectic state in heart failure patients is an independent 
predictor of mortality (50% at 18 months).
147
 Gustafsson et al
148
 retrospectively studied 
4700 hospitalised patients with heart failure. In this study, the survival rate was also 
higher in the obese group compared with the low BMI group, whereas survival rate of 
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patients with LV systolic dysfunction followed a U-shaped curve with the lowest rate of 
death in normal weight patients. 
 
In most studies, the duration of heart failure was not taken into account. This may be a 
critical factor because patients with a longer duration of heart failure have a lower 
likelihood of survival. The mortality of heart failure is approximately 45% and 60% at 1 
and 5 years respectively after diagnosis.
149, 150
 More recent statistic
151
 from American 
Heart Association highlighted that based on 44 years follow up of Framingham heart 
study, 80% men and 70% of women with heart failure and aged <65 years died within 8 
years. Finally, most studies only assessed BMI, which may be an inaccurate indicator of 
total body fat because of fluid retention. One study has looked at the percentage body fat 
in term of skin fold thickness
152
 but this methodology did not give information on the 
distribution of the fat. No detailed studies of body composition and body fat distribution 
in heart failure have been carried out.  
 
To date there has not been a study of cardiac function pre and post therapeutic weight 
loss intervention in obese heart failure patients, there has been an isolated case report in 
which heart failure was reversed in a case a morbidly obese patient following dietary 
intervention.
153
 
 
1.5. Weight loss intervention  
1.5.1. Low and very low calorie liquid diet 
Very low calorie liquid diets (VLCD) are formulated foods with an energy content of 
between approximately 450 and 800 kilocalories daily. These foods are intended for use, 
as presented, except for the addition of water where applicable, as the sole dietary 
source of energy and all essential nutrients required in excess weight loss programmes. 
Over the years the definitions of VLCD and low calorie liquid diet (LCD) have changed 
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with regard to the energy restriction level. In the early days more emphasis was given on 
the very-low calorie level with values of 250 kcal/d or less. With the introduction of the 
international CODEX standardization and legislation by the U.S. Food and Drug 
Administration and the European Union on this type of food restriction,
154
 VLCDs are 
now defined as total diet replacements with <800 kcal and >400 to 450 kcal/d. Diets 
consisting of between 800 and 1200 kcal/d are classified as LCDs, whereas meal 
replacements are limited to 200 to 400 kcal. These types of definitions and regulations 
using fixed energy levels for all users ignore individual differences in body size and thus 
energy requirements. Therefore, the use of VLCDs and LCDs results in significantly 
different weight loss for different groups, for instance, between men and women.   
 
The Codex Alimentarius Commission has developed a standard for formula foods for 
use in VLCD for weight deduction. CODEX was created in 1963 by Food and 
Agriculture Organization and World Health Organisation to develop food standards, 
guidelines and related texts such as codes of practice under the Joint FAO/WHO Food 
Standards Programme. Accordingly, the products used in VLCD should comply with the 
following composition and quality factors.
154
 CODEX also defines that the content of 
the diet should be not less than 50 g of protein, 50 g of carbohydrate, 3 g of linoleic acid 
as fat and vitamins and minerals supplement.
154
 
 
Patients may experience polyuria in first few weeks of VLCD/LCD because of loss of 
fluid and glycogen.
155
 This effect is enhanced by a reduction in plasma insulin levels 
causing less sodium retention; increasing levels of natriuretic hormones and glucagon; 
increasing ketonuria causing extra sodium and potassium loss together with water. There 
are a number of minor side effects also reported with VLCD/LCD. Dry mouth, 
constipation, headache, dizziness/orthostatic hypotension, fatigue, cold intolerance, dry 
skin, menstrual irregularities and hair loss are common side effects during therapy. 
Occasionally, cholelithiasis has been reported although it is more frequently in United 
State compared to Europe. A certain amount of fat is required to stimulate gall bladder 
contraction and subsequent emptying of bile preventing stone formation. In Europe, it is 
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requirement that higher fatty acid of 7g or more per day is included in VLCD and this 
probably explains the difference in incidence. The National Institute of Health has 
therefore recommended consuming an extra 10g of fat.
156
 Fatal dysrrhythmias were 
reported in 1970s when there was imbalance use of VLCD.
157, 158
  Extensive evaluation 
of modern VLCD/LCD did not show increased risk of cardiac arrhythmia nor prolonged 
QT interval.
159
 
 
VLCD/LCDs are used to promote short-term weight loss in obese patients. However, 
long-term maintenance of weight loss is generally poor. Anderson, J.W et al
160
 followed 
up a group of patients who achieved an average 29.7kg weight loss induced by VLCD 
over 5 months.  Subjects regained an average of 2.5% per month of their lost weight 
during the first two to three years of follow-up. An average of 73.4% of their weight loss 
was regained during the first three years. When successful weight maintenance was 
defined as maintaining a weight loss of 5% or 10% of initial (pre-treatment) body 
weight, 40% were maintaining a 5% weight loss at five years and 25% were maintaining 
a weight loss of 10% at 7 years. 
 
Gilden and Wadden
161
 conducted a meta-analysis of six randomised control trials 
comparing VLCD and LCD. In the short term, participants in the VLCD programme 
achieved better weight loss compared with LCD with the mean weight loss of 
16.1±1.6%  Vs 9.7 ±2.4% respectively (p <0.001). At follow up (mean =1.9± 1.6 years) 
assessment, the difference between these two groups were small (mean weight loss of 
6.3 ± 3.2% in VLCD and 5 ± 4% and LCD) and not significant (p> 0.2). As regards to 
weight related co-morbidities, there was no difference in HbA1C, lipid profile or systolic 
blood pressure. Changes in the cardiovascular risk factors were not measured. Side 
effects encounter included mild reversible alopecia, precipitation of gouty arthritis, 
transient cold intolerance and constipation were common in VLCD group. The duration 
of each therapy was not associated with the degree of weight loss. 
 
Weight loss induced by LCD has some effects on the sympathetic nervous system. 
Sowers et al
162
 demonstrated following VLCD, there was reduction in both blood 
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pressure (BP) and NE level at supine and upright. A significant correlation in reduction 
in NE level and BP was also observed. The authors concluded that the reduction in BP 
in obese patients on diet with VLCD seems to result in at least in part from reduced SNS 
activity. 
 
Pharmacotherapy following VLCD provides better long term weight maintenance 
compared with placebo. Finer et al
163
 conducted a randomised controlled study where 8 
weeks of VLCD was followed by either dexfenfluramine 15mg bd or placebo for 26 
weeks.  With dexfenfluramine therapy, patients achieved a further 5.8± 1.8 kg weight 
loss in contrast to placebo group who regained 2.9 ±1.3 kg. The total weight loss after 
34 weeks was 21.3±2.6 versus 11.3±1.9 kg. Anderson et al also demonstrated similar 
findings.
163, 164
 Dexfenfluramine was however removed from the market in 1997 
because of its association with valvulopathy.
165
 Similarly, Apfelbaum et al
166
 showed 
that, after  initial 4 weeks of a VLCD, during which patients lost 7.6 kg, those 
randomized to 1 year of treatment with sibutramine achieved a cumulative loss of 12.8 
kg at the end of this time, compared with a loss of 7.1 kg for placebo-treated individuals 
(p=0.004). Mathus-Vliegen
167
 prescribed a VLCD for 3 months, which induced an 
initial weight loss of 15.2 kg. Participants were then randomly assigned to sibutramine 
(10 mg/d) or placebo for an additional 15 months. At month 18, patients in the 
sibutramine group maintained a loss of 10.7 kg, compared with 8.5 kg for those 
prescribed placebo (p = 0.008). Thus, sibutramine slowed but did not prevent weight 
regain after a 15-kg loss. 
1.5.2. Anti-obesity drugs 
Pharmacotherapy for obesity and diabetes has been well advanced recently. Newer 
therapies have been developed targeting on different receptors as described in (Figure 
1.7). Some of these drug groups are at an early phase of drug development. At the time 
this study took place, three drugs were available and licensed: orlistat, sibutramine and 
rimonabant. However, subsequently sibutramine and rimonabant were withdrawn. 
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Figure 1.7. Drug targets for anti-obesity and anti-diabetes therapy 
CCK = cholecystokinin, PYY= peptide YY, GLP-1 = Glucagon like peptide-1, DDPIV 
inhibitor = dipeptidyl peptidase-4 inhibitor, CARD= cocaine and amphetamine 
regulated transcript, NPY=  neuropeptide Y, SGLT2 inhibitor =Sodium Glucose 
Cotransporter Inhibitors. (Figure was provided by the courtesy of Dr N Finer). 
 
 
 
Orlistat is a potent, specific long acting gastrointestinal lipase inhibitor.  It forms a 
covalent bond with the serine site of the gastric and pancreatic lipase. It prevents 
hydrolysis of dietary triglyceride into absorbable free fatty acid and monoglyceride and 
therefore limits absorption of these into the circulation.
168
 It is indicated in conjunction 
with calorie restriction in obese patients with BMI ≥30kg/m2 or overweight patients 
(BMI ≥28kg/m2) with associated risk factors (hypertension, diabetes and 
hypercholesterolaemia). The 4 year XENDOS (Xenicle prevention of diabetes in obese 
subjects) clinical trial
169
 demonstrated that 60% patients on orlistat and 35% patients on 
placebo lost > 5% of initial body weight at the end of 12 weeks. Of those, 63% and 52% 
of orlistat and placebo group respectively continued to lose >10% at the end of one year. 
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Rimonabant was a cannabinoid receptor 1 (CB1 receptor) antagonist. CB1 receptors have 
been shown to play an important role in food intake, energy balance and are directly 
implicated in lipid and glucose metabolism. CB1 receptors are located centrally in the 
hypothalamus
170
 and mesolimbic
171
 region in the brain, and peripherally in adipose 
tissue, liver, skeletal muscle and the gastro-intestinal tract. In the brain, the 
hypothalamus plays a principal role in the control of feeding and regulation of body 
weight, and CB1 receptor stimulation leads to dopamine release in the nucleus 
accumbens shell, which increases motivation to eat.
172
 These effects result in increased 
food intake and fat accumulation. Peripherally, endocannabinoid system (ECS) 
overactivation promotes lipogenesis at the level of adipose tissue 
173
 and the liver.
174
 
ECS activity in the GI tract interferes with feelings of satiety, and CB1 receptor 
stimulation of skeletal muscle decreases glucose uptake. All of these central and 
peripheral effects contribute to the increased risk of dyslipidaemia, insulin resistance, 
glucose intolerance and increased cardiometabolic risk.
172
 Blocking CB1 receptors by 
Rimonanbant, therefore produced weight loss. In the RIO- North America (rimonabant 
in obesity) study, patients on rimonabant 20mg for one year achieved weight losses of 
≥5% and ≥10% in over 62% and 32% of patients respectively, compared with 33% and 
16% respectively, of control subjects on placebos.
175
 
 
However, there were concerns regarding major psychiatric symptoms in patients taking 
Rimonabant. Up to the end of Jan 2008, there was1971 reported reactions from UK. 
44% (876) of those were psychiatric reactions. The most common psychiatric reactions 
were depression and related disorders of mood and associated symptoms. 52 reactions 
involved suicidal and self-harming thoughts or behaviours, most of which were suicidal 
ideations (42 reports). Because of its major side effect of psychiatric symptoms, the 
Medicines and Health-care-products Regulatory Agency (MHRA) alerted health care 
professional in May 2008.
176
 The European Medicines Agency (EMEA) recommended 
the suspension of the marketing authorisation for Rimonabant in October 2008. In 
December 2008, the drug was withdrawn when the marketing authorisation holder 
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(MAH) responsible it (Sanofi-Aventis) notified the European Commission of its 
decision to voluntarily withdraw its marketing authorisation. 
 
Sibutramine was a beta phenethylamine which selectively inhibited the reuptake of 
serotonin and norepinephrine and to a lesser degree, dopamine (Figure 1.8). It produced 
weight loss mainly by enhancing satiety
177
 and to some extent increasing 
thermogenesis.
178, 179
 In a meta analysis of sibutramine studies,
180
 a statistically 
significant beneficial weight loss effect of sibutramine therapy was noted compared to 
placebo (a 4.3 kg with 95% CI: 3.6-4.9 kg versus 4.6% with 95% CI: 3.8-5.4%) greater 
weight loss. In addition, 15% (95% CI: 4-27%) more subjects achieved a 10% or greater 
weight loss with sibutramine than with placebo therapy. 
 
Figure 1. 8. Mechanism of Sibutramine demonstrating the inhibition of 
norepinephrine and serotonin reuptake from nerve endings 
 
Pictures adapted from: 
http://www.drugabuse.gov/pubs/teaching/teaching4/Teaching.html 
 
In Jan 2010, European Medicines Agency (EMA) issue a ―dear health care professional 
letter‖ following a review the data from a large study ―The Sibutramine Cardiovascular 
outcomes (SCOUT) study‖.181  It was a randomised, double-blind, placebo controlled 
study in approximately 10,000 obese and overweight patients with cardiovascular 
disease and/or type 2 diabetes treated over a six year period. The purpose of the study 
Sibutramine 
Sibutramine 
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was to determine the long-term effect of sibutramine treatment on cardiovascular 
outcomes in overweight and obese patients at risk of a cardiovascular event. There was a 
16% increased risk of cardiovascular events (myocardial infarction and stroke) in 
sibutramine treated patient compared with placebo (hazard ratio 1.161 [95% CI 1.029–
1.311]; p=0.016). The Committee noted that the mean weight loss with sibutramine was 
approximately 2-4 kg more than placebo in most trials. It concluded that the risk of the 
medicine outweighed the benefit and therefore recommended the suspension of 
marketing authorisation across Europe. 
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CHAPTER 2: HYPOTHESIS   
2.1. Study hypothesis  
The hypothesis of this study was that weight loss intervention in obese patients with 
heart failure or high CVD risk would improve cardiac performance measured as peak 
VO2 and reduce biomarkers of cardiac risks. 
2.2. Study Objectives 
The primary objective of this study was to investigate the effect of acute weight loss (6 
weeks) and weight loss maintenance (16 weeks) on cardiac reserve in obese patients 
with heart failure or high cardiovascular risk.  
 
The secondary objectives were  
 to describe measures of cardiac function and risks (plasma BNP, resting plasma 
norepinephrine, autonomic activities, cardiac output, left ventricular function and 
antioxidant profile) in obese patients with heart failure and/or high CVD risk.  
 to compare two methodologies of body composition measurement i.e., Four 
compartment model and quantitative MRI. 
2.3. End Points 
The primary end point of the study was peak VO2 following acute weight loss (week 6) 
and weight loss maintenance phase (week16).  
The secondary end points were  
 LVEF, HRV, resting plasma BNP, resting plasma norepinephrine, antioxidant 
profile, ALT, cholesterol, hsCRP, fasting plasma glucose and insulin, 
adiponectin, leptin, TNF-α and IL-6, exploratory analysis relating changing in 
the endpoints to FM and FFM changes. 
 Comparison of FM measured by 4C model Vs quantitative MRI.  
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CHAPTER 3: METHODS 
3.1. Study design 
The original plan of this study was to conduct a randomised controlled study in obese 
patients with heart failure, comparing a weight loss intervention with intensive diet Vs 
non-intervention. A non-intervention group was assumed to be necessary to provide 
information on the background progression or regression of heart failure without weight 
loss and in the impossibility of providing a placebo weight loss diet. Since the study is 
designed to assess the benefit (or harm) of weight loss, it would be ethically appropriate 
for such a non-intervention control group. However, since it seemed unlikely that there 
will be significantly measurable changes in cardiac function in the non-intervention 
group over the study period of 16 weeks, randomisation would be 3:1 intervention/ non-
intervention.   
3.1.1. Sample size calculation 
G*Power 3.1 software (Heinrich-Heinec University, Duesseldorf, Geremy)  was used 
for the power calculations and were based on a study by Kanoupakis et al.
182
 This was a 
study of patients undergoing bariatric surgery with a mean BMI of 52 kg/m
2
, they 
showed a peak VO2 at baseline of 19 ml/kg/min 3.9 (SD) that improved by 40% after a 
64% weight loss. The study was on metabolically healthy more obese individuals who 
lost more weight than our study population. We therefore adjusted our assumptions as 
Table 3.1. Different sample sizes were then examined and plotted against power (Figure 
3.1).  It was calculated that 23 subjects would be needed to detect a 10% improvement 
in peak VO2 after a 10% weight loss at an effect size of 0.655, p value <0.05 and 85% 
power (Table 3.2). To achieve 3:1 intervention Vs non-intervention ratio, the number in 
intervention group was increased to 24 with an additional 8 patients were to be recruited 
as the non-intervention control group.  
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Table 3. 1. Assumptions of our study comparing with Kanoupakis et al for 
sample size calculation  
Parameter Kanoupakis et 
al 
Our 
study 
Baseline weight 139kg  110kg 
Percentage weigh loss 64% 10% 
Peak VO2 at baseline 19% 19% 
Improvement in peak VO2 at the end of 
intervention 
40% 10% 
SD difference 3.9% 2.9%
* 
Power  85% 
 
*SD was estimated at 75% of Kanoupakis study in a view of smaller changes in weight 
and peak VO2. 
Figure 3. 1. X-Y plot for a range of sample size against power  
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Table 3.2. Sample size calculation generated by G*Power 3.1 software 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.6551724 
 α err prob = 0.05 
 Power (1-β err prob) = 0.85 
Output: Noncentrality parameter δ = 3.1420964 
 Critical t = 2.0738731 
 Df = 22 
 Total sample size = 23 
 Actual power = 0.8513855 
 
Randomisation was carried out using the web base tool ―Research Randomizer‖ at 
http://www.randomizer.org. 9 set of 4 unique numbers per set was calculated with the 
range from 1 to 4. Number 1, 2 and 3 were allocated for active weight management and 
number 4 was allocated for control. The randomisation sheet was kept in a research 
folder at the Clinical research facility and study nurse was responsible for identifing the 
code at the end of the screening visit. 
 
A pilot study of 6 subjects was undertaken in advance of the full study to assess 
feasibility and safety. Due to recruitment and other logistical issues, this thesis is based 
upon the pilot study of 6 patients and a further 8 patients from the main study (all of 
whom had the weight loss intervention) of whom 11 completed the trial. 
 
The study was approved by South Cambridgeshire Ethics committees on the 26 April 
2006. (REC ref: 06/Q0108/37) and sponsored by Research and Development 
Department, Cambridge University Hospital NHS Foundation Trust. (R&D ref: 
A090622). 
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3.2. Study population 
Eleven obese patients with heart failure or additional cardiovascular risk were recruited 
for study. Obesity was defined as a BMI of ≥30 kg/m2. 
3.2.1. Inclusion criteria 
Subjects met all inclusion criteria. 
 Obese patients defined at BMI of ≥30 and  50 kg/m2  
 Age ≥25 and  70 years 
 Stable heart failure patients of  NHYA class II or III  OR subjects with one of               
additional cardiovascular risks 
 Hypertension 
 Dyslipidaemia defined by having lipid lowering therapy or HDL<1 mmol/l, LDL 
>3.5 mmol/l or total cholesterol and HDL ratio >5 
 Diabetes or pre-diabetes (impaired fasting glucose level of ≥ 6.1 mmol/l) 
 History of ischaemic heart disease 
The diagnosis of heart failure was based on standard criteria of symptoms of more than 
6 months with confirmed LV impairment on echocardiogram.  
3.2.2. Exclusion criteria 
 Those unable to give informed consent 
 Recent history weight loss (2 kg or 5% weight loss within 3 months) prior to study  
 Patients who had changed their heart failure medication in the previous 6 weeks or 
who were likely to have therapy changes during the study period (16 weeks) 
 Subjects with renal impairment defined by creatinine >170 µmol/l 
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 Obese subjects who were unlikely or unwilling to the adhere to weight loss diet 
 Subjects who are unable to do the cardiopulmonary exercise 
 Peripheral vascular disease of a degree to prohibit undertaking exercise test 
 Recent (within three months) history of acute myocardial infarction or unstable 
angina 
 Uncontrolled arrhythmias causing symptoms or haemodynamic compromise 
(systolic BP <90 mmHg) 
 Any significant valvular heart disease 
 Inadequately controlled hypertension defined by resting blood pressure > 
170/95mmHg 
 Pregnancy (actual or planned) 
3.3. Study Schedule 
3.3.1. Recruitment  
Obese patients with heart failure or additional cardiovascular risk were recruited from 
the cardiology, diabetes, hypertension and obesity clinics at Addenbrooke‘s hospital, 
Cambridge. Recruitment was extended to General practitioners, the community heart 
failure nurse and other cardiology departments at Luton and Dunstable, Bedford and 
West Suffolk Hospitals. With the permission from research and development 
department (R&D) at Addenbrooke‘s Hospital discharge summary database was also 
search for the codes of the obesity (E66) and heart failure (I50) in the diagnosis and or 
co-morbidities for previous one year for all in patient admissions. Echocardiogram 
reports were also reviewed for patients with heart failure through out the study. Detail of 
the recruitment process was illustrated on  Figure 3.2. 
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Figure 3. 2. Recruitment Process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 Potential subjects identified 
   8 -Diabetes Clinic  
   4 -Obesity Clinic  
   4 -Hypertension Clinic  
   5 -Cardiology Clinic 
   2 -General Practitioners  
   2 -Regional cardiology departments  
 24 -Hospital discharge letters 
 23 -Echocardiography reports  
34 Subjects invited to study 
 19 Face to face invitations 
 15 Invitations by letters 
 5 subjects identified from Hospital 
discharge letters died 
 14 subjects of above list were not eligible 
 19 subjects from Echo report list were 
not eligible 
17 Subjects accepted invitation  
 12 from face to face invitation 
   5 from invitation by letter 
2 Subjects failed at screening (1- not able 
to exercise, 1- severe LVEF <15% and 
would not be safe to take part in the 
study)  
 15 subjects recruited for the study 
 6 pilots 
 9 subjects for main study (first 3 
were randomised) 
2 subjects withdrew from study  
 1 - could not tolerate LELD 
 1 – diagnosed with breast cancer 
 
  12 subjects completed the study 
 4 subject from pilot study 
 8 subjects for main study (first 3 
were randomised- 1 control and 
2 LELD group) 
Data from 1 controlled subject was excluded 
from analysis 
 
 
 Complete data was presented on 11 
subjects 
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Subjects were given information leaflets about the study so that they could read and 
discuss them at home prior to giving consent at a later date (>48 hours). Patients then 
attended one screening and 3 main measurement visits (week 0, 6 and 16). In addition, 
they attended 10 interim visits for monitoring and safety assessments. (Figure 3.3) 
Figure 3. 3. Schematic diagram of schedules for each subject  
(LELD = low energy liquid diet, WMD = weight loss maintenance diet, P= pre-
screening (invitation), S= screening visit, M= Measurement visit, I = interim visits) 
 
3.3.2. Screening visit 
A detailed medical history and physical examination was undertaken to assess whether 
subjects were eligible for the study. Subjects fulfilling the entry criteria of the study 
were asked to give informed consent. Blood for biochemistry and antioxidant profile 
was taken. Patients underwent cardiopulmonary exercise testing for peak VO2 in order 
to acclimatise themselves with the equipment and the procedure.  An echocardiogram 
was performed for confirmation of the diagnosis of heart failure as well as exclusion of 
any significant valvular heart disease. Following this visit, patients who still met the 
inclusion criteria were invited to continue in the study. 
 
Chapter 3: Methods  
44 
3.3.3. Measurement Visits (week 0, 6 and 16) and interim visits 
Subjects attended the Clinical Research Facility (CRF) at Addenbrooke‘s Centre of 
Clinical Investigation (ACCI) at 9am on the study day. Subjects stayed overnight (i.e., 
for 36 hours) and all measurements listed were performed during the stay in the 
department.  
3.4. Induction of acute weight loss and weight loss maintenance 
A milk-based low energy liquid diet was provided for induction of acute weight loss. 
The terminology of low energy liquid diet (LELD) was used because it is low in energy 
(800- 1000kcal) and liquid. Both factors are important components of the intervention. 
The regimen is routinely used to achieve rapid weight loss by specialists in weight loss 
management clinics worldwide and also in the Obesity Clinic at Addenbrooke‘s 
Hospital. We prescribed a diet based on semi skimmed milk to provide between 800 
kcals/day for women with BMI <40kg/m
2
 and 1000 calories per day for all men and 
women with a higher BMI. Patients were instructed to consume 2 – 2.5 gram of sodium 
intake in the form of either Bovril or stock cubes. In addition, one to two sachet of  
fybogel ('Ispaghula husk' ) and mineral and vitamin supplements (two Sanatogen gold
®
 
tablets- Bayer plc, Berkshire, UK) were also provided everyday. Each Sanatogen gold
® 
tablet includes Vitamin A 800ug, Vitamin D 5ug, Vitamin E 10mg, Vitamin C 60mg, 
Thiamin 1.4mg, Riboflavin 1.6mg, Niacin 18mg, Vitamin B6 2mg, Folic Acid 200ug, 
Vitamin B12 1ug, Biotin 0.15mg, Pantothenic Acid 6mg, Beta Carotene 400ug, Vitamin 
K 30ug, Calcium 173mg, Phosphorus 144mg, Iron 14mg, Magnesium 120mg, Zinc 
15mg, Iodine 150ug, Copper 2mg, Boron 150ug, Chloride 36.3mg, Chromium 25ug, 
Manganese 2.5mg, Molybdenum 25ug, Nickel 5ug, Potassium 40mg , Selenium 25ug, 
Silicon 2mg mg, Tin 10ug and Vanadium 10ug). This was the sole source of nutrition 
for the first 6 weeks. For those who found ‗simple‘ milk unpalatable, we provided an 
alternative diet using commercially available products (e.g., Slim Fast
®
, Surrey, UK).  
Patients maintained the liquid diet for 6 weeks during which time they were seen 
weekly. After 6 weeks, solid food was reintroduced into their diet, based upon an energy 
intake that would be weight loss maintaining (WLM). The energy value of the WLM 
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diet was calculated to match the daily energy expenditure. It was derived from standard 
equations relating height, weight and age to basal metabolic rate (BMR) and Harris 
Benedict Formula
183
 as follow: 
Equation 2  
For men,  
BMR  = 66.5 + (13.75 x weight in kg) + (5.003 x height in cm) - (6.775 x age) 
For women,  
BMR = 655.1 + (9.563 x weight in kg) + (1.850 x height cm) - (4.676 x age) 
Total Caloric Requirements equal the BMR multiplied by the activity factors. Activity 
factors range from 1.2 to over 2 (Table 3.3). 
 
Table 3. 3. Harris Benedict Formula for activity levels/factors 
Activity level Description of activity Activity Factor: (BMR 
to be multiply by) 
sedentary little or no exercise 1.2 
lightly active light exercise/sports 1-3 
days/week 
1.375 
moderately active moderate exercise/sports 3-5 
days/week 
1.55 
very active hard exercise/sports 6-7 days 
a week 
1.725 
extra active very hard exercise/sports & 
physical job or 2x training 
1.9 
 
In order to allow for incomplete compliance, no adjustment for energy costs of activity 
or exercise were made, so in practice this diet only gave 80% approximately of energy 
needs (based upon a predicted physical activity level of 1.2). Orlistat (Roche Xenical
®, 
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Welwyn Garden City, UK) 120mg tds was used in order to aid weight loss maintenance 
during this second phase.  
3.5. Cardiopulmonary exercise testing 
3.5.1. Introduction 
Cardiopulmonary exercise testing (CPET) is relatively non-invasive, dynamic, 
physiological test that allows the simultaneous study of responses from cardiovascular 
and ventilatory systems to a known exercise stress (both sub-maximal and peak 
exercise) through the measurement of gas exchange at the airway: oxygen uptake (VO2), 
carbon dioxide output (VCO2), and minute ventilation (VE), and the cardiovascular 
measurements: ECG, heart rate, and blood pressure. These cardiovascular 
measurements, importantly, interrelate with the gas exchange measurement. This 
interrelation provides additional information because it relates them to the actual energy 
expended during exercise rather than relying on indirect estimates of energy. VO2 and 
VCO2 reflect oxygen consumption and carbon dioxide production during cellular 
metabolism. Wasserman
184
 described the chain of events in gas exchanges during 
exercise (Figure 3.4). The increase in ventilation during exercise causes recruitment and 
vasodilatation of the pulmonary blood vessels, increase pulmonary blood flow, and 
subsequent increase in cardiac output (stroke volume and heart rate) and the dilatation of 
the selected peripheral vascular bed. This in turn causes a large increase in oxygen 
extraction and utilization by the muscle (QO2), resulting in an increased CO2 production 
(QCO2) which is then transported to the lungs via the systemic and pulmonary 
circulation. Therefore, gas exchange measurements reflect functions of not only 
pulmonary but also cardiac and vascular function. The use of CPET in the management 
of various cardiopulmonary diseases is increasing with the understanding that resting 
pulmonary and cardiac function testing cannot reliably predict exercise performance and 
functional capacity. Furthermore, overall health status correlates better with exercise 
tolerance rather than with resting measurements. It provides relevant information for 
clinical decision making e.g., assessment for heart transplantation.
110
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Figure 3. 4. Wasserman’s Wheels showing gas exchanges during exercise  
 
Resp rate = respiratory rate, Vt= tital volume (volume of air inspired with each breath), VA = alveolar ventilation (total volume of 
fresh air entering the alveoli per minute), VD = physiological dead space, SV =stroke volume, HR = heart rate, QCO2 = cellular carbon 
dioxide output, QO2 = cellular oxygen uptake, CO2 PROD = carbon dioxide production, O2 CONSUM = oxygen consumption. The 
functional interdependence of the physiological parameters was represented by gears. (adapted from reference 
184
) 
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3.5.2. Exercise equipments  
3.5.2.1. MedGraphics UltimaTM Cardio2 system  
 
This is a combined system of Breezesuite Gas Exchange software and PC based ECG 
(Medical Graphics Corporation, Saint Paul, Minnesota.). It provides an integrated 12- 
lead stress ECG combined with breath-by- breath measurement of O2 and CO2 
production in the air. Air flow calibration was performed each day of the CPET and gas 
analyser calibration was performed prior to each test according to manufacturer 
protocol.  
3.5.2.2. The motor-driven treadmill 
It imposes progressively increasing exercise stress through a combination of speed and 
grade (elevation) increases.  
3.5.2.3. Blood pressure machine 
A semi-automated recorder (Quinton STBP-680; Quinton Instruments, Seattle, Wash) 
was used to measure blood pressure non-invasively every two minutes throughout the 
test.  
 
3.5.3. Procedure 
a. The subject was interviewed again to make sure there was no contraindication 
for CPET.  
b. The detail procedure was explained with an emphasis to report any chest pain, 
breathlessness, dizziness, fainting or should they feel they needed to stop 
immediately. An Emergency stop button was provided should he/she needed to 
stop immediately.  
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c. At least two staff (myself and one staff nurse/ technician) were present 
throughout the study. 
d. A 12-lead ECG, blood pressure and oxygen saturation monitoring equipments 
were attached to the patient and baseline measurements were performed. ECG 
and oxygen saturation were recorded continuously throughout the study. Blood 
pressure was recorded every two minutes.  
e. The appropriate preVent mask (Medical Graphics Corporation, Saint Paul, 
Minnesota.) was chosen and fitted according to the instruction to make sure there 
was no air leak (Figure 3.5) and it was then attached to the pneumotach which is 
connected to the gas analyser. 
f. CPET started according to the Naughton protocol185 ( Figure 3.6). Patients were 
encouraged to exercise to maximum effort guided by perceived effort of exertion 
according to Borg‘s scale (Table 3.5) and anaerobic threshold (Figure 3.7). 
g. The aim was to achieve Borg‘s scale of 17.  
h. Exercise was discontinued if the patients expressed any symptom of chest pain 
or distress or met any of the termination criteria (Table 3.4). 
3.5.4. preVent Mask Selection and Fitting Instructions: 
Correct selection and fitting of the mask was done to ensure a leak-free fit for both 
exercise and metabolism assessment (Figure 3.5). A proper fit was performed as 
follows: 
a. The narrow strap (upper) was positioned on the back, near the ―crown‖ of the 
head and the wide strap (lower) was positioned across the back of the neck. 
b. The top of the mask with the shapeable aluminium strap was pulled up to the top 
(bridge) of the nose and formed to fit securely around the nose. 
c. The bottom of the mask was pulled securely under the chin so that the material 
between the nose and chin was slightly stretched. The mask wrapped under the 
chin about 2.5cm. 
d. The sensor coupler was located comfortably in front of the mouth.  
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Figure 3. 5.  photograph showing fitting instructions of preVent Mask 
 
3.5.5. Naughton Exercise Protocol  
The modified Naughton protocol (Figure 3.6) starts at a lower metabolic equivalence 
(MET) than full Bruce protocol. Workload increased by 1-MET per stage, thus allowing 
better-tolerated gradual progression in exercise and a more accurate assessment of 
exertional capacity. There are seven stages with each stage lasting two minutes. During 
the first stage of exercise, the treadmill speed was set to 1mph and 0% grade. For stage 2 
(minute three to four), the speed was increased to 2.0 mph while the grade remained at 
0%. From stage 3 onward (minutes 5), the speed was maintained at 2.0 mph, and the 
grade was increased 3.5% every two min until it reached the stage 7 (minute 12) and 
then no more increase in exercise work load but continue the test to patient‘s maximum 
effort. A set of strict criteria for the termination of exercise was followed (Table 3.4).
116
 
Patients were encouraged to exercise to their maximal effort. It was guided by Borg‘s 
scale of perceived exertion (Table 3.5). 
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Figure 3. 6. Schematic diagram of Naughton Exercise protocol  
 
Table 3. 4 Indication for Exercise Termination 
Chest pain suggestive of ischaemia 
Ischaemic ECG changes 
Complex ectopy 
Second or third degree heart block 
Fall in systolic pressure >20 mmHg from the highest value during the test 
Hypertension (> 250mm Hg systolic; >120 mm Hg diastolic) 
Severe de-saturation: SaO2 ≤ 80% when accompanied by symptoms and signs of severe 
hypoxemia 
Sudden pallor 
Loss of coordination 
Mental confusion 
Dizziness or faintness 
Sign of respiratory failure 
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Table 3. 5. Rate of Perceived Exertion: Borg’s scale (6-20) 
 
6   
7  very, very light 
8   
9  very light 
10   
11  fairly light 
12   
13  somewhat hard 
14   
15  hard 
16   
17  very hard 
18   
19  very, very hard 
20   
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3.5.6. Physiological measurements and definitions 
 Peak VO2  
Peak VO2 is the highest VO2 during maximum exercise. It was referenced as 
absolute value (L/min) or corrected by individual‘s body mass (ml/kg/min). 
 Respiratory exchange ratio (RER)  
RER is also known as gas exchange ratio and is the ratio of VCO2/VO2.  
 V-slope  
It is the relationship of VCO2 to VO2.  
 Anaerobic threshold (AT)  
Anaerobic threshold (AT) is also called as lactate threshold and it indicates the point 
at which anaerobic metabolism is necessary to supplement the existing aerobic 
metabolism. It is the VO2 at which changes in V-slope occurs. There are various 
ways to guide the point where AT occurs (Figure 3.7 and 3.8). 
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Figure 3. 7. Physiological measurements during CPET  
 
 
 
Example diagram generated by the software at the time of CPET.  
VCO2  = carbondioxide production, RER (green dot) = respiratory exchange ratio, 
AT(green dotted line)= anaerobic threshold, VO2 = oxygen consumption, PETO2= end-
tidal PO2,  VE= minute ventilation . At AT (green intermittent line), VCO2 (blue dot) 
rises in proportionate to VO2 and RER (green dot) starts to rise abruptly. 
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Figure 3. 8. Schematic diagram showing determination of anaerobic threshold 
 
 VE/ VCO2 slope  
VE/ VCO2 slope is the relationship between ventilation and the CO2 production. (section 
1.3.3). It represents the ventilatory response. The slope can be calculated from data 
recorded from initial exercise up to the time of either the peak exercise or the ventilatory 
threshold (VT). Both preVT and peak VE/VCO2 slopes are significant predictors of 
cardiac mortality.
186
 In our study, the data calculation was made only up to the point of 
peak exercise because some patients did not achieve ventilator threshold. Each VE and 
VCO2 data, from the initiation of exercise to
 
peak, were input into spreadsheet software 
(Microsoft Excel,
 
Microsoft Corp., Bellevue, Washington) and  the VE/VCO2
 
slopes 
were then calculated via least squares linear regression (y = mx + b, m = slope, b= 
intersect) (Figure 3.9). 
 
Because both units of VE and VCO2 were L/min, the slope did 
not have a unit.  
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Figure 3. 9. Schematic diagram demonstrating VE/VCO2 slope  
 
VCO2 = CO2 production, VE=minute ventilation, y = mx + b, m = slope, b= intersect 
VE/VCO2 slope demonstrating a linear relation between ventilation (VE) and the CO2 
production.  
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3.6. Trans-thoracic Echocardiogram 
Two dimensional echocardiograms were kindly performed by Dr Patrick Heck, 
Research Fellow in the cardiology department at each measurement visit by using Vivid 
7 GE Medical Systems, Piscataway, New Jersey, USA. The operator variability was 
minimised as it was performed by the same individual. Data were captured at the time of 
each measurement. Analysis was performed offline by using the software Pac PC 
version 7 GE Medical Systems, USA. The contractile function of the ventricles was 
derived from quantitative measurement of the volume, area, and linear dimension of the 
left ventricular cavity. These measurements were obtained from multiple tomographic 
planes including parasternal long axis, parasternal short axis, apical four chamber, apical 
two chamber and apical long axis view.  
The following measurements were performed.  
 LVEF  
 LV mass 
 Systolic pulmonary arterial pressure 
 End-diastolic thickness of the intra ventricular septum and posterior wall 
 Right ventricular systolic pressure 
 
The ventricular volume measured by 2D echocardiogram is based on tracing of the 
echocardiographic border at end-diastole and end-systole in one or more tomographic 
planes (Figure 3.10). This allows measurement of end-diastolic (EDV) and end-systolic 
volume (ESV) respectively which is required for ejection fraction determination. The 
stroke volume is the difference between EDV and ESV and subsequent ejection fraction 
can be calculated from the equation (Equation 3). 
Equation 3 EF (%) = (SV / EDV) X 100%  
EF = ejection fraction, SV = stroke volume, EDV= end diastolic volume
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Figure 3. 10. Example for left ventricular volume calculation 
 
Images on the left demonstrate the 2D echocardiographic view and those on the right 
demonstrates geographic model. For biplane apical method, apical four-chamber view 
and two-chamber view are used to trace the endocardial borders. This allowed the 
measurement of series of orthogonal diameters (a and b). The volume was then 
calculated based on the stacked disks assumption of ―Simpson‘s rule‖ following the 
guidelines of Schiller and colleagues.
187
 The single plane Ellipsoid method again used 
the apical 4 chamber view to calculate the 2D area (A) and length (L) in one single 
view. Hemisphere-cylinder method uses endocardial area at midventricular level (Am) 
on short axis view and length (L) in long axis view.  
 
a
Apex
septal
Basal septal
b
Base apex
b1
a1
Biplane Apical
Area (A)
Length (L)
Area (A)
L
Single plane Ellipsoid
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3.7. Heart rate variability 
In normal cardiovascular physiology, it has been shown that heart rate and blood 
pressure spontaneously fluctuate.
188
 Heart rate variability (HRV) is the temporal beat-to-
beat variation/alteration of heart rate.
189
 In a 12 lead ECG, the maximal positive QRS 
deflection is called ―R‖ wave and duration between two adjacent ―R‖ indicates R-R 
interval. In healthy subjects at resting condition, the R-R interval varies periodically 
with respiration; shortens during inspiration and lengthen during expiration. This 
phenomenon is known as sinus arrhythmia. This is predominantly mediated by post-
synaptic parasympathetic (vagal) activity on the heart. Vagal withdrawal results in over-
activation of counter regulatory system, the sympathetic control of cardiac rhythm. 
Reduced HRV implies reduced vagal activity. HRV thus has been a balance of 
parasympathetic and sympathetic activity. HRV was measured by two different 
methods: time domain and the frequency domain.  
 
Time domain method 
Before analysing HRV, non-sinus-originated beats from continuous ECG recording have 
to be removed. The intervals of two adjacent QRS complexes from sinus node 
depolarization is called NN (normal-normal) interval.
143
 Other variables can be 
calculated are as follows
143
: 
 Mean NN interval 
 Standard deviation of the NN interval (SDNN) 
 Standard deviation of average NN interval (SDANN) 
 Square root of the mean squared differences of successive NN interval (SMSSD) 
 The number if NN intervals differences of successive NN interval greater than 
50ms (NN50) 
 Proportion derived by dividing NN50 by total number of NN interval (pNN50) 
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Frequency domain method 
The frequency domain was calculated by power spectrum analysis which provides the 
basic information of how power (i.e. variance) distributes as a function of frequency.
143
 
Three main spectral components were distinguished in a spectrum calculated from short-
term recordings of 2 to 5 min: very low frequency (VLF, 0.0033-0.04 Hz), low 
frequency (LF, 0.04-0.15 Hz), and high frequency (HF, 0.15-0.4 Hz) components. LF is 
an index of both parasympathetic and sympathetic activities whereas VLF and HF are 
sympathetic and parasympathetic activities respectively.
190
 LF:HF ratio can therefore be 
an indicator of sympatho-vagal balance. In normal individuals, circadian changes in 
HRV are present with high HF at night and high LF during daytime.
191
  
3.8. Body Composition  
3.8.1. Anthropometry 
At the onset of the study, height was measured to the nearest 5mm by using a wall 
mounted stadiometer (Seca 242, Hamburg, Germany). In all measurements, weight was 
measured as an integral part of Air displacement plethysmography, BodPod procedure 
(detail on 3.8.2), the methodological validity of which had been established during 
previous study against calibrated electronic scales.
192
 Body mass index was calculated 
(see Chapter 1). Waist circumference, hip circumference and waist hip ratio were 
measured according to Table 3.6.
193
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Table 3. 6. Measurement of the waist, hip and waist-to-hip ratio 
1. Locate the waist. The waist was located at the smallest circumference of the torso and 
was not necessarily at the umbilicus. In whom the waist was not present, the smallest 
horizontal circumference between the 12th rib and the iliac crest was measured. 
2. Measure the waist. The patient was unclothed at the waist and standing with abdomen 
relaxed, arms at sides, and feet together. Non-stretchable tape measure was used and 
care was taken not compress the skin. 
3. Locate the hip. The hip was located as the maximal posterior extension of the 
buttocks. If the anterior abdominal wall was sagged, it was included in the measurement. 
4. Measure the hip. Hip was measured with patient wearing underwear and stood tall but 
relaxed with arms at sides. Again, non-stretchable tape measure was used and care was 
taken not compress the skin 
5. Calculate the waist-to-hip ratio. Divide the waist circumference by the hip 
circumference 
 
3.8.2. Measurement of Body Volume: Air displacement plethysmography (ADP)  
Measurement of body volume is an important contribution to multi-component models 
of body composition. (See page 74, 3.8.5) Traditionally, body volume has been assessed 
using hydro-densitometry (under water weighing) using Archimedes‘s principle.194, 195 
However, this technique requires cumbersome in-house equipment, restricting its 
availability, and is unsuitable for most patients. Air displacement plethysmography 
(Bodpod
®
, Life Measurement Instruments, Califonia, USA), has been developed an 
alternative technique. It uses the same principle of hydrostatic weighing but uses air 
instead of water. It measures the volume of air a person's body displaces while sitting 
inside a chamber. Comparing Underwater weighing and Bodpod,  measurement of body 
density and percent-fat-estimate in different age, sex and BMI groups, showed a strong 
correlation (r = 0.94 for both, standard error of the estimate = 0.0073 kg/L and 3.58% 
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respectively, p < 0.001 for both).
196
  BodPod had a better precision (standard deviation 
of differences between duplicate measurements divided by √2) than hydro-densitometry 
(0.38 kg Vs 0.68 kg respectively for fat mass)
192
 and is also suitable to measure a wide 
range of body sizes.
197
  
3.8.2.1.  The basic operating principles  
 Densitometry/density 
With ADP technology, body composition is calculated by body densitometry/density.   
Equation 4 Density = Mass / Volume 
Densitometry is based on modelling the body into two compartments: a fat compartment 
and a fat-free mass compartment. The fat-free mass (FFM) compartment consists of 
protein, water, mineral, and glycogen. (Figure 3.11)  
Figure 3. 11. Schematic diagram of body composition compartments 
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Based on the density of fat and lean tissue, the relative proportion of body fat and lean 
body mass (fat free mass) was calculated from the subject‘s body density. A higher 
density reflects a higher proportion of lean tissue because lean tissue is denser than fat 
tissue. From whole body density, the percent body fat can be calculated using the 
equation of Siri
198 
as utilised by the Bodpod software.  
 
 Equation 5 Percent Fat = (495/ density) – 450   
 
Once the percent body fat is calculated, the percent lean body mass can also be 
determined as follows:  
Equation 6 Percent Lean Body Mass = 100 – Percent fat  
 
 Mass and Volume Measurement  
Mass was measured by an integrated electronic scale. Body volume was measured by 
ADP using the principle of Boyle‘s Law which describes the relationship between the 
product pressure (P) and volume (V) within a closed system as constant when 
temperature and moles remain at a fixed measure; both entities remain inversely 
proportional.
199
  
Equation 7 P1 V1 = P2 V2 
The ADP measures interior volume (V2) and pressure (P2) of the empty chamber 
directly. Then, when the subject is inside, there is a change in the chamber volume 
occurred. Hence, body volume (V1) of the subject can be derived by measuring the 
pressure (P1) response to this change. 
 Thoracic gas volume 
The air trapped in the thoracic cavity is not part of the body volume and this must be 
accounted for as it is included in the raw BV measurement. The manufacturer‘s software 
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applies certain corrections to the thoracic gas volume (litres) using equation described 
by Crapo et al
200
 
 
 Surface area artefact 
Clothing and hair can contribute significant volume that may result in significant impact 
on Volume measurements. Therefore, it is important that subjects should wear minimal, 
form-fitting clothing and a cap to compress the hair on the head.  
The presence of the subject in the ADP creates an adiabatic condition because the 
warmer air, approximately 37°C, is more compressible than the ambient air. Due to this 
isothermal behaviour, the volume of air in close proximity of the subject's surface can be 
overestimated. This small surface area artefact (an apparent reduction in the subject‘s 
body volume) is automatically calculated by the manufacturer software and provides a 
subject‘s correct body volume.  
 
3.8.2.2. Bodpod® equipment and measurement procedure 
All measurements were carried out by using ADP, performed with Bodpod
® 
 Body 
Composition System (Life Measurement Instruments, Califonia, USA) (Figure 3.12 and 
3.13). It was a dual-chambered, fibre-glass plethysmograph that determines body 
volume by measuring changes in pressure within a closed chamber. The front, or test 
chamber, has a seat that forms a common wall separating it from the rear, or reference 
chamber. It measures volume of air in the anterior chamber using pressure changes 
induced by the oscillating diaphragm according to Boyle‘s laws of relations between 
volume, pressure, and temperature of gases, and provides raw body volume (raw BV; 
litres) for each subject simply from the difference between the volumes of air in this 
chamber, with and without the subject being present.  
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 Bodpod® was calibrated using a standard phantom of known weight and volume 
(a cylinder with a nominal volume of 50 l) prior to the measurement of each 
patient. 
 Duplicated measurements were then performed using the Bodpod according to 
the manufacturer‘s instructions and recommendations, with each subject wearing 
tight-fitting swimsuits and swimming caps. A single ADP procedure consisted of 
two measurements of BV (about 50 seconds each) unless they differed by more 
than 150 ml, in which case the system required that a third measurement be 
performed.  
 Values for these two raw volume measurements, which were uncorrected for the 
effects on BV of isothermal conditions created by the subject due to thoracic gas 
and skin surface area, appeared transiently on the screen during the procedure, 
and were recorded.  
 The thoracic gas volume (litres) was automatically calculated and air volume 
next to the skin was corrected to achieve the actual body volume. (see above) 
 Body weight (mass) and body volume (BV) were used to calculate the body 
density from which assessment of body composition, particularly fat mass (FM) 
and fat-free mass (FFM) were calculated. (see 3.8.2.1) 
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Figure 3. 12. Principle of Air displacement plethysmography (BodPod) 
 
Figure 3. 13.  Body Composition measurement by Bodpod
®
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3.8.3. Total Body Water 
Total body water (TBW) can be measured by an isotope dilution method by 
administering a known tracer which disperses equally throughout body water and which 
can be measured.
201
 The tracers of choice are stable, nonradioactive isotopes of water 
containing deuterium or 18-oxygen. Deuterium was used in this study. Patients were 
fasted overnight and a baseline saliva sample was collected on the morning of 
measurement for 
2
H/
1
H determination. Then, an oral dose of deuterium oxide (
2
H2O) 
(0.07 g/kg body weight) was administered and saliva samples were collected at 3, 4, 5 
and 6 hour after the dose to capture the period of maximum plateau enrichment of the
 
2
H2O within the body. The samples were frozen at -30˙C until they were transferred to 
MRC Human Nutrition Research (HNR), Cambridge. Measurement of 
2
H/
1
H 
enrichment in each sample was performed at HNR using isotope ratio mass 
spectrometry
202
 which allowed the precise measurement of stable isotope.
203
 
2
H2O 
dilution space was determined using the following equation
204
  
Equation 8 
2
H2O (kg) = [D x T (Ed-Et) / d x (Es-Ep)] / 1000 
D (g)  the amount of oral dosing solution administered to the subject  
T (g)  the amount of deionised tap water used to dilute a sample of the dosing solution 
d (g).  
All expressed as delta value (‰)  
Ed  the enrichment of the diluted dose d in T  
Et  the enrichment of the tap water diluent 
Es  the mean enrichment of the post dose samples 
Ep the mean enrichment of the pre dose sample 
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Total body water (TBW in kg) was calculated by reducing 
2
H2O dilution space values 
by 4% to account for the exchange of deuterium with non-aqueous hydrogen
205
  and 
then Lean Body Mass (LBM) calculated as: 
 
Equation 9 LMB (kg) = TBW/ hyd    
 
Where hyd represents an assumed hydration fraction of 73% for LBM.
206
 Finally, fat 
mass (FM (kg)) was calculated as the difference between weight and LBM: 
Equation 10 FM = Wt  -  FFM   
And % TBW and % Fat was calculated as a proportion of body weight. 
 
3.8.4. Dual Energy X-ray Absorptiometry 
3.8.4.1. Background 
Bone mineral density was previously measured by a single photon-emitting radioactive 
source and a scintillation counter positioning on the other side of the wrist. The number 
of detected counts was related to the amount of attenuating calcium or bone present. 
This single photon system evolved to a dual-photon system, now based on a filtered x-
ray source and referred to as dual-energy x-ray absorptiometry (DXA). It is a non-
invasive technique that measures the differential attenuation of two X-rays as they pass 
through the body (Figure 3.14Figure 3. 14) and permits measurements
 
of body 
composition.   It distinguishes bone mineral from soft tissue and subsequently divides 
the latter to FM and fat free soft tissue
207, 208
 based upon the following principles: 
 X-ray attenuation increases with increasing atomic number. Relative to lean tissue 
(water, protein,
 
and carbohydrate), fat contains a higher proportion of carbon
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(atomic no. = 6) to oxygen (atomic no. = 8) and thus has lower
 
average atomic 
number. Therefore, lean tissue has a higher X-ray attenuation than fat, and this 
differential attenuation is greater
 
for high- than for low-energy X-rays.  
 The ratio of high to low-energy X-ray attenuation coefficients (DXA ratio or R 
value) is the
 
fundamental DXA measurement employed to calculate body 
composition. Using ―R‖ value, mass fraction of each component in two 
compartments can be determined. R value for the soft tissue (lean and fat) is 
directly proportionate to the amount of fat in the tissue.
209
  
 Non-skeletal tissue is assigned to fat and lean compartments, and the differential 
attenuation of
 
low- and high-energy X-rays is employed to calculate the relative
 
proportions of fat and lean tissue.  
 
Figure 3. 14. Body Composition measurement by DXA scan 
 
 
The data may also be analysed to yield information about the composition of the whole 
body or of individual segments (Figure 3.15 and 3.16), e.g., limbs or abdominal 
regions.
208
 The precision errors (1SD) for total body bone mineral density, percent fat, 
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fat mass and lean tissue mass were 0.01 g/cm
2 
,  1.4%,  1 kg and 0.8 kg respectively.
208
 
However, one of the limitation of DXA is the size of the scanning area (approximately 
190 x 60cm) and weight limit (130Kg for the machine used in the present study). For 
this reason, it cannot be used in the very obese patients. The manufacturer, GE Lunar 
cooperation, Maidson, Wisconsin, has recently developed a newer machine to overcome 
this issue.  
3.8.4.2. Equipment and measurement procedure 
 Prodigy Bone densitometry (GE Lunar, Madison, WI) was used to measure whole body 
FFM, consisting of lean mass and bone mineral content (BMC), and FM.  
 Subjects lay on the table while the scanner arm passes over them in a rectilinear 
manner. The typical scan duration was 10–12 min, depending on the height of the 
subject while the DXA scanner performed multiple fast speed transverse scans from 
head to toe with 1 cm intervals. The radiation exposure per scan was estimated to be 
1 µSv, which was lower than the average daily background radiation level in UK (7 
µSv). The software package was used by only one member of the investigator team.   
 BMC, FM and lean mass were derived according to computer algorithms provided 
by the manufacturer (Lunar software version 8.1). Body weight was obtained by 
adding lean mass, BMC and FM. Percentage body fat was calculated as FM relative 
to body weight. FFM was computed as the sum of lean mass and BMC. Bone 
mineral density (BMD) is BMC normalised for bone size and is expressed as grams 
per centimetre squared.  
 Subjects who did not have DXA measurement at baseline (exceeded weight limit of 
>130 kg) had DXA in their 6 week visit if they achieved a body weight below 
130kg. The BMC value of week 6 measurement was used for four compartment 
model assuming no change during acute weight loss period of 6 weeks.  
 Subjects, in whom their body size (the width) exceeded the scanner area, were 
scanned without part of left upper limb. The data was analysed for both measured 
total and individual segments of FM. FM measured on the area of part of that limb 
was subtracted from and whole FM. Then, FM of the right upper limb area was 
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added to FM to achieve total body FM assuming FM is equal between left to right 
upper limb. Example of such a calculation is shown in Figure 3.17. 
 
Figure 3. 15. Dural Energy X-ray Absorptiometry (DXA) 
Left panel illustrates the bone mineral component whereas right panel showed the soft 
tissue component. The various lines across indicate different regions and separate body 
composition of these regions were available for analysis.   
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Figure 3. 16. Body composition data of the whole body and individual segments 
derived from DXA 
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It was assumed that the composition of left and the right arm area were the same. Fat 
mass (FM) from the area of left arm ( →   699g) was subtracted from the measured 
total fat mass   (       40814g). Then FM from right arm area (           1886g) was 
added to the measured total FM to achieve patient actual total fat mass (42001g). 
Similar calculation was made for the others: lean, BMC and fat free mass. 
 
Figure 3. 17. Calculation of a body composition in a patient in whom the body width 
exceeds the scanning area. 
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3.8.5. Body composition Models 
Basic two-compartment model measures fat and fat-free mass. Its use was limited by 
assumptions regarding the consistency of composition of fat free mass. The FM, which 
is defined
 
as chemically extractable fat, is assumed to have a density of
 
0.9007 g/cm
3 
and 
be anhydrous,
210
 whereas the FFM is regarded as having
 
a density of 1.1000 g/cm
3
 and a 
water content of 73.72%.
211
 To overcome this limitation, Siri
198
 proposed a three-
compartment model. This model measures the three major distinct chemical components 
within body: fat, water and the remaining fat-free dry mass (FFDM). It is based on the 
measurements of both body density and total body water while a constant mineral-to-
protein ratio of 0.35 is assumed. It overcomes some uncertainties concerning the 
hydration fraction of fat free mass.
211
 Taking into account the various assumed densities 
of the 3 components and the assumed constant ratio of protein to mineral, FM was 
calculated from the basic measurements as follows: 
Equation 11 FM (kg) = [(2.220 x BV) – (0.764 x TBW)] – (1.465 x BW) 
BV is body volume in litres, TBW is in litres, and BW is body weight in kilograms. 
 
The four-compartment model was based on principles similar to those adopted for the 
three-compartment model, but involved additional measurement of bone mineral by 
DXA, allowing the body to be segregated into fat, water, mineral and protein.
212
 The 
density of fat-free mass (Dffm) was calculated from the mass and volume of each 
individual component (water, protein and mineral). Fuller et al
212
 showed that there is a 
considerable inter-individual variation in the density of fat-free mass. This model, 
therefore, is more robust in minimising inter-individual variability in the composition of 
FFM. 
Equation 12 FM (kg) = [(2.747x BV) – (0.710 x TBW)] + [(1.460 x A) – (2.050 x 
BW)]  
where A is BMC determined by DXA (in kg). Total-body mineral mass was calculated 
as BMC x 1.2741.  
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This model was used for the body composition measurement in the study as it is now 
well established and widely used method of measuring body composition.
213 
 
 
Figure 3. 18. Schematic diagram showing body composition models 
(FFM =fat free mass, FFDM= fat free dry mass, A= 2 compartment 
model, B= 3 compartment model, C= 4 compartment model) 
 
 
 
 
 
 
 
 
 
 
3.8.6. Body composition with whole body quantitative MRI  
This is a novel quantitative magnetic resonance (QMR) methodology (EchoMRI-AH, 
Echo Medical Systems, LLC, Houston, TX USA) for measurement of whole-body fat 
and lean mass in humans.  It uses the differences in the nuclear magnetic resonance 
(NMR) properties of hydrogen atoms in organic and non-organic environments to 
fractionate signals originating from fat, lean tissue and free water.
214
 QMR measures 
body composition in live, un-anaesthetised small animals, and has become the method 
of preference for measuring their fat mass. It has been reported that changes in fat and 
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lean mass in mice weighing typically 25g can be measured with a coefficient of 
variation that ranges from 0.34% to 0.71%.
214
 This technology has now been scaled for 
adult human application (EchoMRI-AHTM).  This device is designed to measure total 
body fat, lean mass, body fluid, and total body water in adult with body weight from 60 
to 250kg.
214 
The device is based on magnetic resonance principle i.e., no ionizing 
radiation. 
3.9. Biochemistry 
Venous blood was drawn in the fasting state and plasma was immediately extracted and 
stored at -20 C. 
3.9.1. B-type Natriuretic Peptide (BNP) 
Plasma BNP concentration was measured at rest and at the recovery phase of exercise 
testing. It was repeated at week 6 and 16. Triage
®
 BNP test kid (Biosite
®
 Incorporated, 
California) was used for analysis. It is a single use fluorescence immunoassay device 
design to determine the concentration of BNP in EDTA-anticoagulated plasma samples. 
All the tests were performed in one batch at the end of the study. 
3.9.2. Plasma norepinephrine level 
Resting plasma norepinephrine levels were measured by the High Performance Liquid 
Chromatography electrochemical (HPLC- EC) technique (Figure 3.19). This is a well-
established assay used for daily clinical practice. This method of analysis relies on 
extraction of catecholamines from plasma by their absorption to solid alumina at pH 8.6. 
Subsequent elution at pH 4 and injection onto an HPLC system allows separation of 
analytes of interest by their varying retention on a C18 column, the time separated 
catecholamines are then detected by oxidation in the cell of the electrochemical detector, 
the resulting current produced being proportional to the concentration of analyte. 
Standard solutions containing known concentrations of catecholamines are used to 
calibrate the detector, allowing the calculation of levels in patient and QC samples. A 
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non-naturally occurring catecholamine, dihydroxybenzylamine (DHBA) is used as an 
internal standard to correct for any losses in the extraction procedure.  
 
Figure 3. 19. High Performance Liquid Chromatography Standard 
 
3.9.3. Highly sensitive C-reactive protein 
C reactive protein was an acute phase protein secreted by hepatocytes in response to 
infection and inflammation.
215
 CRP was a moderate predictor of coronary heart disease 
(CHD). CRP > 2mg/l  was predicted to be associated with higher CHD comparing with 
a group with CRP of <0.78 mg/l (odd ratio 1.92, with 95% CI of 1.68 to 2.18).
216
 
 
Standard CRP assay measures the CRP levels which are increased up to 1000 folds. 
However, the assay was not sensitive enough to detect normal range and therefore not 
suitable to use as a predictor of cardiovascular risks.
217
 Subsequently, newer highly 
sensitive CRP (hsCRP) assays have been developed with a lower limit detection  level 
of 0.1 mg per litre.
218, 219
 In the present study, CRP were measured by using high-
sensitivity, two-site enzyme linked immunoassay (ELISA). This assay was similar to the 
one used in west of Scotland coronary prevention study .
220
 It uses a peroxidase-
conjugated rabbit antihuman C-reactive protein antibody (DK2600, Dako, Glostrup, 
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Denmark) and a polyclonal anti–C-reactive protein capture antibody. The lower limit of 
the working range of the assay was 0.1 mg per litre.  
 
3.9.4. Antioxidant Profile 
Oxidant stress plays a critical role in the pathogenesis of endothelial dysfunction.
221
 
Systemic processes that invoke endothelial dysfunction include a stress-induced 
activation of intracellular oxidative signalling, with secondary modulation of LDL 
oxidation, nitric oxide (NO) bioavailability and vascular inflammatory gene 
expression.
222
 These processes may be modulated by factors such as obesity, weight loss 
and dietary composition (macronutrient and micronutrient intake).
223
   Obesity has been 
associated with enhanced oxidant stress.
222, 224
 The possible causes include increased 
oxygen consumption, increased fat deposition, diminished antioxidant capacity and an 
increased rate of free radical formation i.e. superoxide anion.
225
  These abnormalities 
have been shown to be reversible with weight loss.
225, 226
 Oxidative stress can be 
measured by different methods including lipid peroxidation, total antioxidant status 
(TAS), erythrocyte-reduced glutathione, erythrocyte superoxides dismutase and LDL 
oxidation. In this study, ferric reducing ability of plasma (FRAP) assay was used to 
assess TAS i.e., the total reactive (‗antioxidant‘) reactive capacity of the biological fluid. 
The FRAP assay was developed by Benzie and Strain in 1996.
227
 It was based on the 
principle that in low pH of 3.6, reduction from ferric (Fe
+++
) to ferrous (Fe
++
) ion causes 
formation of coloured ferrous-tridyltriazine complex. The absorbance increase at 593nm 
in test reaction mixture were compared with those of known ferrous ion concentration to 
provide FRAP value.
227
  The higher the FRAP value, the higher the TAS. 
3.9.5. Other Biochemistry  
Urea and electrolytes, liver function test, fasting lipid profile, fasting glucose, fasting 
insulin level for HOMA model,
228
 HbA1C, adiponectin, leptin and TNFα were 
measured at baseline and each measurement visit. 
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Fasting glucose, Insulin and HOMA model 
Insulin was assayed in singleton on a 1235 Auto DELFIA (Perkin Elmer Life Sciences 
(Wallac Oy, Turku, Finland) automatic immunoassay system using a two-step time 
resolved fluorometric assay (Kit No. B080-101). All reagents, standards and 
consumables are those recommended and supplied by the manufacturer. A series of 
lyophilised calibrators are supplied with the kit. The calibrators are referenced to WHO 
1st IRP 66/304. The Lower limit of detection was 1.3 pmol/l. Between batch 
imprecision were 3.1% at 29 pmol/l , 2.1% at 79.4 pmol/l, 1.9% at 277 pmol/l & 2.0% at 
705 pmol/l.
229
 HOMA model (HOMA2) was downloaded from 
http://www.dtu.ox.ac.uk/homacalculator/index.php; Diabetes Trial Unit, the Oxford 
Centre for Diabetes, Endocrinology and Metabolism. Fasting glucose and insulin values 
were required for to calculate the HOMA2. 
 
Adiponectin and Leptin 
Adiponectin is an adipokine secreted from matured adipocytes.
230
 Adiponectin acts as a 
insulin sensitiser and exerts anti-inflammatory activites.
231
 Low adiponectin levels were 
reported in diseases with accelerated atherosclerosis (insulin resistant, type 2 diabetes, 
obesity, coronary artery disease)
232-234
 and an important predictor of cardiovascular 
event.
235
  
 
Leptin is an adipokine with a 167-aminoacid peptide. Circulating leptin levels increased 
with obesity and correlates strongly with the percentage body fat.
236
 Studies reported 
correlations of leptin levels with established CVD (cholesterol, blood pressure),
237, 238
 
vascular dysfunction,
239
  and inflammation.
240
  
 
 In the present study, adiponectin and leptin were assayed by two-site microtitre plate-
based DELFIA
241
  with a  lower limit of detection at 30 ng/ml  for adiponectin and 
0.1ng/l for leptin. Antibodies and standards reagents were supplied by R&D Systems 
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(R&D Systems Europe, Abingdon, UK). Between-batch imprecision for adiponectin 
were 5.4% at 3.6 µg/ml, 5.2% at 9.2 µg/ml and 5.8% at 15.5 µg/ml. The assay measured 
‗total‘ adiponectin.  The relative reactivity of the various forms of adiponectin found in 
human serum was not known with this assay. Between-batch imprecision for leptin were 
7.1% at 2.7 ng/ml, 3.9% at 14.9 ng/ml and 5.7% at 54.9 ng/ml.  
 
Interleutin-6 
Interleukin 6 (IL-6) is a cytokine produced in various tissues in response to tissue injury 
or infection. IL-6 exerts proinflammatory effects and stimulates the liver to produce 
positive acute-phase proteins. High levels of IL-6 have been shown to be associated with 
high CHD risk.
242
  
In the present study, IL-6 was assayed by a two-site microtitre plate-based enzyme 
linked immuno-solvent assay (ELISA) with the reagent supplied by R&D Systems 
(R&D Systems Europe, Abingdon UK). The lower limit of detection of the assay was 
0.7 pg/ml. Imprecision Data between-batch were 3.4% at 29 pg/ml, 8.8% at 157 pg/ml 
and 8.2% at 203 pg/ml. 
 
Tumour necrosis factor- alpha 
Tumour necrosis factor- alpha (TNF-α), is a pleiotropic adiopokine. The increased level 
of TNF-α promotes a proinflammatory state, impair the preadipocytes differentiation 
and induce insulin resistance
243
 and endothelial dysfunction.
244
 In the present study, 
TNF-α was assayed by quantitative ELISA technique with the reagent supplied by R&D 
Systems (R&D Systems Europe, Abingdon UK). The mean lower limit of detection of 
the assay was 0.391 pg/ml. Imprecision Data between-batch were 7% at 5.97pg/ml, 
8.3% at 37.4pg/ml, 6.4% at 282pg/ml and 6.3% at 3869 pg/ml.  
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3.10. Statistical analysis 
Data were analysed using SPSS software (version 12) and GraphPad Prism software.  
Changes of peak VO2 (primary end point) and other various parameters at week 0, 6 and 
16 were analysed by repeated measure ANOVA. 
This particular statistical test was used with the assumption that 
1. matching of variables would be effective 
2. subjects would be independent  
3. random variability would be distributed according to a Gaussian distribution 
4. comparisons would be made over 3 points in time that were defined by one factor 
(weight loss intervention) 
 
The primary end point was powered and analysed on the assumption that data would be 
normally distributed because  
1. No a priori reason to expect a skewed or bivariate distribution because entry criteria 
were tight. 
2. The Kanoupakis et al182 paper that was used for the sample size calculation of our 
study was reported used parametric tests. 
3. The planned sample size (N=24) would also make it likely that parametric tests be 
more appropriate. 
 
Further exploration was made by post hoc contrast testing with Bonferroni‘s adjustment. 
Bivariate correlation analysis was calculated to assess a possible relationship between 
peak VO2 and other study variables of prognostic indicators of heart failure; and 
between fat mass and other variables including haemodynamic parameters and 
biochemistry. Relationships between variables were assessed by Pearson‘s linear 
correlation. Bland- Altman analyses were used to compare two different techniques of 
measurement of fat mass. Fat mass difference Vs mean fat mass between 4C and QMRI. 
Fat mass and fat free mass changes over time was analysed by using 2 way repeated 
measure ANOVA. Data were presented as mean±SD. Range was given when relevant.  
Chapter 4. Results 
82 
 
 
 
 
 
CHAPTER 4: 
 
 
RESULTS 
  
Chapter 4. Results 
83 
CHAPTER 4:    RESULTS 
The result will be described as following: 
 Baseline characteristics 
 Body composition changes 
 Cardiac performance, haemodynamic changes and sympathetic activity 
 Metabolic profile and biochemical parameters 
 
4.1. Baseline characteristics - Results 
A total of 14 patients were recruited, of whom 11 patients completed the study. Three 
patients withdrew from the study (two could not follow strict diets and one was 
diagnosed with breast carcinoma.) The mean age was 54.7±9.7 years and mean BMI 
was 38.28±4.73kg/m
2 
(range 33.31-48.21). Three patients (33%) were morbidly obese 
(BMI >40 kg/m
2
) and all of them were also diagnosed with hypertension. The 
background cardiovascular risk profile and treatments are shown in Table 4.1. As 
recruitment was mainly carried out in diabetes clinic, 8 patients (73%) had underlying 
type 2 diabetes.  Among them, one patient was diet controlled, one was on insulin alone, 
4 were on oral anti-diabetes drugs and two on both oral glucose lowering therapy and 
insulin. The daily insulin requirements were 37, 86 and 95 units/day at baseline. The 
first patient managed without insulin by week 16. The insulin requirement for the latter 
reduced to 8 and 32 units by week 16.  Eight patients (88%) met the international 
diabetes Federation (IDF) criteria for metabolic syndrome. Baseline demographics, body 
composition, haemodynamic characteristics and baseline biochemistry of the 11patients 
who completed the study, were demonstrated in Table 4.2 and 4.3.  
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Table 4. 1. Background cardiovascular risk factors and pharmacotherapy 
(N=11) 
 
Number of patients (n) 
Total (male) 
Cardiovascular risk factors 
Heart failure 4 (2) 
Hypertension 8 (6) 
Ischaemic heart disease 3 (2) 
Type 2 diabetes 8 (6) 
Dyslipidaemia 8 (7) 
Pharmacotherapy 
Heart failure medication 3 (2) 
Antihypertensive therapy 5 (1) 
Insulin therapy 3 (1) 
Oral anti-diabetic therapy 6 (5) 
Statin therapy 4 (4) 
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Table 4. 2. Baseline demographics, body composition and haemodynamic 
characteristics 
 N=11 
Age (years)  54.7±9.7 (42-68) 
Body weight (kg) 112.7±23.25 (84.2-148.3) 
BMI (kg/m
2
) 38.28±4.73 (33.31-48.21) 
Waist circumference (cm) 121.7±13.75 (99-145) 
Fat mass (kg) 50.58±14.86 (33.17-80.03) 
Fat free mass (kg) 62.29±12.58 (43.35-83.97) 
Systolic BP (mmHg) 142.7±19.26 (119-173) 
Diastolic BP (mmHg) 81.55±9.92 (63-100) 
Resting heart rate (bpm) 76.18±16.94 (56-109) 
Left ventricular ejection fraction (%) 49±19.15 (29-64) 
Left ventricular mass (g) 296.5±74.67 (172-431.5) 
Peak VO2 (ml/kg/min) 18.33±4.53 (12.3-27.5) 
Values represent means ± standard deviation, (  ) indicates range. 
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Table 4. 3. Baseline Biochemistry  
 N=11 
Fasting glucose (mmol/l) 7.436±2.66 (4.1-13.3) 
HbA1c (%) 6.88±1.3 (5.5-9.3) 
Fasting insulin (pmol/l) 83.63±44.31  (48-188)
* 
Cholesterol (mmol/l) 4.2±0.60 (3.50-5.50) 
Triglyceride (mmol/l) 1.9±0.88 (1.0-3.8) 
HDL Cholesterol (mmol/l) 1.05±0.27 (0.68-1.49) 
LDL cholesterol (mmol/l) 2.34±0.58 (1.62-3.33) 
ALT (U/L) 41±20.81 (16-88) 
C-reactive protein (ng/l) 4.45±3.30 (0.66-9.7) 
TNF-α (pmol/l) 3.87±1.68 (1.90-6.78) 
Adiponectin (µg/ml) 4.63±2.34 (1.5-7.3) 
Leptin (µg/l) 52.87±48.88 (12.9-174) 
24h urinary NE (nmol/24h)  396.8±254.5 (132-975) 
Plasma norepinephrine (ng/l) 435±142.4 (227-686) 
Plasma BNP (pg/ml) 74.09±109.8 (5-303) 
Values represent means ± standard deviation, (  ) indicates range. * was based n=8 
(excluded patients treated with insulin) 
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4.2. Baseline characteristics – Discussions 
Our cohort had high proportion of patients with diabetes (88%). Among them, 50% was 
recruited from the diabetes clinic and the rest from elsewhere. This reflected that a high 
prevalence of diabetes in patients with high cardiovascular risk group.  Unfortunately, 
only 4 patients (33%) were diagnosed heart failure prior to the recruitment.  Therefore, 
the mean LVEF was not very low at 49%. Only 3 patients had LVEF <45% at baseline. 
None of our patients had a level of NE above the poor prognosis cut off (>600pmol/l). 
This reflected our recruitment exclusion criteria of severe heart failure group (NYHA 
grade IV). Two out of four patients with heart failure had pVO2 lower than the cut off 
criteria (14 ml/kg/min) for heart transplantation at baseline (13.1 and 12.3 ml/kg/min). 
In fact, the later patient was previously on cardiac transplant list and then taken out from 
the list as her clinical symptoms had improved with anti-heart failure therapy. With the 
advanced in medical therapy, patients were remarkably asymptomatic despite their 
advanced disease. Similarly, one patient was excluded from the study after screening 
due to very poor LVEF of <15% and had very low peak VO2 at 10ml/kg/min. 
Surprisingly he managed to perform cardiopulmonary exercise testing to Naughton stage 
3 and his NYHA was stage II.  
 
4.3. Weight loss intervention – result 
LELD with a calorie of 800-100kal was well tolerated. 12 out of 13 patients completed 
Liquid phase of intensive dietary programme (initial 6 weeks). Only one patient could 
not tolerate the diet and dropped out from the study. One patient, who completed the 
liquid phase, withdrew from the study at week 7 following the diagnosis of breast 
cancer. One patient chose the commercial nutrition supplement (Slim Fast
®
, Surrey, 
UK) than milk. All patients lost weight with a range from 6.6 kg to 23 kg at 6 weeks and 
4.9 to 32.1 kg at week 16 (p <0.0001) (Figure 4.1).  Detailed body composition changes 
were demonstrated in section 4.5. 
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Figure 4. 1. Weight loss in individuals at week 6 and week 16  
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4.4. Weight loss intervention – Discussion 
This study suggested that the use of LELD with calories of 800- 1000kcal is safe in 
inducing acute weight loss in obese patients with heart failure and or high 
cardiovascular risk, particularly in the group of type 2 diabetes treated with insulin. 
Patients generally tolerated the diet well apart from minor side effects, i.e., constipation 
and diuresis. Indeed exercise tolerance also improved with weight loss. However, 
regular close follow up was needed to manage the haemodynamic and metabolic 
changes that required adjustment of therapy for their underlying co-morbidities. Weight 
loss in patients with diabetes were generally more difficult than patients without 
diabetes.
245
 One possible explanation would be the potential risk of hypoglycaemia with 
glucose lowering therapy following a restriction of calorie/carbohydrate intake. In 
addition, most of the glucose lowering agents including insulin, sulphonyurea and 
thiozolidinediones were known to be associated with weight gain.   In the present study, 
glucose monitoring was closely supervised and glucose lowering therapy was actively 
titrated down. It proved that patients with diabetes could loose weight effectively if they 
were able to restrict to their energy intake providing energy deficit. Orlistat used in the 
later phase of the study aided to maintain the weight. All patients had tolerated orlistat 
well without gastrointestinal side effect. This was achieved by patients following a strict 
reduction of dietary fat intake below 70g per day. 
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4.5. Body composition changes - Results 
All results were expressed as changes at week 6 (acute weight loss) and week 16 
(weight loss maintenance) comparing to the baseline. As stated above, following the 
intensive diet, a significant mean±SD weight loss of 12 kg±4.6 was achieved at 6 weeks 
and maintained until the end of study (mean 14.2 kg±7.3, p <0.0001) (Figure 4.2). 
Similarly, there was a significant reduction in mean waist circumference from baseline 
(10.55 cm±5.55 and 14.05 cm±7.38 at week 6 and week 16 respectively, p<0.0001) 
(Figure 4.2) but there were no changes in waist/hip ratio. The detail changes in body 
composition analysis at week 6 and week 16 are demonstrated in Table 4.4. With weight 
loss, there were significant reductions in all components of body composition: FM (8.04 
kg±3.23 and 11.21 kg±5.82), FFM (4.17 kg±2.05 and 3.24 kg±3), total body water 
(TBW) (3.88 kg±2.55 and 3.34 kg±3.47) and fat free dry mass (FFDM) (1.02 kg±0.43 
and 1.05 kg±0.96) at week 6 and 16 respectively (p<0.0001 for first three parameters 
and <0.0003 for the last one). Therefore, FM loss was much greater than the FFM loss 
(22.14% Versus 5.23% at week 16). There was an initial mean 4.17 kg loss of FFM at 
the end of weight loss phase (week 6), 0.93 kg of which was then regained at week 16 
(Figure 4.3). When the percentage body composition changes were measured against 
total body mass, reductions in the percent FM were seen whereas significant increases in 
other compartments; percent FFM, TBW and FFDM at week 6 and week 16 resulting in 
more favourable changes i.e., a healthier body composition. 
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Figure 4. 2. Changes in body mass and waist circumferences 
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Bar graph representing means and standard error of means. N=11. The omnibus 
significance for the trend was p<0.0001. The significant was determined by 1-way 
ANOVA repeated measures, and post hoc testing with Bonferroni‘s adjustment.  
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Table 4. 4. Effect on body composition following weight loss and weight loss 
maintenance  
Body composition  Baseline  Week 6 Week 16 P value 
Total mass, kg 112.7±23.3 100.7±20.2* 98.5±22.2* <0.0001 
FM, kg 50.6±14.9 42.5±13.6* 39.4±15.1* <0.0001 
FFM, kg 62.29±12.6 58.12±11.1* 59.05±11.7* <0.0001 
TBW, kg 47.9±9.9 44±8* 44.6±8.7* <0.0001 
FFDM, kg 14.62±2.7 13.6±2.8* 13.57±2.9* <0.0003 
Percent FM (%) 44.35±5.9 41.95±6.9 39.47±8.5* <0.0003 
Percent FFM (%) 55.49±7 58.65±8.6 61.68±1.8* 0.0003 
Percent TBW (%) 42.4±4.1 44±4.6 45.7±5.8* 0.0009 
Percent FFDM (%) 13.05±1.5 13.66±1.7 14.06±1.7* 0.0032 
 
Values represent mean ± standard deviation. N=11. Significance was determined by one 
way ANOVA with repeated measure. When the omnibus test was significant (final 
column), Bonferroni multiple comparisons was performed for baseline versus week 6, 
baseline versus week 16. Significant difference is indicated by * (p <0.01). There was 
no significant difference between week 6 and week 16 for any of the parameters.  
FM= fat mass, FFM = fat free mass, TBW = total body water, FFDM = fat free dry 
mass. 
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Figure 4. 3. Comparison of fat mass Vs fat free mass loss/gain (4C model) 
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 Delta 6-0 = mass changes between week 6 (at the end of acute weight loss phase) 
and week 0 (baseline),  
 Delta 16-6 = mass changes between week 16 and 6 
 Delta 16-0 = mass changes between week 16 and 0   
Bar graph represents means and standard error of means. N=11. The omnibus 
significance for interaction between fat mass and fat free mass changes was p=0.015 
and post hoc testing with Bonferroni‘s adjustment.  
 
  
The body composition measured by a newer technique i.e., quantitative MRI (QMR) 
was shown in Figure 4.4. This method also demonstrated a significant loss in both FM 
and FFM (7.05 and 9.86 kg of FM, and 4.95 and 4.84 kg of FFM at week 6 and week 16 
respectively; p<0.0001 for all).  
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Figure 4. 4. Fat mass and fat free mass changes measured by quantitative MR 
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Bar graph representing means and standard error of means. N=11. The omnibus 
significance for the trend was p<0.0001. The significant was determined by 1-way 
ANOVA repeated measures, and post hoc testing with Bonferroni‘s adjustment.  
 
The relationship between QMR estimates of absolute fat mass and those obtained with 
the 4C model was illustrated in a correlation plot (Figure 4.5).The Pearson correlations 
were high at 0.98, 0.99 and 0.98 for week 0, week 6 and week 16 data respectively. 
However, high correlations were not sufficient to demonstrate agreement because they 
were strongly influenced by the variance of measurement in the population in which it 
was assessed. Bland Altman plots were a more appropriate method of assessing the 
degree of agreement. These plot the difference between two methods against the mean 
of the methods, disclosing the variability, any systematic difference between the means, 
without assuming that either method has superior properties. Figure 4.6 demonstrated 
that measurements of fat mass by 4C were higher than those obtained with QMR at 
week 0 and week 6 but lower at week 16. The regression lines showed no significant 
slopes but did demonstrate the mean differences (bias) ± SD of 0.94kg±2.56, 0.18±2.7 
and -0.67kg±2.69 for week 0, week 6 and week 16 data. The large 95% confident 
intervals on the plot reflect that either technique was not correct particularly at the time 
of acute weight loss. Measurement precision, however, remained high.  
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Figure 4. 5. Correlation plots comparing fat mass by QMR and 4C model 
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A= baseline fat mass at week 0, B= fat mass at week 6 and C= fat mass at week 16.  
The solid line is a linear regression through the data points. The dotted line is the line of 
identity between the two methods. 
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Figure 4. 6. Bland-Altman graph of absolute Fat mass measured by 4C and 
QMR techniques  
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The horizontal line is the line of identity of two methods. A linear regression through the 
data points is shown with a solid line (red- week 0, black – week 6 and green – week 
16), with dashed lines defining the boundaries of the 95% confidence intervals. 
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Similarly, fat mass loss measured by the different methods showed strong correlation 
(Figure 4.7). Bland-Altman analysis also showed no significant slope when they were 
plotted against delta fat mass (fat mass loss) at week 6 and 16 compared with week 0 
(Figure 4.8).  
 
Figure 4. 7.  Correlation plots comparing delta fat mass by QMR and 4C model 
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The dotted line is the line of identity of two methods. A linear regression through the 
data points is shown with a solid line (red- week 6 -0, yellow – week 16 –0).  
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Figure 4. 8. Bland-Altman graph of delta Fat mass (FM loss) comparing 4C and 
QMR techniques 
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The horizontal line is the line of identity of two methods. A linear regression through the 
data points is shown with a solid line (red= week 6 -0, black = week 16-0), with dashed 
lines defining the boundaries of the 95% confidence intervals. At week 6, FM loss from 
baseline, measured by 4C was higher than QMR. The reverse was seen at week 16.
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Three patients did not have DXA at baseline due to their initial weight exceeding the 
scan‘s weight limit. Therefore, FM measured by DXA was not used to compare with 
other techniques. However, DXA was used in the calculation of the 4C model as well as 
assessing regional fat weight loss. Android FM was contributed by visceral/abdominal 
FM.  
Traditionally, waist and hip circumferences were used to measure the pattern of obesity 
i.e., android or gynoid obesity (section 1.1.2). In the current study, regional FM i.e., FM 
at android (abdominal/visceral) and gynoid (pelvis) regions measured by DXA were 
used to assess the pattern of obesity.  Changes in android and gynoid regional fat mass 
ratio (AG ratio) at week 6 and week 16 from baseline were shown in Figure 4.9. AG 
ratio significantly improved (reduced) from a baseline value of 0.70± 0.19 to 0.65 ±0.15 
at week 6 and 0.60±0.16 kg at week 16 following weight loss (p=0.0136).  
 
Figure 4. 9.  Android and gynoid fat mass ratio measured by DXA 
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Bar graph representing means and standard error of means. N=8. The omnibus 
significance for the trend was p=0.0136. The significant was determined by 1-way 
ANOVA repeated measures, and post hoc testing with Bonferroni‘s adjustment.  
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The reduction in android FM (from week 0 to week 6) was significantly correlated with 
reduction in total body mass, total body FM and gynoid FM and fasting insulin level. 
(Figure 4.10) 
 
Figure 4. 10. Correlation of changes in (android) visceral fat mass measured by 
DXA (week 16 – week 0) with changes in other body composition 
measures and fasting plasma insulin level 
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A) total body mass, B) total FM C) gynoid (pelvis) fat mass and D) fasting plasma 
insulin level 
It demonstrated correlations between changes in android (visceral) FM (kg) and other 
collected variables in patients with obesity and heart failure/ high CVD risk. Correlation 
and significance was determined using Pearson‘s Correlation test. Correlation is 
significant* at the level 0.05. 
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The correlation between the fat mass measured by 4C and other putative variables are 
illustrated in Table 4.5. As expected, FM was significantly correlated with waist 
circumferences and plasma leptin level (correlation coefficient 0.595 and 0.712, p = 
0.027 and 0.014 respectively). However, other variables including cardiac performance 
parameters (peak VO2, anaerobic threshold, LVEF, LV mass), metabolic profile (total 
cholesterol, HDL, LDL, trigycerides, ALT, fasting glucose, insulin), resting BNP, 
plasma norepinephrine sensitive CRP, TNFα and total antioxidant profile (FRAP) did 
not show any significant correlation with fat mass. 
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Table 4. 5. Correlations between 4C fat mass and putative variables  
 
Variable  
Correlation  
Coefficient 
Significance 
Waist circumference 0.595 0.027* 
Peak VO2(ml/kg/min) -0.371 0.13 
Anaerobic threshold (ml/kg/min) -0.35 0.15 
LVEF (%) 0.191 0.29 
LV mass (g) 0.434 0.19 
Resting BNP (pg/ml) 0.147 0.34 
Sensitive CRP (ng/l) -0.24 0.23 
Plasma NE (ng/l) 0.339 0.15 
Fasting insulin (pmol/l) -0.158 0.32 
ALT (U/l) 0.442 0.09 
Total cholesterol (mmol/l) 0.254 0.23 
Fasting insulin (pmol/l) 0.263 0.22 
Adiponectin (µg/ml) 0.505 0.057 
Leptin (µg/l) 0.712 0.014* 
TNF-α (pmol/l) 0.069 0.43 
TAS-FRAP (µmol/l) 0.147 0.342 
Table demonstrates correlations between fat mass (kg) and other collected variables in 
patients with obesity and heart failure/ high CVD risk. Correlation and significance was 
determined using Pearson‘s Correlation test. Correlation is significant* at the level 0.05. 
Chapter 4. Results 
102 
4.6. Body composition changes - Discussions 
The aim for achieving acute weight loss and the weight loss maintenance were met. 
Both clinically and statistically significant weight loss (mean 10.6%) was achieved at 6 
weeks and maintained until the end of the study (mean 12.6%). As expected, loss of fat 
mass was much greater than loss of lean mass (22.14% Vs 5.23%, p <0.0001). The lean 
mass loss was greater at week 6 than at week 16 (6.7% Vs 5.2%). This can be explained 
by the fact that early weight loss following a low calorie diet used glycolysis as an initial 
fuel source. Kreitzman et al
246
 measured total body potassium loss to estimated 
glycogen loss on the basis that each gram of glycogen is associated with 0.45mmol of 
potassium loss. In the first 4 days of VLCD, there was an average of 180mmol loss of 
total body potassium and hence equivalent glycogen depletion of around 400g. 
Krotkiewski M et al
247
 also confirmed the loss of glycogen following VLCD by 
performing skeletal muscle biopsies. The estimate of glycogen storage in lean subjects 
in a fed state is generally around 400-500g with associated water of average of 1.6kg 
(range from 1.2-2kg i.e., three to four times the glycogen weight). This accounts for the 
initial weight loss of 2-2.5kg following VLCD. Glycogen, as carbohydrate, contributes 
4kcal/g whereas fat yields 9kcal/g of energy. Therefore, it requires about 2500kcal 
deficit to achieve 2.5kg of weight loss by glycolysis (burning glycogen) whereas a 
22500kcal deficit will be required to burn fat (lipolysis) 
248
 (Equation 13 and Equation 
14). 
 Equation 13.  
2.5kg weight loss = 2.5/ 1.6 x 400g glycogen = 625g of glycogen = 625 x 4kcal = 
2500kcal deficit 
Equation 14.  
2.5kg weight loss = 2500g fat = 2500 x 9kcal fat = 22500kcal deficit 
 
If a person‘s daily energy expenditure is at around 2300 kcal/day and calorie intake of 
1000kcal/day, (1300kcal/day energy deficit) it will take him 17.3 days to achieve 2.5 kg 
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fat loss. Therefore weight loss of 2.5-4kg in a week by restricting energy intake of 
1000kcal/day cannot be entirely the fat loss but contributed to glycolysis and fluid loss. 
 
The patterns in body composition changes were encouraging. Though all 4 components 
have reduced in mass, if changes were illustrated as a percentage of total mass, FM was 
reduced in contrast to FFM which was increased. In addition, these body composition 
changes were in parallel to an improvement in their metabolic profile. (see section 4.9). 
 
The changes in regional fat loss assessed by DXA were interesting. Though there were 
reduction in both android and gynoid FM, a significant reduction in AG fat mass ratio 
was also demonstrated. The AG ratio has not been used to assess the differential fat 
mass loss before and it suggested a possible reduction of FM more from the intra 
abdominal region than that of around the pelvic region. In addition, reduction in android 
fat ratio was also strongly associated with fasting plasma insulin level which may imply 
a reduction in degree of insulin resistance. The current study did not measure specific 
visceral FM differentiating it from subcutaneous abdominal FM. Therefore, future 
studies to compare the DXA with other imaging modalities such as MRI or proton-
magnetic resonance spectroscopy ((1)H-MRS to assess the regional fat mass would have 
been useful to correlate with other various metabolic changes. DXA scan used in the 
study was not ideal for morbidly obese patients and newer scanning that accommodates 
larger body size would have been more desirable. As a consequence, apart from BMC, 
body composition data (FM, regional FM changes) in three individuals from the current 
study was not able to be included in the data analysis. 
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4.7. Cardiac performance, haemodynamic changes and sympathetic activity -
Results 
For each cardiopulmonary exercise test, all patients achieved the Borg scale of 17. 
Individuals could exercise longer post weight loss (12±5.2, 14.5±5.1, 16±5 min at week 
0, 6 and 16 respectively, p=0.0013), achieving a higher Naughton stage (5.7±1.3, 
6.5±0.8, 6.7±0.6 p=0.0006).  At baseline, peak VO2 correlated significantly with a 
number of other cardiac prognostic indicators. The detailed correlation was shown in 
Table 4.6. Left ventricular ejection fraction, left ventricular mass, plasma BNP and 
anaerobic threshold significantly correlated with peak VO2.  
 
 Table 4. 6. Correlations between peak VO2 and putative variables at baseline 
 
Variable  Correlation Coefficient Significance 
4C Fat mass (kg) -0.338 0.15 
LVEF (%) 0.589 0.028* 
LV mass (g) 0.551 0.04* 
Anaerobic threshold (ml/kg/min) 0.931 <0.0001* 
Resting BNP (pg/ml) 0.610 0.031* 
Sensitive CRP (ng/l) 0.041 0.45 
Plasma NE (ng/l) 0.162 0.32 
Urinary NE (nmol/24h) -0.311 0.19 
 
Table demonstrates correlations between peak VO2 and other collected variables in 
patients with obesity and heart failure/ high CVD risk. Correlation and significance was 
determined using Pearson‘s Correlation test. Correlation is significant* at the 0.05 level.
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The primary end of the study, Peak VO2 corrected for BW (ml/kg/min) showed 14.34% 
and 13.26% improvement (18.33±4.5, 20.96±4.8, 20.76±4.8 ml/kg/min, p= 0.0095) 
(Figure 4.11). There were no significant changes in absolute peak VO2 (ml/min), peak 
VO2 corrected for FFM (ml/fat free mass kg/min), anaerobic threshold and VE/VCO2 
slope.  
 
Figure 4. 11.  Peak VO2 changes (adjusted for body mass) 
 
Bar graph represents means and standard error of means. N=11. The omnibus 
significance for the trend was p=0.0095. The significant was determined by 1-way 
ANOVA repeated measures, and post hoc testing with Bonferroni‘s adjustment.  
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 The effect of WL and WLM on cardiac performance, haemodynamic changes and 
sympathetic activity are demonstrated in Table 4.7. Echocardiogram did not show any 
significant changes in LV ejection fraction, LV mass, interventricular septal thickness or 
posterior wall thickness. Measurement of right ventricular systolic pressure and systolic 
pulmonary arterial pressure was not available in some cases due to the lack of 
significant regurgitant flow across the valve. Therefore analysis was not carried out for 
those measurements.  
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Table 4. 7. Effect of weight loss and weight loss maintenance on cardiac 
performance, haemodynamic changes and sympathetic activity 
 baseline Week 6 Week 16 P value 
Peak VO2 (ml/kg/min)⁺ 18.33±4.5 20.96±4.8* 20.76±4.83
*
 0.0095 
Peak VO2 (ml/min)⁺⁺ 2107±605 2083±596 2054±471 0.8 
Peak VO2 (ml/ FFM kg/min)⁺⁺⁺ 33.74±6.6 35.84±8.3 34.82±5.5 0.4 
AT (ml/kg/min) 12.08±2.5 13.89±3.2 13.63±3.2 0.07 
VE/VCO2 slope  27.61±5.2 28.36±6.9 26.74±5.7 0.2 
LVEF (%) 49±13.2 49.73±15 52.45±14.6 0.08 
LV mass (g) 296.5±74.7 264.5±83.9 271.5±78.2 0.057 
IVS thickness (cm) 1.24±0.08 1.16±0.17 1.17±0.09 0.2 
Posterior wall thickness (cm) 1.14±0.16 1.03±0.14 1.08±0.1 0.3 
Systolic BP (mmHg) 142.7±19 120.5±15* 131.5±14 0.0008 
Diastolic BP (mmHg) 81.5±9.9 74.2±13.6 80.2±8.8 0.1 
Resting heart rate (bpm) 76.1±16.9 65±12.7* 65.5±14.7* 0.007 
Plasma NE (ng/l) 435±142 328.4±134* 318.5±124* 0.03 
24h urinary NE (nmol/24h) 397±255 227±105* 297±153 0.009 
Plasma BNP (pg/ml) 74.09±109 55.53±95 72.73±109 0.2037 
LF power(ms
2
) 66.94±65.8 103.9±97.12 149.7±102.3* 0.0036 
HF (ms
2
) 67.08±67.3 94.67±123 246±291* 0.0334 
SDNN (ms) 34.46±20 40.7±17.5 49.15±22.1 0.1 
SMSSD (ms) 32.7±30 27.3±16.8 34±18.4 0.6 
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Values represent mean ± standard deviation. n=11. Significance was determined by one 
way ANOVA with repeated measure. When the omnibus test was significant (final 
column), Bonferroni multiple comparisons was performed for baseline versus week 6, 
baseline versus week 16. Significant difference is indicated by * (p <0.01). There was 
no significant difference between week 6 and week 16 for any of the parameters.  
 
Heart rate variability parameters: HF (high frequency), LF (low frequency), SDNN 
(Standard deviation of the NN interval, SMSSD (Square root of the mean squared 
differences of successive NN interval)  
 
⁺ indicates value corrected by body mass whereas ⁺⁺ was absolute value and ⁺⁺⁺ being 
values corrected by fat free mass, NE (norepinephrine). 
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The systolic BP and heart rate reduced significantly (142.7±0.16 to 120.5±15 and 
131.5±14 mmHg, p= 0.0008) (Figure 4.12) but there was no change in diastolic blood 
pressure. The degree of fall in BP likely to be more significant as four out of five 
patients (80%) who were on antihypertensive therapy needed to reduce their medication 
during WL to prevent hypotension.  
 
Figure 4. 12. Systolic blood pressure and heart rate changes 
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Bar graph represents means and standard error of means. N=11. The omnibus 
significance for the trend was p=0.0008 for systolic BP and 0.007 for heart rate. The 
significant was determined by 1-way ANOVA repeated measures, and post hoc testing 
with Bonferroni‘s adjustment. 
 
In terms of changes in autonomic activities, there were significant reductions in resting 
heart rate (76.1±16.9 to 65±12.7 and 65±14.7bpm, p=0.007) (Figure 4.12), plasma 
norepinephrine (435±142 to 328.4±134 and 318.5±124 ng/l, p= 0.03) and 24 hour 
urinary norepinephrine level (397±255 to 227±105 and 297±153, p=0.009) from 
baseline to week 6 and week 16 respectively (Figure 4.13). Heart rate variability 
measurements demonstrated significant increases in both low frequency (LF) and high 
frequency power (HF) in the frequency domain but no significant changes were noted in 
LF/HF ratio. Time domain assessment did not show any significant changes in SDNN 
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and SMSSD. Overall it can be concluded that there was an improvement in sympathetic 
activity.   
 
Figure 4. 13. Changes in resting plasma and urine norepinephrine level 
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Bar graph represents means and standard error of means. N=11. The omnibus 
significance for the trend was p=0.0311 for plasma and p=0.0094 for urine 
norepinephrine. The significant was determined by 1-way ANOVA repeated measures, 
and post hoc testing with Bonferroni‘s adjustment.  
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Figure 4. 14. Changes in high frequency and low frequency power (heart rate 
variability)  
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Bar graph represents means and standard error of means. (N=11) The omnibus 
significance for the trend was p=0.0334 for high frequency power and p=0.0036 for low 
frequency power. The significant was determined by 1-way ANOVA repeated measures, 
and post hoc testing with Bonferroni‘s adjustment.  
 
The correlation of fat mass with other various parameters of sympathetic activity at 
baseline was shown on (Table 4.8) These included heart rate, systolic blood pressure, 
heart rate variability (HF, LF, LF/HF ratio, RSMDD, SDNN) and plasma 
norepinephrine. There was no significant correlation seen in any of those parameters. 
The lack of association could be explained by the influence of other factors on 
sympathetic activities such as therapy with antihypertensive medication, the 
heterogeneity of their underlying cardiac status (NYHA status of heart failure from 
normal to stage 3) and presence or absence of diabetes. 
 
  
Chapter 4. Results 
112 
Table 4. 8. Correlations between Fat Mass measured by 4C and putative 
variables of sympathetic activities at baseline 
Variable  Correlation Coefficient Significance 
Heart rate -0.013 0.97 
Systolic BP 0.235 0.49 
Diastolic BP -0.216 0.52 
High frequency power 0.076 0.82 
Low frequency power 0.053 0.88 
LF/HF ratio -0.204 0.55 
SDNN -0.119 0.73 
RMSSD -0.249 0.46 
Plasma NE -0.239 0.48 
Table demonstrates correlations between Fat mass and other collected variables of 
autonomic function (sympathetic activity) in patients with obesity and heart failure/ high 
CVD risk. Correlation and significance was determined using Pearson‘s Correlation test. 
Correlation is significant* at the level 0.05. None of the parameters of sympathetic 
activity was significantly correlated with fat mass at baseline.  
 
Figure 4.5 showed the inverse correlation between LVEF and the resting plasma BNP 
level and log plasma BNP level indicating known relationship of BNP as a marker of 
left ventricular function. However, there were no significant correlations between 
changes in BNP at week 16 to baseline (delta BNP) with changes in other collective 
parameters including LVEF, body composition measurement, peak VO2, plasma 
insulin, plasma norepinephrine and heart rate variability. (Table 4.9) 
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Figure 4. 15. Correlation between left ventricular ejection fraction and plasma 
BNP 
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Left ventricular ejection fraction (LVEF) correlated with plasma BNP in obese patients 
with heart failure and or high cardiovascular risk. A represents correlation between BNP 
and LVEF whereas B represents those of log BNP and LVEF. Both graphs demonstrated 
significantly higher BNP and log BNP levels as LVEF levels become lower.  
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Table 4. 9. Correlations between changes in resting plasma BNP at week 16 
from baseline (delta BNP) and putative variables  
 
Variable  Correlation Coefficient Significance 
   
Delta weight (kg) 0.071 0.84 
Delta 4C Fat mass (kg) 0.008 0.98 
Delta 4C Fat Free Mass (kg) 0.19 0.58 
Delta LVEF (%) 0.05 0.88 
Delta Peak VO2 0.007 0.98 
Delta Plasma insulin (pmol/l) 0.311 0.35 
Delta Plasma NE (ng/l) -0.248 0.463 
Delta HF (heart rate variability) -0.062 0.86 
Delta LF (heart rate variability) -0.41 0.21 
 
Table demonstrates correlations between plasma BNP changes from baseline to 16 
weeks and other collected variables in patients with obesity and heart failure/ high CVD 
risk. Correlation and significance were determined using Pearson‘s Correlation test. 
Correlation is significant* at the 0.05 level. 
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4.8. Cardiac performance, haemodynamic changes and sympathetic activity -                             
Discussions 
All patients tolerated the cardiopulmonary exercise testing well. With weight loss, the 
endurance of individuals improved because the exercise time taken to a similar Borg 
scale took longer to reach and they achieved a higher Naughton stage. Peak VO2 is 
generally reported after correction for patient body mass (ml/kg/min) or as an absolute 
value (L/min).  It is debatable as to how to report pVO2 in people who lost weight. Some 
suggest pVO2 in reference to the lean body mass (FFM) would be a better index because 
fat metabolism does not contribute much to VO2.
249, 250
 So far, there is no consensus 
conclusion for how to report pVO2 as yet. In this study, when pVO2 was reported as a 
standard way i.e., corrected for BW (ml/kg/min), 
110, 114, 115
 an improvement was seen. 
This is intuitively ‗correct‘ i.e. it represents the fact that they could exercise more. The 
absolute peak VO2 (ml/min) and that corrected for FFM (ml/lean mass kg/min) were 
however not affected by weight loss. This could also imply no deterioration of pVO2 by 
weight loss. On the other hands, there were no significant changes in other prognostic 
markers of cardiopulmonary exercise, anaerobic threshold and VE/VCO2 slope. 
 
Other than the mechanism of VO2/kg effect, it was possible that weight loss improved 
cardiac performance by reduction in intramyocellular lipid and/or selective reduction of 
epicardial fat. Increase epicardial fat is common in morbidly obese individuals and it has 
been linked to visceral adiposity and insulin resistant.
251, 252
 MRI spectroscopy has been 
used to quantify triglyceride content in human myocardium (intramyocellular 
triglyceride) and found it to be significantly increased in obese compared with normal-
weight subjects.
251
 Weight loss following VLCD in obese patients with type 2 diabetes 
significantly decreased myocardial triglyceride level, reduce left ventricular mass and 
improved LV diastolic function.
253
  Improved LV diastolic function and decreased  in 
LV mass was demonstrated by average reduction of epicardial fat thickness of 4mm 
with VLCD of 6 months.
254
 Therefore, measurement of both total body fat mass and the 
intramyocellular triglyceride would have been useful to provide further information. 
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Overall, it would be reasonable to conclude that the peak VO2 should still be a primary 
end point because it represented an overall functional status i.e., cardiac performance. 
 
 
Echocardiography did not show any significant changes in LV ejection fraction, LV 
mass, interventricular septal thickness or posterior wall thickness. This was predicted 
due to the relatively short duration of the study and hence, LVEF was not chosen as a 
primary outcome. However, the trend in LVEF increased with a decreased in LV mass 
and IVS thickness. This might suggest an improvement in overall cardiac function. 
Echocardiography was technically difficult in obese individuals and could provide poor 
image quality. Measurement of cardiac parameters by Cardiac MRI was intended before 
the study was conducted. Unfortunately, the machine was yet not available when the 
study was conducted. On the other hand, three of our cohort would not fit in to the 
proposed MRI machine at baseline because their waist circumferences would have 
exceeded the upper limit of the machine. 
 
Despite discontinuation of antihypertensive therapy, systolic BP reduced significantly 
by an average of 22.18 and 11 mmHg at 6 weeks and 16 weeks respectively compared 
with the baseline. This could be explained by understanding the mechanism of 
hypertension in obesity. The reduction of systolic BP was thought to be related to 
changes in cardiac output (CO) and systemic peripheral resistance (SVR) (BP = CO x 
SVR).  As described, obesity is associated with haemodynamic changes as well as 
increased peripheral vascular resistance by enhancing endothelial dysfunction, insulin 
resistance, and stimulation of the sympathetic nervous system and release of adipokines 
(session 1.2). Reduced renal sodium excretion, volume expansion and sympathetic 
nervous system stimulation are recognised features of changes seen in obese 
individuals.
255
  Hyperinsulinaemia enhances renal sodium retention not only directly, 
through its effects on renal tubules,
256
 but also indirectly, through stimulation of the 
sympathetic nervous system
257
  and through increased angiotensin II-mediated 
aldosterone secretion.
258
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In this study, we have used a fixed amount of diet (800kcal/day for women with 
BMI<40 and 1000kcals/day for all men and women with higher BMI) in the initial 6 
weeks of a low energy liquid diet phase. It was likely that the salt content of this 
regimen was lower than the subjects‘ previous intake. In addition, as previously stated, 
in the initial phase of acute weight loss, diuresis occurred as patients lost a significant 
amount of glycogen and water.
259, 260
 This resulted in a relative intravascular fluid loss, 
reduced peripheral resistance and subsequent reduction in blood pressure. In the steady 
state of weight maintenance, individuals regained 50% of weight they lost during the 
WL phase. The degree of overall systolic BP reduction during WLM phase is therefore 
more likely as a consequence of weight loss. This was mediated by reductions in resting 
heart rates, improvements in sympathetic nervous system function (reduced 
noradrenaline level, improved heart rate variability) as well as reductions in fasting 
insulin levels indicating a degree of improvement in insulin resistance. The degree of 
reduction in systolic BP can be compared with the UK Prospective Diabetes Study 
where 10 mmHg reduction of mean systolic BP was associated with a reduction in 12% 
of any diabetes related complication, 15% of deaths related to diabetes, 11% of 
myocardial infarction and 13% of microvascular complications.
114, 261
 
 
The measures of sympathetic activity (resting heart rate, resting plasma norepineprine 
and heart rate variability) showed significant improvements. The improvement in HRV 
was mainly seen in the frequency domain i.e., increased high frequency power and low 
frequency power. Parasympathetic activity contributes both components whereas 
sympathetic activity mainly contributes to LF. The reducing trend in the LF/HF ratio 
although not significantly, confirmed the contribution of LF was likely from the 
parasympathetic component. The time domain parameters did not significantly change. 
In general, longer recording for over 24 hours usually provides better information with 
regards to time domain measurement.  Unfortunately, it was not able to perform in the 
current study because the recording tape had to come of for various body composition 
measurements and patients would have required staying one more night to achieve this. 
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In addition, it was predicted that 15 min recording would also give reasonable 
information of HRV. 
 
Sympathetic system over-activation in this study group was contributed by impact of 
their body mass as well as their underlying cardiac status. As stated detail in section 
1.3.6, there is a significant association between sympathetic over-activation and 
cardiovascular mortality. Obesity has an impact on cardiac autonomic function. A 10% 
increase in body weight is associated with a decline in parasympathetic tone and 
increased sympathetic activity, accompanied by a raised heart rate.
262
 Conversely, heart 
rate declines during weight reduction.
262 
Several studies have shown that obesity is 
associated with reduced heart rate variability (HRV) and hence impairment of 
autonomic function in obesity.
263-265
 Kim et al
263
 have reported a high level of Fat mass 
was associated with lower level of LF (r = -0.34) and lower level of root mean square 
difference of successive NN interval (RMSSD) (r=-0.33).  Sympathetic activation is also 
associated with hypertension,
266
 hyperinsulinaemia
257
 and type 2 diabetes.
266
  In 
experimental rats, calorie restriction induced a decrease in norepinephrine (NE) turn-
over rate, i.e., reduced sympathetic activity in contrast to overfeeding which stimulate 
SNS activity.
267
A 10% weight loss in severely obese patients is associated with 
significant improvement in autonomic nervous system cardiac modulation (decreased 
heart rate and increase HRV).
265 
The present study confirmed the finding of an 
improvement in HRV after achieving 12% weight loss.  Similarly, Karason et al
268
 has 
demonstrated that following a mean of 28% weight loss in obese patients after weight-
reducing gastroplasty, there were improvements in autonomic functions (reduction 
blood pressure and norepinephrine excretion and increments in SDANN and HF values). 
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4.9. Metabolic profile and biochemistry - Results 
The detail changes in metabolic profile and biochemistry were illustrated in Table 4.10. 
With regards to glycaemia, all insulin treated patients achieved at least a 60% reduction 
in their insulin requirement. One patient managed to come off insulin all together and 
subsequently she only needed metformin. In those who were not treated with insulin, 
fasting insulin levels were significantly reduced (83.6±44.3 to 52.9±32 and 56.2±48.1 
pmol/l, p=0.0117). Among all the patients, glycaemic control generally improved and 
two patients remained euglycaemic despite being no glucose lowering agent. There was 
a significant improvement in HbA1c at the end of 16 weeks (from baseline of 7.22±1.4 
to 6.35±1.83% at week 16). Though there was a trend in lower fasting glucose levels, it 
was not statistically significant.  
 
Total cholesterol levels were significantly reduced during acute weight loss phase 
(4.18±0.6 to 3.47±0.06 mmol/l), but increased during WLM (3.93±0.7mmol/l). The 
initial reduction was due to the statistically and clinically significant reduction in 
triglyceride levels (1.9±0.93 to 1.2±0.62 mmol/l) and a trend toward lower levels of 
HDL. TG continued to fall significantly during WLM phase to 1.29±0.49 mmol/l 
whereas HDL increased (not statistically significant). LDL cholesterol, however slightly 
increased during WLM phase (2.35±0.6 to 2.43±0.7 mmol/l) from baseline towards the 
end of the study.  
 
Significant improvements in other metabolic parameters i.e., ALT, TNF-α and CRP 
were also seen. There was no change in adiponectin and IL-6 levels. Unfortunately, 
there were no report for 3 IL-6 samples because there were some errors in the laboratory 
and therefore reports of these individual were not included in the analysis. The analysis 
was therefore based upon 8 individuals. As expected, leptin levels were reduced during 
the acute weight loss phase. The levels then increased during WLM or re-feeding phase 
but were still lower than baseline. Total antioxidant status (TAS) measured by FRAP 
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assay was significantly reduced. (From baseline of 886±258 to 760±221 and 689±178 
µmol/l, p=0.0009).  
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Table 4. 10 Effect of weight loss and weight loss maintenance on metabolic 
profile and other biochemistry 
 baseline Week 6 Week 16 P value 
Fasting glucose (mmol/l) 7.44±2.66 6.72±2.68 6.35±1.83 0.1 
Fasting insulin
#
 (pmol/l) 83.6±44.3 52.9±32* 56.2±48.1 0.2 
HbA1c (%)  7.22±1.4 6.6±1.2 6.3±1.5* 0.0117 
Adiponectin (µg/ml) 4.62±2.3 3.85±1.9 4.51±2.5 0.4 
Leptin (µg/l) 52.87±4.9 18.2±12.8* 37.47±25.3 0.0126 
ALT (U/l) 41±20.8 35.8±15.5 26.8±8.2* 0.0368 
Total cholesterol (mmol/l) 4.18±0.6 3.47±0.6* 3.93±0.7
+ 
0.0005 
LDL (mmol/l) 2.35±0.6 2.07±0.6 2.42±0.7
+ 
0.0155 
HDL (mmol/l) 1.01±0.24 0.92±0.17 1.05±0.23 0.053 
TG (mmol/l) 1.90±0.93 1.2±0.62* 1.29±0.49* 0.0037 
Sensitive CRP (ng/l) 4.34±3.15 2.81±2.61** 3.04±2.77* 0.0024 
TNF-α (pmol/l) 3.87±1.7 3.46±1.6 2.74±2.2* 0.0159 
IL-6 (pmol/l)
o 
1.109±1.51 1.003±1.29 1.27±1.3 0.7787 
TAS-FRAP (µmol/l) 886±258 760±221* 689±178* 0.0009 
Values represent mean ± standard deviation. N=11. Significance was determined by one 
way ANOVA with repeated measure. When the omnibus test was significant (final 
column), Bonferroni multiple comparisons were performed for baseline versus week 6, 
baseline versus week 16 and week 6 versus week 16. Significant difference is indicated 
by * for first two comparisons and by  
+ 
for the significance difference between week 6 
versus week 16(p<0.05). IL-6 levels
o
 were based on N=8. 
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4.10. Metabolic profile and biochemistry – Discussions 
With weight loss, glycaemia undoubtedly improved in patients with diabetes. Being a 
long term marker, HbA1c improvement was only seen in the latter phase of the study. 
The fall in fasting insulin level together with reduction in requirement of insulin, and 
other glucose lowering therapy also indicated better glycaemic control and reduced 
insulin resistance. Initially, HOMA2 model was intended to use to assess insulin 
resistance. However, three patients from our cohort were treated with insulin and further 
two patients had insulin levels lower than 20pmol/l at week 16 and therefore 
inappropriate for HOMA analysis. HOMA2 analysis required insulin level range 
between 20 to 400pmol/l.
269
  
 
Better glycaemic control was the likely reason why fasting triglyceride fell during acute 
weight loss and WLM. The trend of transient HDL fall was usually seen in patient 
undergoing intensive dieting. The underlying mechanism was not entirely clear. Serum 
ALT, an indicator of non alcoholic hepatic liver disease, was also significantly reduced. 
There has been concerned of weight loss in patients with hepatic steatosis previously 
because of the rising trend in ALT.
270, 271
 However, growing evidence suggested that 
increased ALT was transient following weight loss and it would fall down to baseline or 
lower in long term. Gasteyger et al
272
 has showed that weight loss induced by low 
calorie diet in obese individuals showed immediate reduction in ALT in men and 
transient small elevation of ALT in women which returned to baseline at the 32 weeks. 
In the current study, only one male patient had a transient rise (1.5 fold upper limit of 
normal) was seen but it was then reduced below the baseline at week 16. All remaining 
patients had a reduction in ALT at both week 6 and week 16. 
 
Significant improvements in other markers of systemic inflammation i.e, TNF-α  and 
hsCRP were also demonstrated with weight loss. Evidence showed that CRP was an 
independent predictor of cardiovascular disease.
273-275
 CRP level was strongly correlated 
with insulin resistance.
276, 277
 In type 2 diabetes, CRP level had a strong relationship 
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with degree of total and abdominal adiposity, blood pressure and apolipoprotein and 
triglyceride, independent of genetic influence.
278
 The association was probably 
explained by the fact that IL-6, secreted by adipocytes (an adipokine) was known to be 
potent stimulant of CRP secretion from liver.
279
  
A significant reduction in the CRP level in the current study therefore was likely be 
contributed by reduction in fat mass. However reduction in total FM and abdominal FM 
(android) was not significantly correlated to reduction in CRP.  
 
There was no change in adiponectin level.  Low levels of adiponectin are found in obese 
individuals
280
 and those with type 2 diabetes.
281
 Previously, decreased secretion of 
adiponectin in the setting of intra-abdominal adiposity suggested an increased 
cardiovascular risk. However, recent studies suggested that it was not a strong 
prognostic indicators for CVD risk.
282, 283
  In addition, emerging evidences showed a 
reduced adiponectin was correlated with reduced survival in patients with high CVD 
risk or established CVD patients. 
284, 285
 The underlying mechanism was not clear. 
Therefore, at present, adiponectin is probably not a reliable marker as a monitor of 
disease progression in established CVD patients.   
 
Being a satiety hormone, leptin level decreased during the acute weight loss phase due 
to the low energy intake (relative starvation). The level then increased during the WLM 
or re-feeding phase but still lower than baseline. Reduction in leptin level was 
predictable following reduction in fat mass. Overall, it can be concluded that the 
components of metabolic syndrome and adipokine levels improved with acute weight 
loss and WLM. 
 
Interestingly, total antioxidant status (TAS) measured by the FRAP assay was 
significantly reduced. The exact reason was not entirely clear. TAS may have decreased 
due to a lack or a reduction in antioxidant levels in the diet compared to baseline levels 
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as we did not provide any extra vegetable or fruit during acute weight loss. Crujeiras et 
al
286
 showed a trend for an increase in TAS following weight loss with high fruit intake 
and a lack of change in TAS following weight loss and low fruit intake.  In addition, 
uric acid level could influence TAS. The present study was also confounded by the fact 
that all our patients were on vitamins and minerals in WL phase. Oxidant stress is 
dependent on not only the level of antioxidants but also free radical production.  We did 
not measure lipid hydroperoxide which would probably assess the degree of oxidant 
stress.
287
  
 
As stated on section 3.9.4, our current study measured TAS by the using FRAP assay. 
The assay was simple, speedy, inexpensive, and robust and does not require specialized 
equipment. However, because it relied on the reducing ability of Fe
+++
 to Fe
++
 and the 
redox potential of Fe
+++
/Fe
++ 
is 0.77 V, any compound having redox potential lower than 
this could reduce Fe
+++
 to Fe
++ 
resulting in a false and high FRAP value.
288
  The assay 
was also based on the hypothesis that the redox reactions proceed rapidly (4 min). 
However, some antioxidant compounds such as polyphenols (e.g., ascorbic acid)  reduce 
Fe
+++
 very slowly and the reaction does not reach steady state even after several hours of 
reaction
289
. In addition, the assay does not measure thiol antioxidants, such as 
glutathione.
290
 Some compounds such as bilirubin could give a false high FRAP value 
because its oxidized product beliverdin absorbs strongly at 593 nm, maximum 
absorption of ferrous-tridyltriazine complex
291
 In the current study, we measured 
bilirubin level for a safety parameter and no significant changes in the level  was noted.  
 
 
There are many other methods for in vitro determination of antioxidant capacity. They 
differ from each other in terms of mechanisms of reaction, oxidant and target/probe 
species, reaction conditions, and in the form that results are expressed.
292
 The most 
commonly used methods were  
a) Assays based on biological oxidants  
o peroxyl radical 
o superoxide radical anion  
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o hydrogen peroxide 
o hydroxyl radical 
o hypochlorous acid 
o singlet oxygen 
o nitric oxide radical, and  
o peroxynitrite 
b) Non-biological assays  
o scavenging of 2,2_-azinobis-(3-ethylbenzothiazoline-6-sulphonate) 
radical cation (TEAC assay) 
o scavenging of 2,2-diphenyl-1-picrylhydrazyl radical (DPPH• assay)  
o Folin–Ciocalteu reducing capacity (FC assay)  
o electrochemical total reducing capacity 
 
Various methods show various aspects of TAS and each of them have their own 
pitfalls.
293
 In order to show a complete TAS, therefore, would require performing many 
of those assays. In the current study, assessing TAS was not the main aim. In addition, 
we did not have the capacity to perform many of those assays. Therefore the FRAP 
assay which was automated and high through put, was chosen and we believed that it 
would provide a putative index of anti-oxidant capacity. In retrospect, the detail history 
of dietary intake i.e, different anti-oxidant capacity of their diet that might impact on the 
FRAP assay should have been taken. On the other hand, limiting the diet in patients who 
were already restricted their calorie intake would have been difficult and might have 
provoked drop out from the study.  
 
 
Log transformed BNP correlated significantly with LVEF at baseline in line with the 
literature. However, changes in BNP level were not statistically significant. There was a 
trend of reduction in BNP at the end of 6
th
 week but it had risen again at 16
th
 weeks 
almost to the baseline. Evidence showed that the BNP level was inversely proportionate 
to BMI.
131
 The possible explanation was either due to reduction in BNP production or 
increased clearance of BNP from circulation. The clearance of BNP was mediated by 
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expression of the natriuretic peptide clearance receptor (NPR-C) in adipose tissue.
294
  
Subsequently Das et al
131
 demonstrated that  BMI was also inversely associated with 
aminoterminal -proBNP (NT-proBNP). NT-proBNP was not believed to bind NPR-C.
295
 
The authors therefore have concluded that increased clearance was an unlikely 
mechanism of such an association. They also demonstrated that lean mass measured by 
DXA, not the fat mass, was associated with low BNP and NT-proBNP. More recently, 
Chainani-Wu et al
296
 conducted a prospective study of 125 patients with either 
established coronary heart disease or high cardiovascular risk for life style intervention. 
It was observed that the mean BNP level increased from 18 to 28 pg/ml with a mean 
reduction in BMI by 2.5kg/m
2
.  The percent changes in BNP were inversely associated 
with the percent changes in BMI. Therefore, the authors have suggested using BNP as a 
marker of disease progression needed to take into account weight changes. Unlike 
Chainani-Wu et al, our study did not show a correlation with changes in BNP with 
changes in fat mass, fat free mass, insulin or catecholamine. We have used a gold 
standard body composition measurement and other biomarkers. But our cohort had a 
large spectrum of diseases from high CVD risk to established heart failure patients. The 
heart failure patients had a higher BNP at baseline. In addition, our cohort was likely to 
be too small to show a statistically significant difference. 
Chapter 4. Results 
127 
4.11. Exploratory analysis of changes in fat mass and fat free mass – results 
Further analysis was carried out to investigate correlations between changes in FM and 
the changes in other body composition measures, pVO2 , cardiac function (LVEF and 
LV mass), parameters for sympathetic activity (plasma NE and HRV), metabolic 
parameters (fasting cholesterol, insulin, glucose and CRP). (Table 4.11) As predicted, a 
FM loss was closely and significantly correlated with the degree of weight loss (r= 
0.912, p<0.0001) but not with FFM.  
 
Interestingly, FM loss with significantly and positively correlated with changes in 
absolute pVO2 (ml/min) (r=0.793, p=0.004) and pVO2 corrected by lean mass (ml/FFM 
kg/min) (r=0.645, p=0.032) but not with pVO2 corrected by body mass (ml/kg/min) 
(Figure 4.16). There was no significant correlation with other parameters. 
 
Similar correlation of FFM changes and various parameters were demonstrated in Table 
4.12. Again, the FFM loss was significantly associated with the degree of weight loss 
but not as strong as the correlation between the FM loss and the weight loss (Pearson r 
of 0.912 Vs 0.637, p of <0.0001 and 0.035 respectively). An interesting and negative 
correlation was noted in between the FFM loss and the pVO2 corrected by body mass 
(ml/kg/min) (r= -0.688, p=0.019) (Figure 4.17).  The correlation was not significant 
when pVO2 was corrected with FFM or presented as an absolute value. Similarly, the 
FFM loss showed no significant correlation was noted with changes in other parameters
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Table 4. 11. Correlation of changes in FM (week 16 – 0) with other putative 
variables 
Parameter Pearson r 95% confidence 
interval 
P value (two-
tailed) 
R 
squared 
delta weight (kg) 0.912 0.689 to 0.977 <0.0001*** 0.832 
delta FFM (kg) 0.281 -0.384 to 0.753 0.404 0.079 
delta pVO2 (ml/kg/min) 0.079 -0.547 to 0.648 0.818 0.006 
delta pVO2 (ml/min) 0.793 0.369 to 0.944 0.004** 0.630 
delta pVO2 (ml/FFM kg/min) 0.645 0.073 to 0.897 0.032* 0.416 
delta LVEF (%) -0.339 -0.780 to 0.327 0.308 0.115 
delta LV mass (g) 0.431 -0.228 to 0.819 0.186 0.186 
delta BNP (pg/ml) -0.159 -0.693 to 0.487 0.641 0.025 
delta HF (ms
2
) 0.070 -0.554 to 0.643 0.839 0.005 
delta LF (ms
2
) 0.454 -0.201 to 0.828 0.161 0.206 
delta plasma NE (ng/l) -0.029 -0.618 to 0.581 0.932 0.001 
delta insulin (pmol/l) 0.478 -0.171 to 0.838 0.137 0.229 
delta CRP (ng/l) -0.019 -0.612 to 0.588 0.955 0.0003 
delta Choesterol (mmol/l) 0.363 -0.340 to 0.775 0.272 0.132 
delta glucose (mmol/l) -0.192 -0.710 to 0.461 0.573 0.037 
 
Table demonstrates correlations between FM changes from baseline to 16 weeks and 
other collected variables in patients with obesity and heart failure/ high CVD risk. 
(N=11) Correlation and significance were determined using Pearson‘s Correlation test. 
Correlation as significant* at the 0.05 level. FM=fat mass, FFM= fat free mass, pVO2 = 
peak VO2, LVEF=left ventricular ejection fraction, LV mass= left ventricular mass, 
CRP = BNP= b-type natriuretic peptide, HF=high frequency, LF= low frequency, 
NE=norepinephrine, c- reactive protein 
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Table 4. 12. Correlation of changes in FFM (week 16 – 0) with other putative 
variables 
Parameter Pearson r 95% confidence 
interval 
P value 
(two-tailed) 
R 
squared 
delta weight (kg) 0.637 0.060 to 0.895 0.035* 0.406 
delta FM (kg) 0.281 -0.38 to 0.754 0.404 0.079 
delta pVO2 (ml/kg/min) -0.688 -0.912 to -0.150 0.019* 0.473 
delta pVO2 (ml/min) -0.161 -0.694 to 0.486 0.636 0.026 
delta pVO2 
(ml/FFMkg/min) -0.391 -0.803 to 0.273 0.234 0.153 
delta LVEF (%) -0.167 -0.697 to 0.481 0.623 0.028 
delta LV mass (g) 0.381 -0.284 to 0.799 0.248 0.145 
delta BNP (pg/ml) 0.090 -0.539 to 0.655 0.792 0.008 
delta HF (ms2) -0.111 -0.667 to 0.524 0.745 0.012 
delta LF (ms2) 0.184 -0.468 to 0.706 0.588 0.034 
delta plasma NE (ng/l) 0.255 -0.407 to 0.7413 0.450 0.065 
delta insulin (pmol/l) 0.304 -0.362 to 0.7647 0.363 0.093 
delta CRP (ng/l) 0.106 -0.528 to 0.6635 0.757 0.011 
delta cholesterol (mmol/l) -0.320 -0.776 to 0.337 0.323 0.109 
delta glucose (mmol/l) -0.255 0.741 to 0.408 0.450 0.0648 
 
Table demonstrates correlations between FFM changes from baseline to 16 weeks and 
other collected variables in patients with obesity and heart failure/ high CVD risk. 
(N=11) Correlation and significance were determined using Pearson‘s Correlation test. 
Correlation was significant* at the 0.05 level. FM=fat mass, FFM= fat free mass, pVO2 
= peak VO2, LVEF=left ventricular ejection fraction, LV mass= left ventricular mass, 
CRP = BNP= b-type natriuretic peptide, HF=high frequency, LF= low frequency, 
NE=norepinephrine, c- reactive protein.
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Figure 4. 16. Correlation of changes in FM (week 16 -0) with changes in body 
weight and peak VO2 (week 16 -0) 
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Delta FM correlated with delta body mass and delta pVO2 (week 16-0) in obese patients 
with heart failure and or high cardiovascular risk. A represents correlation with body 
mass loss, B represents correlation with delta PVO2 presented in ml/min (absolute 
value). C represents correlation with delta pVO2 presented in ml/FFM kg/min. All 
graphs demonstrated significantly lower fat mass as delta pVO2 decreased.  
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Figure 4. 17. Correlation of changes in FFM (week 16 -0) with changes in body 
weight and peak VO2 (week 16 -0) 
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Delta FFM correlated with delta body mass and delta pVO2 (week 16-0) in obese 
patients with heart failure and or high cardiovascular risk. A represents correlation with 
body mass loss, B represents correlation with delta PVO2 presented in ml/kg/min 
(corrected by body mass). Graph B demonstrated significantly lower FFM as body mass 
decreased. Graph B demonstrated significantly increased in delta pVO2 as FFM 
decreased. 
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4.12. Exploratory analysis of changes in fat mass and fat free mass - discussion 
Both loss of FM and FFM occurred following the weight loss intervention. However, 
the degree of the correlation of weight loss was much stronger with FM loss than with 
FFM loss. In addition, there was no correlation in between loss of the FM and FFM i.e., 
FFM loss was independent and less of FM loss. This implied an achievement of a much 
healthier body composition following the therapeutic weight loss intervention.  
 
Surprisingly, paradoxical correlations were noted between pVO2 changes with the FM 
and FFM changes.  Peak VO2 changes correlated positively with delta FM (decreasing 
delta FM with decreasing delta pVO2) and negatively with delta FFM (decreasing delta 
FFM with increasing delta pVO2). The correlations were, however, not to a significance 
levels if pVO2 unit was corrected with body mass (for correlation with FM) and as an 
absolute value and corrected by FFM (for correlation with FFM). Peak VO2 measured 
during the cardiopulmonary exercise was influenced by various physiological statuses as 
stated in section 3.5.1and Figure 3.4. Factors that can influence O2 availability are the 
oxygen carrying capacity of the blood (available haemoglobin, arterial O2, CO2 and 
dissociation curve shift with temperature, CO2 and pH), cardiac function (heart rate, 
stroke volume, redistribution of peripheral blood flow, and by the tissues (capillary 
density, mitochondrial density and function, adequacy of perfusion, and tissue 
diffusion).
116
  The skeletal muscle is a very important organ taking up O2 from the 
circulation at maximal exercise (pVO2). Paradoxically, the current study showed 
decreasing in lean body mass (FFM) correlated with increasing in pVO2 following 
weight loss. In addition, adipose tissue does not have an oxygen carrying capacity and 
one would expect to see a reduction in fat mass correlating with increasing in pVO2.  
Again, a paradoxical effect was seen in this study.  
 
It was possible that those findings were be secondary to changes the composition of 
cardiac muscle following weight loss. In the current study, LV mass or LVEF measured 
by Echocardiography did not show any significant changes. However, 
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Echocardiography was technically difficult in obese individuals. In addition, 
Echocardiography was likely not sensitive to detect smaller changes occurred at short 
duration of the study. Evidence suggested that weight loss was associated with reduction 
epicardial fat (triglyceride) level and reduction in LV mass and improvement in diastolic 
function. Therefore, a detail cardiac composition measurement by cardiac MRI would 
be desirable. 
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CHAPTER 5:    LIMITATIONS, SUMMARY AND CONCLUSION 
5.1. Limitations 
5.1.1. Recruitment difficulty 
This study was intended as an initial pilot study to be followed by a randomised 
controlled trial. Patients were recruited from cardiology, obesity and diabetes clinics. 
Recruitment was much harder than anticipated. With advances in medical therapy, 
stable heart failure is now mainly managed in the community. It was found that the 
majority of hospital clinic attendees were not suitable to take part in the study especially 
with the initial stringent inclusion criteria. Therefore, recruitment was extended by 
approaching cardiologists at Bedford Hospital, Luton and Dunstable hospital and West 
Suffolk Hospital as well as Cambridgeshire general practitioners (GP) including a GP 
with a special interest in cardiology and the community heart failure nurse. However, 
very little reposes were received. In retrospect, the study recruitment would have been 
improved in collaboration with other primary and secondary centres before the study 
was conducted. When hospital discharge letters were also searched for codes of the 
obesity (E66) and heart failure (I50), only 24 patients were identified. It was very likely 
that obesity was under recorded, and indeed the majority of these identified cases were 
in the extreme BMI of >40 kg/m
2
. Interestingly, 5 of those patients identified died by the 
time of data search. The rest of the case notes were reviewed and potentially appropriate 
patients were approached by sending out invitation letters with prepaid envelops to reply 
back if there was any interest in participating in the study. Despite all these effort, only 3 
patients were recruited at 9 months after the approval from the study by the Research 
ethic committee (REC). Therefore, a further amendment to the protocol was carried out 
with more relaxed criteria to include obese patients with high cardiovascular risks 
without the diagnosis of heart failure. The amendment was approved by REC (April 
2007). The study was then, decided to base it on extended pilot study with the 11 
patients who were on the active weight loss management programme. There was only 
one control patient who did not have the weight loss intervention and her data was not 
included in the analysis. This thesis was therefore based on the extended pilot study 
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without the control group and was thus under powered. Hence, the impact of natural 
history of disease on the changes seen could not be assessed. 
 
5.1.2. Statistical analysis 
At post hoc analysis, our study showed a greater improvement in peak VO2 (13.2%) 
than predicted (10%) with a mean difference of 2.43 ml/kg/min (18.33 to 20.76 
ml/kg/min). The standard deviation (SD) of the study was larger at 4.65 than estimate of 
2.9. Having small sample size, the study was significantly under power at 34% (Table 
5.1). Although it was under powered, the study has demonstrated the statistically and 
clinically significant improvement of the primary end point, peak VO2. The study did 
not power for assessments of other (secondary) parameters. Since the study was 
significantly under power for the primary end point, confidence interval (CI) for those 
other parameters were large and ―non significant‖ difference (NS) are subject to type 2 
errors. 
 
Table 5. 1. Post hoc analysis: Power calculation 
t tests - Means: Difference between two dependent means (matched pairs) 
Analysis: Post hoc: Compute achieved power  
Input: Tail(s) = Two 
 Effect size dz = 0.5199256 
 α err prob = 0.05 
 Total sample size = 11 
Output: Noncentrality parameter δ = 1.7243981 
 Critical t = 2.2281389 
 Df = 10 
 Power (1-β err prob) = 0.3448195 
 
Data were analysed with parametric test as planned. However because of the smaller 
sample size, non parametric tests would have been more appropriate. On analysis of the 
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primary end point data or log transformed data with histogram confirmed that the data 
were not normally distributed. Nevertheless, the analysis using non parametric Friedman 
test of primary end point (peak VO2) also showed a significant difference in the means 
with a ―p value‖ of 0.0377. Post hoc analysis with Dunn multiple comparison test 
showed significant mean difference from week 0 to 16, but not significant from week 0 
to 6. (Appendix. D) 
 
Base on the study finding, it was calculated that 29 subjects would have been needed to 
detect a 13.2% improvement in peak VO2 after a 13.5% weight loss at an effect size of 
0.586, p value <0.05 and 85% power (Table 5.2). To achieve 3:1 intervention Vs non-
intervention ratio, the number in intervention group was increased to 39 with an 
additional 10 patients were to be recruited as the non-intervention control group. If 10% 
drop out is anticipated, the study would require 43 patients. Different sample sizes could 
be examined that was plotted against power (Figure 5.1). 
 
Table 5. 2. Sample size calculation by G Power software (85% power) 
 
t tests - Means: Difference between two dependent means (matched 
pairs) 
Analysis: A priori: Compute required sample size  
Input: Tail(s) = Two 
 Effect size dz = 0.5863654 
 α err prob = 0.05 
 Power (1-β err prob) = 0.85 
Output: Noncentrality parameter δ = 3.1576743 
 Critical t = 2.0484071 
 Df = 28 
 Total sample size = 29 
 Actual power = 0.8616441 
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Figure 5. 1 X-Y plot for a range of sample size against power  
 
 
5.1.3. Study population 
Our study was initially intended to conduct on obese patients with heart failure. It was 
then extended to include patients with high cardiovascular risk. As a result, there were 
only 4 patients with the diagnosis of heart failure who had completed the study. Being a 
study of a small sample size and having a heterogeneous group of cohort, some of the 
statistically insignificant results the study were prone for the type II errors. On the other 
hand, the current study cohort reflected a group of high cardiovascular risks and had 
provided a good reflection of intended study objectives. 
 
 
5.2. Summary  
This study aimed to see whether WL or WLM was of benefit or harm to patients with 
heart failure and or high cardiovascular risk. While the ―gold standard‖ for such a study 
would involve cardiac or other outcome events, an extremely large and long term study 
would be needed. Therefore, alternative parameters of cardiac performances (pVO2), 
haemodynamic changes, sympathetic activity and metabolic profile were measured 
following active weight loss intervention. Detailed body composition changes 
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(measured by the techniques with high precision using four compartment model, whole 
body quantitative measurement of body fat by MRI) were performed. Weight loss 
intervention was carried out by providing low energy liquid diet of 3.35 MJ-4.19 MJ 
(800- 1000 Kcal/day) and weight loss maintenance was achieved by providing solid 
food which met 80% of daily energy requirement. Unfortunately, due to the recruitment 
difficulties, the study was largely limited by not having a control group. Thus, this data 
presented with in this thesis was based upon 11 pilot patients and under powered. In this 
cohort, the aim of the study was met achieving an acute weight loss and maintaining 
such weight loss toward the end of the study. Both the use of the specific diet and 
inducing rapid weight loss were proven to be safe in this study group. There were 
significant improvements in haemodynamic parameters, cardiac performance in terms of 
peak VO2, sympathetic system activity and various metabolic profiles. 
 
The question remains as to why there were consistent epidemiological data showing that 
low body weight in a group of patients with heart failure have a high risk of 
cardiovascular mortality.
27, 41, 152
 More recently ―the candesartan in heart failure: 
assessment of reduction in mortality and morbidity (CHARM) programme‖297 studied 
mortality of weight changes over 6 months in 6993 heart failure patients. The percentage 
weight loss over 6 months had an increasing association with excess mortality. Patients 
with 5% or greater weight loss in 6 months had over a 50% increased in hazard 
compared with those with stable weight.  
 
However, in these studies, the fall in weight was not voluntary or as a result of a 
therapeutic weight loss. It was likely to reflect an advance in the cardiac disease, or 
could reflect unsafe weight loss practices (e.g. Atkin diets). It is possible that the short 
term nature of our study failed to see the deleterious effects but it seems unlikely. 
Therefore, long term larger outcome studies of weight loss in high risk cardiovascular 
patients are needed to answer the question. Jhaveri  et al
298
 showed a substantial weight 
loss (mean 32kg) following bariatric surgery was associated by significant reduction in 
LV mass (34%) and 16% RV mass measured by cardiovascular magnetic resonance 
Chapter 5. Limitations, Summary and Conclusion 
140 
imaging. The Swedish Obese Subjects Study (SOS)
299, 300
 followed 2000 patients who 
underwent bariatric surgery. With an average of 10 years of follow up, reduction of 
traditional cardiovascular risk factors and the overall risk factor-adjusted mortality 
(30.7%) were seen compared with the controlled group.  
 
Though there were limitations, the present study also carried some major strength. The 
study was unique because it investigated detailed aspects of patient cardiovascular status 
including measurement of cardiac parameters (structure, function and performance), 
haemodynamic parameters and autonomic functions.  This was carried out in parallel to 
measuring body compositions with a gold standard technique (4C) and comprehensive 
assessment of metabolic profile and cardiac risk biomarkers. In addition, the choice of 
the weight loss intervention with LCD was successful reflected by high retention rate 
and achievement of significant weight loss implying adherence to calorie restriction. 
The current study demonstrated the metabolic and clinical safety of weight loss in 
patients with heart failure and or high cardiovascular risk. 
 
5.3. Conclusion 
In this pilot study (N=11), weight loss in patients with heart failure and or high CVD 
risk was associated with improvements in cardiac performance (pVO2), haemodynamic 
parameters (reduction in systolic blood pressure, resting heart rates), autonomic function 
(reduction in resting heart rate, plasma and urine norepinephrine, and increase in HRV) 
and CVD risk profile (cholesterol, CRP) and metabolic profile (decrease in fasting 
glucose, insulin, ALT, TNF-α). The study will form a platform for future multicentre 
randomised control intervention outcome trials. 
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CHAPTER 6: FURTHER DIRECTION 
There was little evidence for the link between high body mass index and the better 
prognosis for heart failure patients and that there is need for well-controlled, large scale 
studies to explore this. Based on the current study, future work could be conducted for a 
larger multicentre control trial of weight loss intervention. In addition to investigating 
current study‘s end points, the future study should aim to investigate outcomes i.e., CV 
deaths and composite cardiovascular events (acute myocardial infarction, heart failure, 
peripheral vascular disease, End stage renal failure) and therefore will be a longer study 
(5 years). The cohort will be stratified into different sub-groups i.e., with or without 
heart failure, diabetes and metabolic syndrome. In term of body composition 
measurements, assessment of differential fat mass (e.g., visceral fat) with proton MR 
spectroscopy will be important. This should be compared with regional fat mass changes 
measured by DXA.  More precise and advance cardiac measurement by Cardiac MRI 
should be included in the study to measure all cardiac parameters which would be 
available from echocardiogram as well as intramyocardial fat (triglyceride) level. To 
achieve a sustainable weight loss at longer period, WLM phase will be reinforced by a) 
use of different weight loss drugs including orlistat and newer glucagon like peptide-1 
(GLP-1) agonists such as Exenetide and Liraglutide and b) life style modification 
(exercise program and calorie restriction). A sub-study could also look at the carotid 
intima-medial thickening and detailed of atherosclerosis assessment by Positron-
emission tomography (PET) CT scanning. Other parameters of psychological issue 
associated with obesity can also be examined.  
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Methods and techniques
IntroductIon
Expanded body fat depots in obese individuals are  associated 
with endocrine and metabolic disturbances that impact 
health and longevity. The usual measures of therapeutic out-
come and benefit are based upon easily measurable surrogates 
such as body mass (BM) and BMI, but ultimately the treat-
ment of obesity aims to reduce the excessive fat mass (FM). 
Unfortunately, at an individual level weight and BMI are indi-
rect and imprecise estimates of body fat content, especially 
across ethnic groups (1), the young, the elderly (2) and those 
with illness or chronic disease (3). Under long-term moderate 
energy deficit, fat loss accounts for 75% of total weight loss, but 
during early or rapid weight loss, or in patients with disease 
states such as heart failure or diabetes (4), fat-free mass loss 
may be as much as 50% (5). Furthermore, individuals vary in 
their adiposity and lean BM, and BMI may misrepresent the 
extent of metabolic disturbance when, for example, an indi-
vidual with a normal FM is categorized as overweight, and 
vice versa. Indeed weight loss induced by diet or pharmaco-
therapy may not accurately represent fat loss, and there is the 
potential for misinterpreting the clinical benefit (or harm) 
from such interventions.
Accurate measurement of body composition is thus of criti-
cal importance in evaluating the efficacy, potential benefits, and 
risks of interventional weight loss. This is recognized by regula-
tory authorities in their guidelines relating to the development 
of antiobesity drugs. The US Food and Drug Administration 
(6) requires that studies “ensure that drug or biologic-induced 
weight loss is caused primarily by a reduction in fat con-
tent, not lean body mass,” and the European Committee for 
Medicinal Products for Human Use similarly comment that 
“measurements using accepted methods selected and justified 
by the applicant should demonstrate that weight loss is associ-
ated with appropriate loss of body fat (as distinct from muscle 
or body water)” (7).
The currently accepted reference method for body composi-
tion brings together (i) BM, (ii) total body water (TBW) mass 
measured by stable isotope dilution (e.g., deuterium oxide, 
D2O), (iii) body volume (BV) usually quantified by air dis-
placement plethysmography, and (iv) bone mineral content 
Quantitative Magnetic Resonance (QMR) for 
Longitudinal Evaluation of Body Composition 
Changes With Two Dietary Regimens
Khin Swe Myint1, Antonella Napolitano2, Sam R. Miller2, Peter R. Murgatroyd3, Maysoon Elkhawad2, 
Derek J.R. Nunez4 and Nick Finer1,3
We have recently reported a validation study of a prototype low-field strength quantitative magnetic resonance (QMR) 
instrument for measurement of human body composition (EchoMRI-AH). QMR was very precise, but underreported 
fat mass (FM) by 2–4 kg when compared to a 4-compartment (4C) model in this cross-sectional study. Here, we report 
the performance of an updated instrument in two longitudinal studies where FM was decreasing. Healthy obese 
volunteers were given a modest energy deficit diet for 8 weeks (study A) and obese patients with heart failure and/
or at high cardiovascular risk were prescribed a low energy liquid diet for 6 weeks (study B). FM was measured at the 
start and end of these periods by QMR, dual-energy X-ray absorptiometry (DXA) and 4C. A higher proportion of the 
weight lost came from fat in study A compared with study B, where loss of total body water (TBW) played a greater 
part. The intraclass correlation between QMR and 4C estimates of FM loss (ΔFat) was 0.95, but 20 of 22 estimates 
of ΔFat by QMR were lower than the corresponding estimate by the 4C model. Bland–Altman analysis demonstrated 
that estimates of FM loss by QMR were ~1.0 and 0.7 kg lower than those obtained with 4C (P = 0.0008) and DXA 
(P = 0.049), respectively. Measurement precision remained high. QMR measurement should prove valuable for 
quantifying modest changes of FM in small trials.
Obesity (2009) doi:10.1038/oby.2009.272
The first two authors contributed equally to this work.
1Institute of Metabolic Science, Metabolic Research Laboratories, Cambridge, UK; 2Clinical Unit in Cambridge, GlaxoSmithKline, Cambridge University Hospital NHS 
Trust, Cambridge, UK; 3Wellcome Trust Clinical Research Facility, Cambridge University Hospital NHS Trust, Cambridge, UK; 4GlaxoSmithKline Metabolic Pathways 
Center of Excellence for Drug Discovery, Research Triangle Park, North Carolina, USA. Correspondence: Antonella Napolitano (Antonella.2.Napolitano@gsk.com)
Received 16 January 2009; accepted 9 July 2009; advance online publication 20 August 2009. doi:10.1038/oby.2009.272
2 www.obesityjournal.org
articles
Methods and techniques
(BMC) obtained by dual-energy X-ray absorptiometry (DXA) 
in a 4-Compartment (4C) model from which absolute fat and 
lean masses are derived. A number of expressions have been 
derived to relate FM to these parameters; in our studies we 
have used the following expression (8):
However, the measurement of the 4C components can be 
inconvenient and in practice FM measured by DXA is more 
widely adopted as a primary measure of body composition, 
due to its reliability and ready availability, but these measure-
ments can be confounded by when body size exceeds the limits 
for the instrument.
Quantitative magnetic resonance (QMR) methodology has 
been widely adopted for measuring body composition in live, 
unanaesthetised small animals (9), and it has become the pre-
ferred technique for measuring longitudinal changes in their 
FM over time. QMR was further developed to provide a con-
venient, noninvasive measurement of human body fat that 
offered the potential to improve on existing methods in preci-
sion and ease of measurement. EchoMRI-AH (EchoMedical 
Systems, Houston TX) is a novel QMR instrument which uses 
tissue-specific nuclear magnetic resonance properties of pro-
tons to separate signals originating from fat, “lean” tissue and 
“free” water and “total body” water (10).
We have recently reported on the use of a prototype 
EchoMRI-AH QMR instrument to measure body composition 
(11). The instrument performed well in tests to simulate body 
composition change using bottles of canola oil, and the level of 
precision was impressively high. In detecting small changes of 
FM, it was three times more precise than other methods such 
as DXA and 4C models.
In our initial validation report (11), changes in body com-
position were simulated and we emphasized that the precision 
and accuracy of QMR-derived estimates for FM change would 
require confirmation in longitudinal studies where subjects gain 
or lose weight. Here we report such an evaluation. We have stud-
ied two separate groups of subjects undergoing dietetic manip-
ulations to reduce energy intake and produce weight (fat) loss. 
The first consisted of healthy overweight or obese volunteers 
who were placed on a modest energy deficit diet and the sec-
ond group were overweight and obese patients with heart fail-
ure and/or at high cardiovascular risk who lost weight rapidly 
following prescription of a low energy liquid diet. This article 
extends the evaluation of QMR methodology by comparing the 
FM changes measured by the new EchoMRI-AH instrument to 
those measured by the 4C and DXA methods in terms of their 
agreement and relative precision. We use this information to 
assess the impact of the precision estimates on the powering of 
studies designed to assess changes in FM by QMR.
Methods and Procedures
The studies were conducted at Addenbrooke’s Hospital, Cambridge, 
UK. The QMR instrument is located in the GlaxoSmithKline Clinical 
Unit in Cambridge, whereas the other measurements of body 
 composition were performed in the adjacent Wellcome Trust Clinical 
Research Facility.
human intervention studies
Study A took advantage of a randomized clinical trial of a weight loss 
agent (EUDRACT 2006-003864-71) to compare the performance 
of the QMR, 4C and DXA methods in the placebo-treated subjects. 
Thirty healthy subjects were recruited by direct advertisement via 
the GlaxoSmithKline Clinical Unit in Cambridge. Inclusion criteria 
included BMI between 30 and 40 kg/m2 and age between 18 and 55 
years. Subjects with type 2 diabetes mellitus were excluded. The use 
of recreational drugs, alcohol, caffeine, and strenuous exercise were 
forbidden. A qualified dietician advised subjects on a hypocaloric 
diet designed to produce a daily energy deficit of 2,510 kJ, based upon 
estimates of energy expenditure derived from standard equations (12) 
assuming a physical activity level of 1.3. After a 2 week run-in on diet 
alone, baseline measurements, including FM assessment, were made. 
Subjects were then randomized in a 3:2 ratio to receive an experi-
mental weight loss compound (n = 18) or identical matched placebo 
tablets (n = 12). Subjects were counselled biweekly for 8 weeks, after 
that they again underwent measurement of body FM by QMR, 4C 
and DXA methods. Data presented here are from the 11 subjects who, 
after unblinding on completion of the study, were found to have been 
randomized to placebo. QMR measurements were performed between 
07:00 and 08:00 in the fasted state. BV (BOD-POD), DXA and D2O 
dilution were performed between 09:00 and 14:00 on the same day 
as QMR measurements. Body weight was measured in light clothing 
before QMR measurements.
In study B, 11 patients with heart failure or other cardiovascular risk 
factors were recruited from the obesity and cardiology clinics at Adden-
brooke’s hospital into a study designed to investigate the impact of rapid 
weight loss on cardiovascular safety and benefit (Cambridge Research 
Ethics Committee Reference 06/Q0108/37). The study included meas-
urements of body composition, VO2 max, cardiac function by echocar-
diography, autonomic nervous system activity and antioxidant status. 
QMR measurements were performed in the morning in a fasted state, 
whereas DXA, BV, and D2O dilution were performed on the same day 
as QMR scans. Body weight was measured in light clothing before QMR 
measurements. Study inclusion criteria included BMI between 30 and 
50 kg/m2, stable heart failure patients of New York Heart Association class 
II or III or patients with additional cardiovascular risk and age between 
25 and 70 years. Subjects were placed on a low energy liquid diet as rou-
tinely used to achieve initial weight loss by the obesity clinic service at 
Addenbrooke’s Hospital. The diet was based on semiskimmed milk and 
provided 3,350–4,490 kJ/day (76–84 g protein), depending on the initial 
BMI. Patients were seen weekly during this phase. After 6 weeks the sub-
jects were advised on a conventional diet designed to provide an energy 
intake that would maintain the weight for a further 10 weeks. Data on the 
11 subjects who completed the initial 6 weeks and who had QMR and 4C 
FM measurements are included here.
The studies were performed in accordance with Good Clinical Prac-
tice guidelines and the 1996 version of the declaration of Helsinki. The 
experimental protocols were approved by the protocol review panel at 
GlaxoSmithKline, the Cambridge Local Research Ethics Committee and 
by the Addenbrooke’s Hospital R&D office and the Wellcome Trust Clini-
cal Research Facility Scientific Advisory Board. All patients gave written 
informed consent to participation.
Body composition measurements
QMR. The characteristics of the QMR have been described previously 
(11). Since that publication, the software algorithm for deconvoluting 
FM has been updated by the manufacturer. These alterations related 
primarily to estimates of TBW, but were also expected to improve the 
precision of the fat measurements.
At the start of each day the QMR instrument was calibrated accord-
ing to manufacturer’s instructions using 45 kg Canola rapeseed oil, 
which has comparable magnetic resonance properties to human fat. 
FM 2.747 BV 0.71 TBW 1.46 BMC 2.05 BM .= × × + × ×( ) ( ) ( ) ( ) 
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The oil composition is: 7% saturated fat, 62% monounsaturated fat, 26% 
 polyunsaturated fat, and 5% of other constituents. In both studies, the 
QMR measurements were made in triplicate over a 10 min period. Room 
temperature was maintained at 22.5 °C.
4c model
In this study, FM was estimated using the following 4C equation (8):
where BV is in litres and all other variables are in kilograms.
BV was derived from a BOD POD (Life Measurement, Concord, CA) 
using its estimates of % body fat and BM as follows (13):
TBW was measured by D2O dilution using a protocol designed in col-
laboration with the Medical Research Council Human Nutrition Research 
Group, Cambridge, UK, who also undertook the deuterium analysis (14). 
Subjects were fasted from 22:00 and at 06:00 the next morning they were 
woken and asked to void urine. A saliva sample and a sample of the 
voided urine were taken for D2O analysis. A drink of D2O-enriched water 
(100 g of 7% by mass D2O in H2O) was then administered, and further 
saliva samples were taken at 4, 5, and 6 h post dose. Up to the 6 h sample, 
the volume of all urine passed was recorded and aliquots were retained 
for D2O analysis to correct for label lost from the body water pool.
DXA. Total body bone mineral mass (BMC), FM, and lean mass were 
estimated from DXA scans (GE Lunar Prodigy; software version 8.1 
GE Lunar, Madison, WI). In study B, three subjects at their first assess-
ment were too heavy for measurement on the DXA instrument. The 
initial visit DXA data from a further three subjects was excluded on the 
basis that, though within the weight range of the instrument, their bone 
mineral content and lean mass estimates showed implausible changes 
between this and subsequent visits, related, we believe, to the initial 
depth of tissue in the trunk. For the 4C model calculation in these 
subjects, bone mineral content for the first visit was assumed to be the 
same as the second visit. DXA data are presented for the remaining five 
subjects.
The “fixed-set” intraclass correlation coefficient (ICC3) was calculated 
to assess the degree of methodological variation between QMR and 4C 
methods (the two methods are considered “fixed” by the study design) 
(15). However, a high ICC is necessary but not sufficient to compare two 
measurements, so in addition the Bland–Altman method(15) was used to 
compare the change in FM measurements obtained by QMR with those 
from the 4C and DXA methods. These statistical analyses were carried 
out using SAS Version 9 for Windows.
Sample-size calculations were performed to assess the impact of QMR 
precision on a range of hypothetical trial designs using variability esti-
mates from our initial report and from the two studies presented in this 
article. Sample-size calculations were performed using PASS 2005.
results
Table 1 shows the baseline demographics and body composi-
tion of subjects, and their response to dietary restriction.
Subjects in study A were prescribed an average energy deficit 
of ~2.7 MJ/day over 8 weeks, and those in study B ~6.7 MJ/day 
over 6 weeks. Assuming a 30 MJ deficit should produce ~1 kg 
weight loss, we anticipated losses of 5 kg for study A (4.8 kg 
achieved) and 9.4 kg for study B (12 kg achieved). The measured 
losses of FM (by 4C) were 4.7 and 8.0 kg, respectively. These 
outcomes suggest good average compliance with the dietary 
interventions. Data also indicate that a greater  proportion of 
the weight loss in study A came from loss of fat than in study B, 
where loss of TBW (derived from the 4C methodology) played 
a greater part.
Some important similarities and differences between the 
studies are illustrated in Figure 1a,b. Loss of FM and BM was 
achieved by all subjects except for one in study A. The baseline 
BM and FM were considerably more heterogeneous, and the 
degree of weight loss much greater, in study B. These two inter-
ventions therefore provide a good range of fat loss with which 
to compare the measurement methods, as well as two different 
clinical samples with differing body composition with which 
to make comparisons.
The relationship between QMR estimates of FM loss (ΔFat) 
and those obtained with the 4C model is illustrated in a cor-
relation plot (Figure 2). The intraclass correlation (ICC3) is 
0.95, which is high. However, a high ICC is not sufficient to 
demonstrate agreement because it is strongly influenced by the 
variance of the measurement in the population in which it is 
assessed. The lack of agreement can be seen by the fact that 
20 of 22 estimates of ΔFat by QMR were lower than the cor-
responding estimate by the 4C model.
Bland and Altman plots are a more appropriate method 
to assess the degree of agreement (16). These plot the differ-
ence between two methods against the mean of the methods, 
 disclosing the variability, any systematic difference between 
methods, and any tendency of the difference to be related to 
the mean, without assuming that either method has superior 
properties. Figure 3a demonstrates that measurements of 
FM loss by QMR are lower than those obtained with the 4C 
FM 2.747  BV   0.71  TBW   1.46  BMC   2.05  B= × × + × ×[ ] [ ]    M[ ]
BV %fat 450 BM
495
.
= + ×( )
table 1 Baseline characteristics and body weight and 
composition changes
Study
A (n = 11) 
(8 weeks)
B (n = 11) 
(6 weeks)
Sex (female:male) 4:7 3:8
Age (years) ± s.d. 42 ± 14 54 ± 10
BMI (kg/m2) ± s.d. 32 ± 1 38 ± 5
BM (kg) ± s.d. 96 ± 11 113 ± 23
Fat (kg) (QMR) ± s.d. 33 ± 6 49 ± 16
Fat (kg) (4C) ± s.d. 37 ± 5 51 ± 15
TBW (kg) ± s.d. 45 ± 8 48 ± 10
Loss of BM (kg) ± s.d. 4.8 ± 3.5 12.0 ± 4.6
Fat loss (kg) (QMR) ± s.d. 3.6 ± 3.0 7.1 ± 4.1
% Fat loss (QMR) ± s.d.a 74 ± 20b 56 ± 17
Fat loss (kg) (4C) ± s.d. 4.7 ± 3.3 8.0 ± 3.2
% Fat loss (4C) ± s.d.a 94 ± 26b 68 ± 12
TBW loss (kg) ± s.d. 0.3 ± 1.5 3.9 ± 2.6
% TBW Loss ± s.d.a 8 ± 23b 31 ± 13
BM, body mass; QMR, quantitative magnetic resonance; TBW, total body water; 
4C, 4-compartment.
aPercentage losses of fat and TBW are calculated relative to loss of BM. bn = 8; 
three patients who lost <2 kg of total body weight are excluded from percentage 
calculations.
4 www.obesityjournal.org
articles
Methods and techniques
model, similar to our previous data for absolute FM (11). The 
regression line shows no significant slope, but does demon-
strate a mean difference of 1.03 kg (P = 0.0008). The standard 
deviation of the differences is 1.2 kg. Similarly, there was no 
significant slope when the difference between methods was 
plotted against absolute BM (data not shown). We note that 
these plots may generate an apparent systematic bias when the 
methods have different standard deviations (17). Assuming 
a standard deviation of 0.43 kg for QMR and 1 kg for 4C, we 
calculate that any bias would be <0.3 kg in the intercept, and 
~0.06 in the slope. Therefore, this effect does not explain the 
difference between the methods, but may contribute to the 
observed nonsignificant slope.
Figure 3b shows the Bland and Altman plot comparing 
QMR to DXA fat loss. The conclusions are broadly similar, 
although the mean difference is slightly smaller (0.68 kg; P = 
0.049). The spread of differences is comparable (standard 
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 deviation of  differences 1.3 kg). Results are sparse for mean fat 
loss above 8 kg due to reliable DXA data only being available 
for five subjects.
For completeness we also include a Bland and Altman plot 
comparing DXA to 4C fat loss in Figure 3c. The 4C model 
estimates average loss of FM 0.19 kg greater than DXA (P = 
0.41). The standard deviation of the differences is 0.9 kg. There 
is some evidence that differences between methods is related to 
gender (mean difference DXA–4C is −0.86 kg for females and 
+0.21 kg for males; P = 0.040).
dIscussIon
In our initial study, QMR provided a convenient method for 
measuring FM rapidly in humans (11). However, with the pro-
totype that was employed in that study, there were some dis-
crepancies in the absolute FM measurements when compared 
to the 4C model, probably due to the complex discrimination 
of fat and nonfat proton signals. On the other hand, simulated 
changes of FM (bottles of canola oil placed on the subject) were 
measured with a high level of accuracy and precision that was 
superior to the 4C model and DXA.
In this article, we have compared the performance of an 
updated QMR instrument, the 4C model and DXA to assess 
FM changes produced by two distinct interventions that 
aimed to decrease FM by reducing energy intake. These dis-
similar cohorts and interventions were chosen to provide a 
broad spectrum of baseline phenotypes, as well as a wide range 
of alterations in FM with which to assess the precision of the 
QMR instrument and its agreement with the 4C model and 
DXA. The differences in the absolute changes in FM between 
study A and B were consistent with a daily energy deficit of 
~2,500 kJ for study A and 6700 kJ for study B. When body com-
position changes were calculated as a percentage of the loss in 
BM, a greater proportion of this change was due to changes in 
TBW for the subjects in study B. This suggests that in the heart 
failure patients there was a more rapid depletion of glycogen 
reserves and perhaps a greater sodium and water diuresis than 
in healthy obese subjects, and therefore a greater decrease of 
TBW in the early phase of weight loss (18).
In terms of agreement, the QMR underreported the esti-
mated fat loss (ΔFat) by an average of 1 kg when compared to 
the 4C model and DXA. This is somewhat better than our pre-
vious data on static assessments of FM (11), and may reflect 
the system upgrade between studies. No slope was detected 
when the difference between ΔFat by QMR and 4C was com-
pared to the average of ΔFat by the two methods (Figure 3), 
indicating that the absolute difference between the methods is 
not affected by the magnitude of the fat loss. Similarly, the dif-
ference between methods was also not affected by absolute BM 
(data not shown). This is encouraging, and indicates that the 
QMR methodology can be used reliably regardless of the body 
composition of the overweight subjects at the time of initiation 
the intervention and the extent of the change in body composi-
tion during the intervention.
With regard to measurement precision of ΔFat for an indi-
vidual subject, the variance of ΔFat will be simply twice the 
variance of the estimate of absolute FM at the start and end of 
the study (assuming independence between the two measure-
ment “errors”). Based on our previous estimate of the standard 
deviation (the square-root of variance) of fat by QMR of 0.43 kg 
for subjects with BMI >30 kg/m2 , this gives an standard devia-
tion for ΔFat for an individual subject of 0.61 kg (i.e., 0.43 kg × 
2), which compares very favorably to other methodologies 
for body composition analysis.
The parameter of interest when designing a parallel-group 
study to compare two interventions is the variance of ΔFat 
between subjects. This variance can be split into two compo-
nents: (i) the measurement variance as described above, and 
(ii) the variance between individuals in their response to inter-
vention. This second “biological” variance is  independent of 
the measurement methodology, instead being driven by aspects 
such as the homogeneity of the population, and the level of 
table 2 standard deviation of ΔFat between subjects (kg)
Standard deviation 
excluding measurement 
variance (σb)
0.5 0.75 1.0 2.0 3.0
QMR 4C QMR 4C QMR 4C QMR 4C QMR 4C
Total s.d. including 
measurement variance (σt)a
0.79 1.12 0.97 1.25 1.17 1.41 2.09 2.24 3.06 3.16
Difference in ΔFat between 
groups (kg)
 0.5 108 212 160 264 232 336 738 840 1,584 1,686
 1.0 30 56 42 68 60 88 186 212 394 422
 1.5 14 26 20 32 28 40 84 96 178 190
 2.0 10 16 14 20 18 24 48 56 102 108
 3.0 6 10 8 10 10 12 24 26 46 50
 5.0 6 6 6 6 6 8 10 12 18 20
Sample-size calculations for fat loss studies using QMR/4C methodology. Sample sizes are total study size (two groups) assuming 90% power and 5% type 1 error.
SD, standard deviation.
aTotal s.d. including measurement variance (σt) is calculated as σt2 = σb2 + σm2, where measurement s.d. (σm) of ΔFat by QMR is 0.61 kg, and by 4C is 1.0 kg.
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compliance with the intervention. In study A and study B, the 
standard deviations of ΔFat subjects were between 3.0 kg and 
4.1 kg, respectively, considerably larger than the pure “techni-
cal” measurement variation.
Table 2 shows sample-size calculations for a range of values 
of the standard deviation of ΔFat between subjects, and for the 
difference in ΔFat between groups. It is clear that for studies 
with larger standard deviation (columns to the right; standard 
deviation ≥2 kg) the reduction in measurement variance can-
not sufficiently reduce sample size to make QMR-based studies 
feasible when compared with other technologies. In situations 
where the difference between interventions is larger (rows to 
the bottom; difference ≥2 kg), the sample size using the 4C 
method is generally small enough to make the studies feasi-
ble with this method anyway, and QMR would not provide an 
advantage other than cost and convenience. The studies where 
QMR may provide most benefit over 4C (or DXA) methods are 
those with smaller standard deviation (0.5–1 kg) and moderate 
difference (1–2 kg), where the sample size may be reduced by 
up to 40% (cells towards the top left). However, studies with 
very small differences (~0.5 kg) require large numbers of sub-
jects whichever methodology is used (top row).
In conclusion, our data indicate that the EchoMRI-AH 
QMR methodology may be ideal for evaluating new antiobes-
ity agents where preclinical promise has to be evaluated rapidly 
in humans to progress only those compounds that show signif-
icant efficacy. By focusing on FM as an inclusion criterion, suc-
cessful interventions can be targeted to individuals most likely 
to respond because they have large fat depots at baseline. Our 
data suggest that this technology should be most advantageous 
for trials investigating moderate changes in FM, as in early 
phase trials, where sources of variation between individuals 
are kept to a minimum.
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ABSTRACT 
 
Effects of rapid weight loss and short-term weight loss maintenance in obese 
patients with cardiovascular risks and/or heart failure: a pilot study 
Myint KS, Northcott S, Heck P, Wright A, Murgatroyd P, Ashby M, Dutka D, 
Dhatariya K, Brown MJ, Finer N. 
 
Background: Despite the strong association of obesity with cardiovascular disease 
(CVD), several studies have shown that in patients with heart failure (HF) lower BMI 
increases mortality. Thus the benefits of weight loss in obese patients with established 
CVD/heart failure could be questioned.  
Materials and methods: 11 obese patients with HF and/or additional CVD risks had 
measurements of body composition (4- compartment model), peak oxygen consumption 
(pVO2), echocardiographic left ventricular ejection fraction (LVEF), and left ventricular 
mass (LVM) and other biomarkers: CRP, plasma norepinephrine (NE), leptin, 
adiponectin after 6 weeks of rapid weight loss (WL) (low energy liquid diet, 1200-1400 
kcal/day) and then 12 weeks of weight loss maintenance (WLM). Data were analysed 
with analysis of variance and Bonferroni‘s multiple comparison post hoc analysis.  
Results: All results mean + SD. Baseline body weight 113.1kg + 23.3 (range 84.2 to 
148.3 kg). Total WL 10 and 12.2kg, fat WL 8.04  and 11.2 kg at week 6 and 18 
respectively (ANOVA: p< 0.0001 for both).  pVO2 increased from 18.33 ± 4.5 to 20.96 
± 4.8 and 20.76 + 4.8 (p =0.0095). There were no significant LVEF or LV mass 
changes. NE (435, 328.4, 318.5ng/l; p=0.03) and CRP (4.452, 2.992, 3.25mg/l; 
p=0.0088) fell clinically and statistically significantly (weeks 0,6, 18). Leptin fell from 
52.9 to 18.2 after rapid WL, but increased to 37.5µg/l at week 18 (ANOVA: p=0.01). 
Total cholesterol (4.2, 3.5, 3.9mmol/l; p = 0.0005) and triglyceride (1.9, 1.2; 1. 3mmol/l 
p= 0.0037) fell, with no significant changes in HDL and LDL cholesterol. ALT fell (41, 
35.8; 26.8IU/l; p=0.0368). No overall change in glucose or blood pressure occurred, but 
some patients need to reduce anti-diabetic and anti-hypertensive medication.  
Conclusions: Acute weight loss was associated with improvement in several CVD risk 
factors without any evidence of excess loss of lean body mass or reduction in cardiac 
performance. These findings are reassuring that both acute weight loss and maintenance 
in the short term of a lower body weight is not associated with evidence of increased 
CVD risk – in fact the reverse was observed.  These data would support the safety of 
conducting larger, outcome studies of therapeutic weight loss in heart failure/CVD 
patients.  
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B. Information for Air displacement plethysmography (BOD-POD) 
 
 
  
Wellcome Trust
Clinical Research Facility
Measurement of
Body Composition by
BOD POD
What is BOD POD?
The BOD POD is an instrument which measures body composition - the amount
of fat and lean in your body.
How is it measured?
The BOD POD works out your body composition from your weight and the
volume of your body.  Your body volume is mesured from the amount of air space
you take up when you sit inside the egg-shaped BOD POD capsule.
What does the measurement involve?
Before anything else, we will show you the BOD POD and explain the
measurement procedure.  Then we will measure your height.  Next we will ask
you to change into your bathing costume and put on a swimming hat that we will
provide.  This is to aviod any air being trapped between your clothing or hair and
your skin.  At the start of the measurement we will weigh you on the BOD POD’s
scale.  Then we will ask you to sit in the BOD POD capsule for the body volume
measurement.  We will close and open the door two or three times during the
measurement.  You will find that, when the door is closed, you have a clear view
through the large window in front of you.  You yourself can open the door at any
time if you wish.
How long does a BOD POD measurement take?
The total time you are in the BOD POD capsule for a measurement will be about
5 minutes.  During this time, the door will only be closed for about 1½ minutes at
a time.  Most studies require a single measurement during your visit, though some
require two.  Occasionally it is necessary to repeat a measurement if we believe it
may be inaccurate.
Will I be able to see the results?
The BOD POD gives results as soon as the measurement is complete.  In most
studies we are able to give you a printed copy of your results straight away,
though in some studies the results may be given to you later.
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C. Information for Dual Energy X-ray Absorptiometry 
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Bone Density and
Body Fat Measurement
by DXA
What is a DXA?
DXA is an instrument which can measure the density of your bone and the
amount of your body which is lean or fat.  DXA stands for Dual-Energy X-ray
Absorptiometer.  It uses very low intensity X-ray to scan part or all your body.
What does the test involve?
Firstly, we will take time to explain the procedure to you and will encourage you
to ask questions about the scan or if you are not sure what we want you to do.
During our explanation we will ask if you have any metal in your body
e.g. plates and screws, and we will ask if you have had any other recent X-rays.
This information helps us to interpret your measurements.
We will then ask you to lie on the DXA scanner couch.  We will help you into
the correct position for the part of your body we want to scan.
When the scan begins, the scanner arm, which carries the “camera”, will pass
over the part of the body to be scanned.  It does not touch you.
It is important that you lie still during the scan, but breathe normally.
The scan does not involve any special drinks, injections or dietary restrictions.
Is radiation involved?
Yes, DXA is an x-ray measurement.  However, the exposure from a DEXA is
very small.  We continually receive X-ray from the atmosphere, and the DXA X-
ray exposure is equivalent to between 30 minutes and a few hours of atmosphirc
X-ray, depending on the areas we scan.  For comparison, a single chest X-ray is
equivalent to about 5 days’ atmospheric radiation.
What if I think I am pregnant?
We will not be able to scan you if you are pregnant.  If you are female aged 12 to
50 years, we will ask if you could be pregnant.  If there is any doubt we will ask
your permission to perform a pregnancy test using a urine sample.
How will I be prepared for the scan?
We may take your height and weight measurements.
We will ask you to remove metal objects – e.g. watches, bracelets and
spectacles.  Rings and ear rings are not a problem.
You can wear your everyday clothing, but will need to remove your shoes.  If
possible avoid wearing any clothing with metal.  If your clothing contains metal,
such as zips or rivets, we may ask you to change
 into a gown or pyjamas which we will provide.
How long does the scan take?
This will depend upon the area to be scanned, but 10 minutes at the most.
Your visit should normally take not more than 30 – 45 minutes in total.
Will I be able to see the results?
After your scan the operator may be able to show you the images from you scan
on the computer screen and may discuss the results with you.
You are welcome to have a printed copy of the image and results if the
researcher is happy for you to have one.
Any other questions?
We hope this information is helpful. If you have any further queries please do
not hesitate to ask.
Preparing
to scan
the hip
Scanning
the spine
 Spine, hip and whole body scan images
If you are particularly interested in the science behind your study, or in the measurements we
make, then please ask - we will be delighted  to spend some time discussing them with you.
Thank you for your interest in our research.
Wellcome Trust Clinical Research Facility
Box 127
Addenbrookes Centre for Clinical Investigation Level 5
Addenbrookes Hospital
Hills Road
Cambridge CB2 2QQ
01223 596055
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D. Deuterium dilution – sample collection sheet 
  
    STUDY TITLE:                 SUBJECT NUMBER:                           DATE:   
  
  _____________               ______________                     _ _ / _ _ / _ _ 
Subject Log Sheet 
 
• Anthropometric Data 
Weight of Subject       _ _. _ _ kg 
Height of Subject (if collected)              _ _. _ _ m 
Date of Dosing       _ _ /_ _ /_ _  
 
• Pre-dose saliva and urine 
Saliva collected       Yes/No 
Urine collected(2ml)     Yes/No 
Date        _ _ /_ _ /_ _ 
Time         ………….am/pm? 
 
• Deuterium dosing 
 Dose Bottle Number     ______ 
 Weight of full dose bottle + dose + straw          _ _ _ . _ _ g 
 Time dose given      ……………. am/pm? 
 Weight of empty dose bottle + straw           _ _ _ . _ _  g 
 Actual weight of dose (full – empty)  __ _ . _ _  g 
 
• 4 hour saliva     Yes/No 
Time (4hour)     ………….am/pm? 
 
• 5 hour saliva     Yes/No 
 Time (5hour)     ………….am/pm? 
 
• 6hour saliva     Yes/No 
Time (6hour)     ………….am/pm? 
 
 
 
 
 
 
 
 
    
   
 
BODY COMPOSITION ANALYSIS  
PLEASE FOLLOW THE INSTRUCTIONS CAREFULLY 
Saliva Sample Collection - small pieces of cotton wool are used to collect samples of saliva. To 
collect: - 
(i) Place cotton wool in the mouth and moisten for 60 seconds or until the cotton wool feels 
saturated. 
(ii) Whilst chewing, remove a 20ml syringe from the packet and take out the plunger from 
the barrel. 
(iii) Place the wet cotton wool into the barrel of the syringe and replace the plunger. 
(iv) Hold the syringe over a collection tube and depress the plunger to squeeze out the saliva 
into the tube. 
(v) Aim to fill each tube to the top with saliva at each collection time point, using extra 
pieces of cotton wool if necessary.  A minimum of 1.0 ml is needed for analysis. 
(vi) Once enough saliva has been collected, the lid should be secured tightly onto each tube 
and the syringe thrown away. 
Dosing 
1) On the day you start the study you must collect a PRE DOSE SAMPLE. It is VERY 
important that this sample is collected BEFORE DRINKING the special water (DOSE), 
and this sample should be put in the bottle marked 'Pre'.  RECORD THE DATE AND 
TIME OF PRE COLLECTION ON YOUR FORM AND ON THE BOTTLE. 
2) DOSE: The dose has been labelled with a number. Record this number on the Log sheet in 
the appropriate space. 
3) The full dose bottle + cap and straw has to be weighed before drinking. Record the weight 
to two decimal places on the front of the sheet. 
4) Use the straw to carefully drink ALL the dose avoiding spillage and then crush the straw 
inside the empty bottle, replace the cap and re-weigh to two decimal places.  Record this 
weight and also the exact time at which the dose was drunk.  The actual weight of dose 
drunk can then be determined by taking away the empty weight from that of the full 
weight. 
Sample Collection after the dose 
 
1) Sample collection after the dose is at 4, 5, and 6 hours.  Samples should be placed into 
appropriately labelled bottles and the dates and times of each collection recorded both on 
paper and on the bottles themselves just in case of loss of documentation.  Fresh equipment 
should be used for each sample collection.  DRINKING SHOULD BE AVOIDED 
THROUGHOUT THE STUDY PERIOD.  HOWEVER, IF ABSOLTELY NECESSARY, IT 
IS IMPORTANT THAT SUBJECTS DO NOT DRINK FOR A MINIMUM OF HALF AN 
HOUR BEFORE COLLECTION OF ANY SAMPLE, DOING SO WILL CONTAMINATE 
THE NEXT SALIVA COLLECTION.   
2) Collected samples should be frozen if possible.  One subject’s entire collection should be 
contained in one bag, included the pre dose separately in it’s own bag. 
3) At the end of the study the samples will be analysed and body composition determined at 
HNR in Cambridge. 
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E. Changes in Peak VO2 analysed by non parametric Friedman test 
Parameter       
Table Analyzed peak VO2     
        
Friedman test       
  P value 0.0377     
  Exact or approximate P value? Exact     
  P value summary *     
  Are means signif. different? (P < 0.05) Yes     
  Number of groups 3     
  Friedman statistic 6.727     
        
Dunn's Multiple Comparison Test Difference in rank sum Significant? P < 0.05? Summary 
  week 0 vs week 6 -10 No ns 
  week 0 vs week 16 -11 Yes * 
 
  
    
  Appendices 
 
F. Samples of data Analysis work sheets 
Parameter           
Table Analyzed 
body 
weight         
            
Repeated Measures ANOVA           
  P value < 0.0001         
  P value summary ***         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 38.04         
  R square 0.7919         
            
 Was the pairing significantly 
effective?           
  R square 0.8964         
  F 83.17         
  P value < 0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 1285 2 642.6     
  Individual (between rows) 14048 10 1405     
  Residual (random) 337.8 20 16.89     
  Total 15671 32       
            
Bonferroni's Multiple Comparison 
Test Mean Diff. t 
Significant? P 
< 0.05? Summary 95% CI of diff 
  week 0 vs week 6 12 6.846 Yes *** 7.419 to 16.58 
  week 0 vs week 16 14.2 8.104 Yes *** 9.624 to 18.78 
  week 6 vs week 16 2.205 1.258 No ns -2.374 to 6.783 
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Parameter           
Table Analyzed BMI         
            
Repeated Measures ANOVA           
  P value < 0.0001         
  P value summary ***         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 44.75         
  R square 0.8174         
            
 Was the pairing significantly 
effective?           
  R square 0.7978         
  F 43.19         
  P value < 0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 145.7 2 72.86     
  Individual (between rows) 703.2 10 70.32     
  Residual (random) 32.56 20 1.628     
  Total 881.5 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 
95% CI of 
diff 
  week 0 vs week 6 4.005 7.361 Yes *** 
2.584 to 
5.427 
  week 0 vs week 16 4.802 8.827 Yes *** 
3.381 to 
6.224 
  week 6 vs week 16 0.7972 1.465 No ns 
-0.6242 to 
2.219 
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Parameter           
Table Analyzed 4C Lean mass         
            
Repeated Measures ANOVA           
  P value P<0.0001         
  P value summary ***         
  Are means signif. different? (P < 0.05) Yes         
  Number of groups 3         
  F 18.05         
  R squared 0.6435         
            
 Was the pairing significantly effective?           
  R squared 0.9619         
  F 141.7         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 105.4 2 52.68     
  Individual (between rows) 4137 10 413.7     
  Residual (random) 58.38 20 2.919     
  Total 4301 32       
            
Bonferroni's Multiple Comparison Test Mean Diff. t 
Significant? P < 
0.05? Summary 95% CI of diff 
  week0 vs week 6 4.167 5.72 Yes *** 2.264 to 6.070 
  week0 vs week 16 3.242 4.451 Yes *** 1.339 to 5.145 
  week 6 vs week 16 -0.925 1.27 No ns 
-2.828 to 
0.9782 
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Parameter           
Table Analyzed 4C fat mass         
            
Repeated Measures ANOVA           
  P value P<0.0001         
  P value summary ***         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 33.14         
  R squared 0.7682         
            
 Was the pairing significantly 
effective?           
  R squared 0.865         
  F 55.26         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 735 2 367.5     
  Individual (between rows) 6129 10 612.9     
  Residual (random) 221.8 20 11.09     
  Total 7086 32       
            
Bonferroni's Multiple Comparison 
Test Mean Diff. t 
Significant? P 
< 0.05? Summary 95% CI of diff 
  week0 vs week 6 8.036 5.659 Yes *** 4.326 to 11.75 
  week0 vs week 16 11.21 7.897 Yes *** 7.505 to 14.92 
  week 6 vs week 16 3.179 2.239 No ns -0.5312 to 6.889 
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Parameter           
Table Analyzed BMC         
            
Repeated Measures ANOVA           
  P value 0.3414         
  P value summary ns         
  Are means signif. different? (P < 
0.05) No         
  Number of groups 3         
  F 1.135         
  R squared 0.1019         
            
 Was the pairing significantly 
effective?           
  R squared 0.9504         
  F 42.7         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P 
< 0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 0.07035 2 0.03517     
  Individual (between rows) 13.23 10 1.323     
  Residual (random) 0.6199 20 0.031     
  Total 13.92 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? 
P < 0.05? Summary 95% CI of diff 
  week 0 vs week 6 -0.1119 1.491 No ns -0.3080 to 0.08422 
  week 0 vs week 16 -0.07009 0.9336 No ns -0.2662 to 0.1260 
  week 6 vs week 16 0.04182 0.557 No ns -0.1543 to 0.2380 
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Table Analyzed FFDM 
 Fat free 
dry mass       
            
Repeated Measures ANOVA           
  P value 0.0003         
  P value summary ***         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 12.73         
  R squared 0.56         
            
 Was the pairing significantly 
effective?           
  R squared 0.9425         
  F 74.56         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 7.86 2 3.93     
  Individual (between rows) 230.2 10 23.02     
  Residual (random) 6.176 20 0.3088     
  Total 244.2 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 95% CI of diff 
  week 0 vs week 6 1.021 4.309 Yes ** 
0.4019 to 
1.640 
  week 0 vs week 16 1.049 4.428 Yes *** 
0.4301 to 
1.668 
  week 6 vs week 16 0.02818 0.1189 No ns 
-0.5908 to 
0.6472 
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Parameter           
Table Analyzed 
Android and 
Gynoid ratio         
            
Repeated Measures 
ANOVA           
  P value 0.0136         
  P value summary *         
  Are means signif. 
different? (P < 0.05) Yes         
  Number of groups 3         
  F 5.929         
  R squared 0.4586         
            
 Was the pairing 
significantly effective?           
  R squared 0.871         
  F 24.94         
  P value P<0.0001         
  P value summary ***         
  Is there significant 
matching? (P < 0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between 
columns) 0.03637 2 0.01819     
  Individual (between rows) 0.5355 7 0.07649     
  Residual (random) 0.04294 14 0.003067     
  Total 0.6148 23       
            
Bonferroni's Multiple 
Comparison Test Mean Diff. t 
Significant? P 
< 0.05? Summary 95% CI of diff 
  week 0 vs week 6 0.0485 1.752 No ns -0.02675 to 0.1238 
  week 0 vs week 16 0.09535 3.444 Yes * 0.02010 to 0.1706 
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Parameter           
Table Analyzed heart rate         
            
Repeated Measures ANOVA           
  P value 0.007         
  P value summary **         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 6.431         
  R squared 0.3914         
            
 Was the pairing significantly 
effective?           
  R squared 0.7009         
  F 7.701         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 881.2 2 440.6     
  Individual (between rows) 5276 10 527.6     
  Residual (random) 1370 20 68.51     
  Total 7528 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 
95% CI of 
diff 
  week 0 vs week 6 11.18 3.168 Yes * 
1.961 to 
20.40 
  week 0 vs week 16 10.73 3.039 Yes * 
1.507 to 
19.95 
  week 6 vs week 16 -0.4545 0.1288 No ns 
-9.675 to 
8.766 
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Parameter           
Table Analyzed 
diastolic 
BP         
            
Repeated Measures ANOVA           
  P value 0.1011         
  P value summary ns         
  Are means signif. different? (P < 
0.05) No         
  Number of groups 3         
  F 2.576         
  R squared 0.2048         
            
 Was the pairing significantly 
effective?           
  R squared 0.5912         
  F 3.638         
  P value 0.0067         
  P value summary **         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 328.8 2 164.4     
  Individual (between rows) 2322 10 232.2     
  Residual (random) 1277 20 63.83     
  Total 3927 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 
95% CI of 
diff 
  week 0 vs week 6 7.273 2.135 No ns 
-1.627 to 
16.17 
  week 0 vs week 16 1.364 0.4003 No ns 
-7.536 to 
10.26 
  week 6 vs week 16 -5.909 1.735 No ns 
-14.81 to 
2.991 
  
    
  Appendices 
 
Parameter           
Table Analyzed  LVd mass         
            
Repeated Measures ANOVA           
  P value 0.1115         
  P value summary ns         
  Are means signif. different? 
(P < 0.05) No         
  Number of groups 3         
  F 2.453         
  R squared 0.197         
            
 Was the pairing significantly 
effective?           
  R squared 0.8534         
  F 14.5         
  P value P<0.0001         
  P value summary ***         
  Is there significant 
matching? (P < 0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between 
columns) 5076 2 2538     
  Individual (between rows) 150000 10 15000     
  Residual (random) 20690 20 1035     
  Total 175800 32       
            
Bonferroni's Multiple 
Comparison Test Mean Diff. t 
Significant? P 
< 0.05? Summary 95% CI of diff 
  week 0 vs week 6 27.68 2.018 No ns -8.149 to 63.52 
  week 0 vs week 16 24.67 1.799 No ns -11.16 to 60.51 
  week 6 vs week 16 -3.01 0.2195 No ns -38.84 to 32.82 
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Parameter           
Table Analyzed 
Exercise 
time         
            
Repeated Measures ANOVA           
  P value 0.0013         
  P value summary **         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 9.402         
  R squared 0.4846         
            
 Was the pairing significantly 
effective?           
  R squared 0.789         
  F 14.51         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 89.48 2 44.74     
  Individual (between rows) 690.3 10 69.03     
  Residual (random) 95.17 20 4.759     
  Total 875 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 95% CI of diff 
  week 0 vs week 6 -2.497 2.685 Yes * 
-4.927 to -
0.06716 
  week 0 vs week 16 -3.992 4.292 Yes ** 
-6.422 to -
1.562 
  week 6 vs week 16 -1.495 1.607 No ns 
-3.925 to 
0.9356 
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Parameter           
Table Analyzed HF         
            
Repeated Measures ANOVA           
  P value 0.0334         
  P value summary *         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 4.13         
  R squared 0.3145         
            
 Was the pairing significantly 
effective?           
  R squared 0.4747         
  F 2.637         
  P value 0.0382         
  P value summary *         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 185700 2 92830     
  Individual (between rows) 533500 9 59270     
  Residual (random) 404600 18 22480     
  Total 1124000 29       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 
95% CI of 
diff 
  week 0 vs week 6 -27.59 0.4115 No ns 
-204.6 to 
149.4 
  week 0 vs  week 16 -179 2.669 Yes * 
-355.9 to -
2.000 
  week 6 vs  week 16 -151.4 2.257 No ns 
-328.3 to 
25.59 
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Parameter         
Table Analyzed 
fasting 
glucsoe       
          
Repeated Measures ANOVA         
  P value 0.1257       
  P value summary ns       
  Are means signif. different? (P < 
0.05) No       
  Number of groups 3       
  F 2.304       
  R squared 0.1873       
          
 Was the pairing significantly 
effective?         
  R squared 0.8026       
  F 10       
  P value P<0.0001       
  P value summary ***       
  Is there significant matching? (P < 
0.05) Yes       
          
ANOVA Table SS df MS   
  Treatment (between columns) 6.764 2 3.382   
  Individual (between rows) 146.8 10 14.68   
  Residual (random) 29.36 20 1.468   
  Total 182.9 32     
          
Newman-Keuls Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? Summary 
  week 16 vs week 0 -1.091 2.986 No ns 
  week 16 vs week 6 -0.3727 --- No ns 
  week 6 vs week 0 -0.7182 --- No ns 
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Parameter           
Table Analyzed HbA1c         
            
Repeated Measures ANOVA           
  P value 0.0117         
  P value summary *         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 5.753         
  R squared 0.3899         
            
 Was the pairing significantly 
effective?           
  R squared 0.8014         
  F 13.23         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 4.266 2 2.133     
  Individual (between rows) 44.15 9 4.905     
  Residual (random) 6.674 18 0.3708     
  Total 55.09 29       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 95% CI of diff 
  week 0 vs week 6 0.63 2.313 No ns 
-0.08867 to 
1.349 
  week 0 vs week 16 0.9 3.305 Yes * 
0.1813 to 
1.619 
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Parameter           
Table Analyzed Choleterol         
            
Repeated Measures ANOVA           
  P value 0.0005         
  P value summary ***         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 11.35         
  R squared 0.5316         
            
 Was the pairing significantly 
effective?           
  R squared 0.6572         
  F 8.187         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 2.839 2 1.419     
  Individual (between rows) 10.24 10 1.024     
  Residual (random) 2.501 20 0.1251     
  Total 15.58 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 95% CI of diff 
  week 0 vs week 6 0.7091 4.702 Yes *** 0.3151 to 1.103 
  week 0 vs week 16 0.2545 1.688 No ns 
-0.1394 to 
0.6485 
  week 6 vs week 16 -0.4545 3.014 Yes * 
-0.8485 to -
0.06059 
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Parameter           
Table Analyzed HDL         
            
Repeated Measures ANOVA           
  P value 0.0526         
  P value summary ns         
  Are means signif. different? (P < 
0.05) No         
  Number of groups 3         
  F 3.425         
  R squared 0.2551         
            
 Was the pairing significantly 
effective?           
  R squared 0.7411         
  F 7.685         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 0.09804 2 0.04902     
  Individual (between rows) 1.1 10 0.11     
  Residual (random) 0.2863 20 0.01431     
  Total 1.484 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 95% CI of diff 
  week 0 vs week 6 0.08818 1.729 No ns 
-0.04510 to 
0.2215 
  week 0 vs week 16 -0.04273 0.8375 No ns 
-0.1760 to 
0.09056 
  week 6 vs week 16 -0.1309 2.566 No ns 
-0.2642 to 
0.002375 
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Parameter           
Table Analyzed Creatinine         
            
Repeated Measures ANOVA           
  P value 0.2885         
  P value summary ns         
  Are means signif. different? (P < 
0.05) No         
  Number of groups 3         
  F 1.323         
  R squared 0.1169         
            
 Was the pairing significantly 
effective?           
  R squared 0.9101         
  F 22.93         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 291.9 2 145.9     
  Individual (between rows) 25290 10 2529     
  Residual (random) 2205 20 110.3     
  Total 27780 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 
95% CI of 
diff 
  week 0 vs week 6 4 0.8933 No ns 
-7.698 to 
15.70 
  week 0 vs week 16 7.273 1.624 No ns 
-4.426 to 
18.97 
  week 6 vs week 16 3.273 0.7309 No ns 
-8.426 to 
14.97 
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Parameter           
Table Analyzed CRP         
            
Repeated Measures ANOVA           
  P value 0.0088         
  P value summary **         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 6.228         
  R squared 0.409         
            
 Was the pairing significantly 
effective?           
  R squared 0.8792         
  F 24.64         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 12.14 2 6.072     
  Individual (between rows) 216.2 9 24.02     
  Residual (random) 17.55 18 0.9749     
  Total 245.9 29       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 
95% CI of 
diff 
  week 0 vs week 6 1.46 3.306 Yes * 
0.2946 to 
2.625 
  week 0 vs week 16 1.202 2.722 Yes * 
0.03663 to 
2.367 
  week 6 vs week 16 -0.258 0.5843 No ns 
-1.423 to 
0.9074 
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Parameter           
Table Analyzed adiponectin         
            
Repeated Measures ANOVA           
  P value 0.4065         
  P value summary ns         
  Are means signif. different? (P < 
0.05) No         
  Number of groups 3         
  F 0.9468         
  R squared 0.09519         
            
 Was the pairing significantly 
effective?           
  R squared 0.7396         
  F 6.277         
  P value 0.0005         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 3.469 2 1.734     
  Individual (between rows) 103.5 9 11.5     
  Residual (random) 32.97 18 1.832     
  Total 139.9 29       
            
Bonferroni's Multiple Comparison 
Test Mean Diff. t 
Significant? 
P < 0.05? Summary 95% CI of diff 
  week 0 vs week 6 0.77 1.272 No ns -0.8274 to 2.367 
  week 0 vs week 16 0.11 0.1817 No ns -1.487 to 1.707 
  week 6 vs week 16 -0.66 1.09 No ns -2.257 to 0.9374 
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Parameter           
Table Analyzed ALT         
            
Repeated Measures ANOVA           
  P value 0.0368         
  P value summary *         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 3.913         
  R squared 0.2813         
            
 Was the pairing significantly 
effective?           
  R squared 0.5288         
  F 3.123         
  P value 0.0145         
  P value summary *         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 1133 2 566.5     
  Individual (between rows) 4520 10 452     
  Residual (random) 2895 20 144.8     
  Total 8548 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 95% CI of diff 
  week 0 vs week 6 5.182 1.01 No ns -8.221 to 18.58 
  week 0 vs week 16 14.18 2.764 Yes * 0.7787 to 27.58 
  week 6 vs week 16 9 1.754 No ns -4.403 to 22.40 
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Parameter           
Table Analyzed 
antioxident 
profile         
            
Repeated Measures ANOVA           
  P value 0.0009         
  P value summary ***         
  Are means signif. different? (P < 
0.05) Yes         
  Number of groups 3         
  F 10.2         
  R squared 0.505         
            
 Was the pairing significantly 
effective?           
  R squared 0.7428         
  F 11.67         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 219100 2 109600     
  Individual (between rows) 1253000 10 125300     
  Residual (random) 214800 20 10740     
  Total 1687000 32       
            
Bonferroni's Multiple Comparison 
Test Mean Diff. t 
Significant? P 
< 0.05? Summary 95% CI of diff 
  week 0 vs week 6 126 2.851 Yes * 10.52 to 241.4 
  week 0 vs week 16 197.1 4.46 Yes *** 81.62 to 312.5 
  week 6 vs week 16 71.11 1.609 No ns -44.34 to 186.5 
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Parameter           
Table Analyzed BNP         
            
Repeated Measures ANOVA           
  P value 0.2037         
  P value summary ns         
  Are means signif. different? (P < 
0.05) No         
  Number of groups 3         
  F 1.725         
  R squared 0.1471         
            
 Was the pairing significantly 
effective?           
  R squared 0.949         
  F 43.67         
  P value P<0.0001         
  P value summary ***         
  Is there significant matching? (P < 
0.05) Yes         
            
ANOVA Table SS df MS     
  Treatment (between columns) 2355 2 1178     
  Individual (between rows) 298100 10 29810     
  Residual (random) 13650 20 682.7     
  Total 314100 32       
            
Bonferroni's Multiple Comparison 
Test 
Mean 
Diff. t 
Significant? P < 
0.05? Summary 
95% CI of 
diff 
  week 0 vs week 6 18.56 1.666 No ns 
-10.54 to 
47.67 
  week 0 vs week 16 1.364 0.1224 No ns 
-27.74 to 
30.47 
  week 6 vs week 16 -17.2 1.544 No ns 
-46.31 to 
11.91 
 
